Chimeric receptor binding proteins resistant to proteolytic degradation

ABSTRACT

The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of 17/564,625, filed Dec. 29, 2021, which is a continuation-in-part of International Application No. PCT/EP2020/088043, filed Dec. 30, 2020 and U.S. Pat. Application No. 17/138,084, filed Dec. 30, 2020, both of which claim benefit and priority to U.S. Provisional Application No. 62/955,278, filed Dec. 30, 2019. This application also claims benefit and priority to U.S. Provisional Application No. 63/132,090, filed Dec. 30, 2020; U.S. Provisional Application No. 63/132,190, filed Dec. 30, 2020; and U.S. Provisional Application No. 63/137,989, filed Jan. 15, 2021 all of which are incorporated herein by reference in their entireties.

SEQUENCE LISTING

This application includes an electronically submitted sequence listing in .xlm format. The .xlm file contains a sequence listing entitled EB2020_08_USDiv_SequenceListing.xml. The sequence listing contained in this .xlm file is part of the specification and is hereby incorporated by reference herein in its entirety.

TECHNICAL FIELD

The present disclosure relates to chimeric receptor binding proteins, in particular derived from bacteriophage receptor binding proteins, able to withstand proteolytic digestion, in particular gastrointestinal proteolytic digestion, bacterial delivery vehicles comprising said chimeric receptor binding proteins, and the use thereof in efficient transfer of a desired payload into a target bacterial cell population, in particular after oral administration.

BACKGROUND

One of the critical aspects to be addressed when considering protein-based DNA delivery vectors, such as packaged phagemids or Eligobiotics®, is their stability in in vivo conditions. Depending on the route of administration, packaged phagemids may be exposed to different factors that may affect their stability and functionality. For instance, orally administered packaged phagemids will have to traverse the gastrointestinal tract: harsh conditions, such as the low pH in the stomach and the presence of certain digestive enzymes, may have a negative effect on the structural stability of the particles.

Phages have evolved to be stable in a wide range of conditions [1]. From the evolutionary perspective, being able to resist these conditions is a clear advantage for any phage.

However, it is well known that many phages are not resistant to low pH values for a long period of time [1], [2], although this can be circumvented by the use of stomach acid neutralizers [3]-[6]. Similarly, some phages have evolved to be resistant to digestive enzymes, such as those found in pancreatic juices (trypsin, chymotrypsin, etc.), while some others are readily degraded [4], [7], [8] although the exact mechanisms of degradation have not been studied in detail.

From these facts, it can be concluded that for the development of a highly successful optimal phage-derived DNA delivery vector, such as an Eligobiotic®, it is useful to obtain a vector which is stable in in vivo conditions.

The present disclosure provides a solution to this need.

A powerful engineering pipeline has been developed to generate phage-derived DNA delivery vectors with improved or modified host ranges as disclosed in WO2020109339. To do this, the natural variability of phage parts has been exploited to generate functional protein chimeras in existing phage scaffolds: for instance, one was able to modify the tropism and injection efficiency of packaged phagemids by modifying the two main host range determinants of lambdoid phages such as the lambda phage, the gpJ and STF (Side Tail Fiber) proteins.

In the course of vector development, it was observed that one had to differentiate between functionality and stability. A given protein chimera (for instance, a STF fusion) can exhibit an ideal functionality, for example can contribute to a high injection efficiency into a target strain in in vitro conditions, but may be affected when exposed to pancreatin (i.e. still functional but less stable). This was an unpredictable aspect of the protein engineering process so far: starting from two different STFs that are not degraded in the presence of pancreatin could yield a protein chimera that was less resistant to proteolytic digestion.

Different direct (on the packaged phagemids itself) or indirect (on the environment of the packaged phagemids) approaches can be envisioned to protect these protein chimera from in vivo proteolytic digestion, e.g. a suitable formulation, such as controlled or delayed release formulations enabling the release of packaged phagemids displaying said protein chimera in the intestine or the colon. The present disclosure shows that another solution is to act directly on said protein chimera.

SUMMARY

The present disclosure is based on the unexpected finding that, by specifically designing a small fusion region (also called linker region) between two different STFs, it is possible to render a chimeric lambda based STF protein, which was initially engineered to be fully functional but was less stable in the presence of pancreatin, both functional and highly stable.

It is worth noting that in natural phage STFs, proteolytically degradable residues exist that due to conformation or interaction with other residues/proteins may not be accessible for degradation in normal conditions. However, such residues may become accessible for degradation when these STFs are used to produce chimeras. It has been specifically demonstrated that introducing point mutations in phenylalanine (F) and lysine (K) residues present in the linker region, corresponding to a region of about 10 to 12 amino acids adjacent to the insertion site of chimeric lambda STF-V10, rendered the chimeric lambda STF-V10 protein partially resistant to pancreatin hence with increased stability, while the original chimeric lambda STF-V10 protein was not resistant to pancreatin at all.

It has also been demonstrated that designing the linker region to include a short sequence which was initially present at the N-terminus end of the C-terminal region of V10 tail fiber used to produce the chimera, rendered the chimeric lambda STF-V10 protein highly resistant to pancreatin (without introducing further mutations in the linker region).

Further it has been demonstrated, in another chimeric receptor binding protein, namely a functional chimeric lambda STF-K5 protein, which was not very stable in the presence of pancreatin, that introducing, in the linker region, the same helix-forming sequence initially present at the N-terminus of the V10 tail fiber, rendered the chimeric STF-K5 protein highly resistant to pancreatin hence strongly stable.

Furthermore, it has been demonstrated, in another functional chimeric lambda STF-K5 protein, which was not very stable in the presence of pancreatin, that introducing, in the linker region another helix-forming sequence present within the STF protein of the Escherichia phage ZG49 (which has homology with the wild-type K5 protein), rendered the chimeric STF-K5 protein very highly resistant to pancreatin.

The present disclosure thus concerns a chimeric receptor binding protein (RBP) resistant to proteolytic digestion, in particular within the gastrointestinal tract, wherein said chimeric RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 up to 70 amino acids, more particularly of 1 up to 30 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion, in particular within the gastrointestinal tract. In a particular embodiment, said chimeric RBP is resistant to proteolytic digestion by pancreatin, and said linker region is designed to be resistant to proteolytic digestion by pancreatin.

In a particular embodiment, said RBP is a side tail fiber (STF) protein, an L-shape fiber, a long tail fiber or a tailspike. In a particular embodiment, said chimeric RBP comprises a portion of a STF protein derived from a lambdoid bacteriophage fused through a designed linker region consisting of 1 up to 70 amino acids (more particularly of 1 up to 30 amino acids), to a portion of a RBP protein derived from a different bacteriophage. In a particular embodiment, said chimeric RBP comprises an N-terminal region of a STF protein derived from a lambdoid bacteriophage, fused through a designed linker region consisting of 1 up to 70 amino acids (more particularly of 1 up to 30 amino acids), to a C-terminal region of a RBP protein derived from a different bacteriophage, wherein said N-terminal region and C-terminal region are fused within a site of the N-terminal STF region, called insertion site, having at least 80% identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 1), ADAKKS (SEQ ID NO: 2), MDETNR (SEQ ID NO: 3), SASAAA (SEQ ID NO: 4), and GAGENS (SEQ ID NO: 5). In a particular embodiment, said insertion site has at least 80% identity with sequence GAGENS (SEQ ID NO: 5). In a particular embodiment, said designed linker region is at the C-terminal end of the insertion site. In a particular embodiment, said designed linker region is part of the N-terminal region or of the C-terminal region of the chimeric RBP.

In a particular embodiment, at least one amino acid of the designed linker region, corresponding to an amino acid of the wildtype domain sequence which is likely to be targeted by trypsin and/or chymotrypsin, is mutated compared to the wildtype domain sequence. In said particular embodiment, said designed linker region may be part of the C-terminal region of the chimeric RBP and said at least one amino acid may be located within the 15 amino acids following the insertion site. In still said particular embodiment, said at least one amino acid may be selected from the group consisting of lysin (K), arginine (R), phenylalanine (F), tryptophan (W), tyrosine (Y) leucine (L) and methionine (M).

In another particular embodiment, said N-terminal region or said C-terminal region comprises the sequence of the linker region, said sequence being identical to the corresponding sequence in the N-terminal region or C-terminal region of the RBP from which it is derived, and said sequence conferring resistance to proteolytic digestion to said chimeric RBP compared to the original chimeric RBP only differing by the absence of said linker region.

In another particular embodiment, said designed linker region comprises or consists of an heterologous amino acid sequence which is not derived from the N-terminal region or from the C-terminal region of the chimeric RBP. In said embodiment, said designed linker region may comprise or consist of an amino acid sequence which is derived from a RBP which is not one of the RBP from which the N-terminal region and the C-terminal region of the chimeric RBP are derived.

In a particular embodiment, said designed linker region may consist of 10 up to 20 amino acids. In said embodiment, said designed linker region may comprise or consist of an amino acid sequence GSATDVMIQL (SEQ ID NO: 6) or GSATDVMIQLA (SEQ ID NO: 7). In said embodiment, said sequence may be located directly after the insertion site.

In an alternative embodiment, said designed linker region may consist of 50 up to 65 amino acids. In said embodiment, said designed linker region may comprise or consist of an amino acid sequence SEQ ID NO: 34 or SEQ ID NO: 37. In said embodiment, said sequence may be located directly after the insertion site.

In a particular embodiment, the designed linker region comprises a helix or helical bundle.

In a particular embodiment, the N-terminal region of said STF protein derived from a lambdoid bacteriophage corresponds to amino acids 1 to 528 of the lambda STF protein of sequence SEQ ID NO: 8. In a particular embodiment, the C-terminal region of said STF protein derived from said different bacteriophage corresponds to amino acids 218 to 875 of the STF protein of sequence SEQ ID NO: 16. In said embodiment, said chimeric RBP may comprise or consist of the sequence SEQ ID NO: 9 or SEQ ID NO: 10. In another particular embodiment, the C-terminal region of said STF protein derived from said different bacteriophage corresponds to amino acids 208 to 875 of the STF protein of sequence SEQ ID NO: 16. In said embodiment, said chimeric RBP may comprise or consist of the sequence SEQ ID NO: 11. In a particular embodiment, the C-terminal region of said STF protein derived from said different bacteriophage corresponds to amino acids 28 to 632 of the STF protein of sequence SEQ ID NO: 12. In said embodiment, said chimeric RBP may comprise or consist of the sequence SEQ ID NO: 13 or SEQ ID NO: 14. In a particular embodiment, the C-terminal region of said STF protein derived from said different bacteriophage corresponds to amino acids 62 to 632 of the STF protein of sequence SEQ ID NO: 12. In said embodiment, said chimeric RBP may comprise or consist of the sequence SEQ ID NO: 38 or SEQ ID NO: 40.

The present disclosure also concerns a lambdoid bacterial delivery vehicle for use in in vivo delivery of a DNA payload of interest into a targeted bacterial cell, wherein said lambdoid delivery vehicle comprises the chimeric RBP provided herein. In a particular embodiment, said chimeric RBP is a chimeric STF protein as disclosed herein. In said embodiment, said chimeric STF protein may be a functional STF protein. In still said embodiment, the delivery vehicle may further comprise a functional lambdoid bacteriophage gpJ protein and/or a functional lambdoid bacteriophage gpH protein. In a particular embodiment, the chimeric STF protein has enzyme activity such as depolymerase activity and the bacterial cell population of interest comprises encapsulated bacteria. In a particular embodiment, one or more of the chimeric STF protein, the gpJ protein and/or the gpH protein are engineered to increase the efficiency of transfer of the DNA payload into a targeted bacterial cell population. In a particular embodiment, the delivery vehicle comprises the chimeric RBP comprising or consisting of the sequence SEQ ID NO: 11 and the gpJ chimeric protein 1A2 comprising or consisting of the sequence SEQ ID NO: 27.

In a particular embodiment, the bacterial cell population is selected from the group consisting of E. coli bacteria, K. pneumoniae and other species of interest.

In a particular embodiment, said bacterial delivery vehicle comprises said DNA payload of interest. In a particular embodiment, the DNA payload comprises a nucleic acid of interest selected from the group consisting of Cas nuclease gene, a Cas9 nuclease gene, a guide RNA, a CRISPR locus, a toxin gene, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, a gene expressing resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor, and a gene expressing a virulence protein or a virulence factor, and or any of their combination. In said embodiment, the nuclease may target cleavage of a host bacterial cell chromosome or a host bacterial cell plasmid. In said embodiment, the cleavage may occur in an antibiotic resistant gene. In a particular embodiment, the nucleic acid of interest encodes a therapeutic protein. In another particular embodiment, the nucleic acid of interest encodes an antisense nucleic acid molecule.

The present disclosure also relates to a pharmaceutical or veterinary composition comprising a bacterial delivery as disclosed herein and a pharmaceutically acceptable carrier. In a particular embodiment, said composition is for oral administration.

The present disclosure also provides a method for in vivo delivery of a DNA payload of interest into a subject comprising, administering to said subject the pharmaceutical or veterinary composition as provided herein.

Another object of the disclosure relates to providing a method for treating a disease or disorder caused by bacteria comprising administering to a subject having a disease or disorder in need of treatment a therapeutically efficient amount of a pharmaceutical or veterinary composition disclosed herein. In a particular embodiment, said disease or disorder is a bacterial infection, a metabolic disorder or a pathology involving bacteria of the human microbiome. In still a particular embodiment, said composition is administered orally.

The present disclosure also provides pharmaceutical or veterinary compositions for use in a method for treating a disease or disorder caused by bacteria. In a particular embodiment, said disease or disorder is a bacterial infection, a metabolic disorder or a pathology involving bacteria of the human microbiome. In still a particular embodiment, said composition is administered orally.

The present disclosure further concerns a method for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population comprising contacting the bacterial population with a bacterial delivery vehicle as provided herein. Another object concerns providing bacterial delivery vehicles for use in a method for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 : Stability of lambda packaged phagemids in SIF (Simulated Intestinal Fluid). Left group of bars, wild-type lambda packaged phagemid produced from CYC3 in MG1655; central group of bars, lambda 1A2-V10 packaged phagemids in MG1656-OmpCO157; right group of bars, 1A2-V10 packaged phagemids on H10 (0157) strain. Y axis shows particle titer per µL.

FIG. 2 : Lambda STF-V10 engineered variants. Arrows depict predicted trypsin and chymotrypsin sites (not all sites shown for clarity reasons)

FIG. 3 : Stability of lambda STF-V10 variants in different conditions. Left group of bars, original lambda STF-V10 variant (SEQ ID NO: 15); second group of bars, STF-V10-[FA] variant (SEQ ID NO: 9); third group of bars, STF-V10-[AAH] variant (SEQ ID NO: 10); fourth group of bars, STF-V10-Helix variant (SEQ ID NO: 11). The Y axis shows CFU count per µL.

FIG. 4 : Shedding of lambda packaged phagemids 1A2 gpJ - STF-V10 (1A2-V10) over time in un-colonized mice (n=3). The dose bars on the left correspond to the titration after production of the packaged phagemids. “black bars”: 1A2 activity; “grey bars”: V10 activity.

FIG. 5 : Shedding of lambda packaged phagemids 1A2 - STF-V10-[FA] (n=4) and 1A2 - STF-V10-[Helix] (n=3) at t=6h after administration in un-colonized mice. “black circles”, 1A2 activity; “white triangle”, V10 activity.

FIG. 6 . Shedding of lambda packaged phagemids 1A2 - STF-V10-[Helix] overtime (n=5 mice) following a single oral administration of these packaged phagemids. Legend: H10Δstx = V10 activity; MG1656-OmpCO157 = 1A2 activity.

FIG. 7 : Percentage of pRFP curing from H10Δstx/pRFP in vivo (n=10 mice) at three different time points after the first dose of the cocktail (1A2 - STF-V10-[FA] and 1A2 - STF-V10-[Helix]) : t = 6 h, black; t = 24 h, light grey; t = 48 h, dark grey.

FIG. 8 : Intestinal decolonization of the STEC strain H10WT overtime after 5 doses of packaged phagemids: colonization overtime of the control group gavaged with buffer (sucrose bicarbonate).

FIG. 9 : Intestinal decolonization of the STEC strain H10WT overtime after 5 doses of packaged phagemids: colonization overtime of the test group treated with lambda packaged phagemids 1A2 - STF-V10-[Helix] .

FIG. 10 : Stability of lambda packaged phagemids 1A2 - K5 in PBS. Black bars, PBS only; white bars, PBS plus pancreatin at pH 6.8. Left group of bars, activity in MG1656-OmpCO157; right group of bars, LMR_503 strain. Y axis shows particle titer per µL.

FIG. 11 : Stability of lambda packaged phagemids 1A2 - K5 5.0 Helix variant. Black bars, PBS only; white bars, PBS plus pancreatin at pH 6.8. Left group of bars, activity in MG1656-OmpCO157; right group of bars, LMR_503 strain. Y axis shows particle titer per µL.

FIG. 12 : Stability of lambda packaged phagemids 1A2 - K5 5.1 Helix variant. Black bars, PBS only; white bars, PBS plus pancreatin at pH 6.8. Left group of bars, activity in MG1656-OmpCO157; right group of bars, LMR_503 strain. Y axis shows particle titer per µL.

FIG. 13 : Overlay of the sedimentation coefficient distribution data of the 3 Eligobiotics (EB) batches analyzed by svAUC in Example 3. The integration ranges for EB packaged with 3 or 4 copies of the payload are depicted by dotted lines.

FIG. 14 : Relative abundance of Eligobiotics® containing either 3 or 4 copies of the payload. Absorbance signals at 260 and 280 nm for each population defined in svAUC were integrated and used to calculate their relative abundance in each batch of Eligobiotics®.

FIG. 15 : Stability of lambda packaged phagemids 1A2 - K5 in PBS. Black bars: PBS only; white bars: PBS plus pancreatin at pH 6.8. Left group of bars: activity in MG1656- OmpCO157; right group of bars: LMR_503 strain. Y axis shows particle titer per µL.

FIG. 16 : Intestinal decolonization of the LMR_503 strain over time after 1 dose of Eligobiotic®. Colonization over time of the test group treated with Eligobiotic® harboring the A8 gpJ, the K5 9.1 STF and the plasmid p775. D8 represents the days after colonization of mice with the LMR_503 strain; T0, T8 represent the time 0 (pre-treatment levels) and 8 h after treatment with Eligobiotic®.

DETAILED DESCRIPTION Chimeric Receptor Binding Protein (RBP)

The present disclosure relates to a chimeric receptor binding protein (RBP) resistant to proteolytic digestion, in particular within the gastrointestinal tract, wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, more particularly of 1 to 30 amino acids, to a portion of a corresponding receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion, in particular within the gastrointestinal tract.

Resistance to Proteolytic Digestion

By “proteolytic digestion” is meant herein proteolysis of a protein mediated by an enzyme having any protease activity. By “proteolytic digestion within the gastrointestinal tract” is meant herein proteolysis of a protein mediated by an enzyme having protease activity in any part of the gastrointestinal tract, such as in the mouth, the esophagus, the stomach, the small intestine or the large intestine. In a particular embodiment, said proteolytic digestion is within the small intestine. In a more particular embodiment, said proteolytic digestion is within the duodenum.

As well-known from the skilled person, proteolytic digestion within the duodenum is mainly affected by bile salts and pancreatin. In a particular embodiment, said proteolytic digestion is by pancreatin. By “pancreatin” is meant herein a mixture of pancreatic enzymes including trypsin and chymotrypsin, and optionally amylase and lipase. In another particular embodiment, said proteolytic digestion is by trypsin and/or chymotrypsin. By “trypsin” is meant herein an enzyme of the EC 3.4.21.4 category, which is a serine protease from the PA clan superfamily, found in the digestive system of many vertebrates, where it hydrolyzes proteins. Typically, trypsin cleaves peptides on the C-terminal side of lysine and arginine amino acid residues, but If a proline residue is on the carboxyl side of the cleavage site, the cleavage may not not occur, and if an acidic residue is on either side of the cleavage site, the rate of hydrolysis may be be slower. By “chymotrypsin” is meant herein an enzyme of the EC 3.4.21.1 category, which is a serine protease from the PA clan superfamily, found in the digestive system of vertebrates, where it hydrolyzes proteins. Typically, chymotrypsin cleaves peptide bonds involving L-isomers of tyrosine, phenylalanine, and tryptophan.

By “resistant to proteolytic digestion” is meant herein that the chimeric RBP is not cleaved by said proteases and/or remains stable when contacted with said proteases and/or keeps its activity when contacted with said proteases. Techniques to determine if a protein is resistant to proteolytic digestion by pancreatin, in particular by trypsin and/or chymotrypsin, typically include exposing said protein to simulated intestinal fluid (SIF) in the presence or absence of pancreatin, typically at 2% w/v, for example at pH 6.8, typically for 3 h, in particular at 37° C., then determining the activity of said treated protein (for example by titration of the bacterial delivery vehicle comprising said chimeric RBP in bacteria which are specifically targeted by packaged phagemid comprising said RBPs) and comparing it with the activity of same but non-treated protein. In the context of the present disclosure, a chimeric RBP is preferably considered as resistant to proteolytic digestion if the titer of the bacterial delivery vehicle comprising said chimeric RBP in bacteria which are specifically targeted by said RBPs decreases of 1 log or less, after treatment with pancreatin, typically at 2% w/v, for example at pH 6.8, typically for 3 h, in particular at 37° C. compared to the titer of the same but non-treated bacterial delivery vehicle comprising the same chimeric RBP targeting the same bacteria.

Chimeric RBP

As used herein, a receptor binding protein or RBP is a polypeptide that recognizes, and optionally binds and/or modifies or degrades a substrate located on the bacterial outer envelope, such as, without limitation, bacterial outer membrane, LPS, capsule, protein receptor, channel, structure such as the flagellum, pili, secretion system. The substrate can be, without limitation, any carbohydrate or modified carbohydrate, any lipid or modified lipid, any protein or modified protein, any amino acid sequence, and any combination thereof.

Such bacteriophage RBPs, from which the RBP portions are derived, include, for example, “L-shape fibers”, “side tail fibers (stfs)”, “long tail fibers” or “tailspikes.” In a preferred embodiment, the RBPs have a host range that is directed to specific bacterial cells of the host or subject microbiome. In one specific aspect, the different RBP of the chimeric RBPis derived from any bacteriophage or from any bacteriocin.

In an embodiment, said chimeric RBP is a chimeric side tail fiber (STF) protein.

In a particular embodiment, the chimeric STF comprises an N-terminal region of an STF derived from a lambdoid bacteriophage, preferably a lambda or lambda-like bacteriophage, fused through said designed linker region, to a C-terminal region of a STF protein derived from a different bacteriophage. Such chimeric RBPs include those having an altered host range and/or biological activity such as, for example, depolymerase activity.

As used herein, lambdoid bacteriophages comprise a group of related viruses that infect bacteria. The viruses are termed lambdoid because one of the first members to be described was lambda (λ). Lambdoid bacteriophages are members of the Caudovirus order (also known as tailed bacteriophages) and include those bacteriophages with similar lifestyles, including, for example, the ability to recombine when intercrossed, possession of identical pairs of cohesive ends, and prophages that are inducible by ultraviolet irradiation. Although members of the order may have genomes that vary at the nucleotide level, they carry regions of sufficient nucleotide sequence identity to guide recombination between themselves, typically giving rise to a fully functional phage that has all the necessary genes. (See, for example, Casjens and Hendrix (2015) Virology 479-480:310-330). For purposes of the present disclosure, lambdoid bacteriophages for use as delivery vehicles, as well as lambdoid STF for use, would be understood generally by one skilled in the art.

Lambdoid phages can be defined as belonging to the lambda supercluster based on genomic analysis [9]. Within this supercluster, several clusters can be distinguished, each having a prototypical phage. The phage-like clusters and their members (between brackets) are: Lambda-like (lambda (λ), HK630, HK629), phi80-like (phi80, HK225, mEp237), N15-like (N15, PY54, phiKO2), HK97-like (HK97, HK022, HK75, HK106, HK140, HK446, HK542, HK544, HK633, mEpX1, mEpX2, mEp234, mEp235, mEp390, ENT39118), ES18-like (ES18, Oslo, SPN3UB), Gifsy-2-like (gifsy-2, gifsy-1, Fels-1, mEp043, mEp213, CP-1639, CTD-Iø, mEp640, FSL_SP-016), BP-4795-like (BP-4795, 2851, stx2-1717, YYZ-2008), SfV-like (SfV, SfII, SflV, SfI, øP27, ST64B), P22-like (P22, L, SPN9CC, ST64T, ST104, ST160, epsilon34, g341, SE1, Emek, φ20, IME10, Sf6, HK620, CUS-3, SPC-P1), APSE-1-like (APSE-1, APSE-2), 933W-like (933W, stx1ø, stx2ø-I, stx2ø-II, stx2-86, min27, ø24B, P13374, TL-2011c, VT2-sakai, VT2ø_272), HK639-like (HK639), øES15-like (øES15), HS2-like (HS2), ENT47970-like (ENT47670), ZF40-like (ZF40), øEt88-like (øEt88). Lambdoid phages further encompass any bacteriophage encoding a RBP having amino acids sequence homology of around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, or around 90% identity for 18 amino acids or more in one or more of three amino acids regions ranging from positions 1-150, 320-460, and 495-560 with reference to the lambda bacteriophage STF sequence SEQ ID NO: 8, independently of other amino acids sequences encoded by said bacteriophage.

In the present disclosure a lambdoid STF protein includes, for example, a protein comprising or consisting of an amino acid sequence with at least 75% identity up to an amino acid corresponding to amino acid 130 of lambda STF (Uniprot P03764 SEQ ID NO: 8), in particular up to amino acid 130 of said lambda STF.

In one aspect, the STF protein includes a protein that comprises or consists of an amino acid sequence with 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with the wild type lambda STF protein amino acid sequence of SEQ ID NO: 8, or with any of the chimeric STF proteins disclosed herein.

As used herein, the percent homology between two sequences is equivalent to the percent identity between the two sequences. The percent identity is calculated in relation to polymers (e.g., polynucleotide or polypeptide) whose sequences have been aligned. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = # of identical positions / total # of positions × 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a BLOSUM62 matrix, a BLOSUM30 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In a specific embodiment the BLOSUM30 matrix is used with gap open penalty of 12 and gap extension penalty of 4.

In the context of the present disclosure, said RBP derived from a bacteriophage (from which is derived the N-terminal region of the chimeric RBP) is resistant to proteolytic digestion as defined above, and said RBP derived from a different bacteriophage (from which is derived the C-terminal region of the chimeric RBP) is also resistant to proteolytic digestion as defined above. Indeed, as explained above, it is shown that, even if these “wild-type” RBPs are resistant to proteolytic digestion, using isolated regions from these stable RBPs to produce chimeras may lead to the production of a chimera which is not resistant to proteolytic digestion.

By “N-terminal region” of a STF protein from a bacteriophage is meant herein an amino acid region of said STF protein starting at the N-terminal end of said STF protein and ending at positions 80-150, 320-460 or 495-560 of said STF protein, said positions being with reference to the lambda bacteriophage STF sequence (SEQ ID NO: 8). By “C-terminal region” of a STF protein from a bacteriophage is meant herein an amino acid region of said STF protein starting at positions 25-150, 320-460 or 495-560 of said STF protein, said positions being with reference to the lambda bacteriophage STF sequence (SEQ ID NO: 8), and ending at the C-terminal end of said STF protein.

In a particular embodiment, the N-terminal region of a STF protein derived from a lambdoid bacteriophage corresponds to amino acids 1 to 528 of the lambda STF protein of sequence SEQ ID NO: 8.

In a particular embodiment, the C-terminal region of said STF protein derived from a different bacteriophage corresponds to amino acids 218 to 875 of the STF protein of sequence SEQ ID NO: 16.

In another particular embodiment, the C-terminal region of said STF protein derived from a different bacteriophage corresponds to amino acids 208 to 875 of the STF protein of sequence SEQ ID NO: 16.

In an alternative embodiment, the C-terminal region of said STF protein derived from a different bacteriophage corresponds to amino acids 28 to 632 of the STF protein of sequence SEQ ID NO: 12.

In an alternative embodiment, the C-terminal region of said STF protein derived from a different bacteriophage corresponds to amino acids 62 to 632 of the STF protein of sequence SEQ ID NO: 12.

In an embodiment, the chimeric STF protein comprises an N-terminal region of a STF protein derived from a lambdoid bacteriophage, preferably from a lambda or lambda-like bacteriophage, fused through said designed linker region to a C-terminal region of a different STF protein wherein said N-terminal region of the chimeric STF protein is fused to said C-terminal region of a different STF protein within one of the amino acids regions selected from positions 80-150, 320-460, or 495-560 of the N-terminal region with reference to the lambda bacteriophage STF sequence (SEQ ID NO: 8). In one aspect, the STF protein from the lambdoid bacteriophage, in particular from the lambda or lambda-like bacteriophage, and the STF protein derived from a different bacteriophage contain homology in one or more of three amino acids regions ranging from positions 80-150, 320-460, and 495-560 of the RBP with reference to the lambda bacteriophage STF sequence (SEQ ID NO: 8). In certain aspects, the homology is around 35% identity for 45 amino acids or more, around 50% identify for 30 amino acids or more, or around 90% identity for 18 amino acids or more within the one or more of three amino acids regions ranging from positions 80-150, 320-460, and 495-560 of the STF protein with reference to the lambda bacteriophage STF sequence. In one specific aspect, the C-terminal region of the chimeric STF protein is derived from a bacteriophage or a bacteriocin. In one aspect, the chimeric STF protein comprises an N-terminal region of a STF protein fused to a C-terminal region of a STF protein derived from a different bacteriophage within one of the amino acids regions selected from positions 80-150, 320-460, or 495-560 of the N-terminal STF region with reference to the lambda bacteriophage STF sequence (SEQ ID NO: 8).

In a particular embodiment, the chimeric RBP comprises an N-terminal region of a STF protein derived from a lambdoid bacteriophage, fused through a designed linker region consisting of 1 to 70 amino acids, more particularly of 1 to 30 amino acids, to a C-terminal region of a STF protein derived from a different bacteriophage, wherein said N-terminal region and C-terminal region are fused within a site of the N-terminal STF region, called insertion site, having at least 80%, 85%, 90%, 95%, 99% or 100% identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 1), ADAKKS (SEQ ID NO: 2), MDETNR (SEQ ID NO: 3), SASAAA (SEQ ID NO: 4), and GAGENS (SEQ ID NO: 5). In a particular embodiment, said insertion site has at least 80%, 85%, 90%, 95%, 99% or 100% identity with the site of sequence GAGENS (SEQ ID NO: 5).

In a particular embodiment, the chimeric RBP provided herein is an engineered branched receptor binding multi-subunit protein complex (“branched-RBP”). The engineered chimeric branched-RBP typically comprises two or more associated RBPs, derived from bacteriophages, which associate with one another based on the presence of interaction domains (IDs). The association of one subunit with another can be non-covalent or covalent. Each of the polypeptide subunits contain IDs that function as “anchors” for association of one subunit RBP with another. In specific embodiments, the chimeric branched-RBP may comprise multiple RBP subunits, including, for example, two, three, four, etc. subunits.

The individual RBP subunit may bring different biological functions to the overall engineered chimeric branched-RBP. Such functions include but are not limited to host recognition and enzymatic activity. Such enzymatic activity includes depolymerase activity. The two or more associated receptor binding proteins of the chimeric branched-RBP include, but are not limited to, chimeric RBPs described herein that comprise a fusion between the N-terminal region of a RBP derived from a lambdoid bacteriophage, in particular from a lambda or lambda-like bacteriophage, and the C-terminal region of a RBP derived from a different bacteriophage wherein said chimeric RBP further comprises an ID domain.

In an alternative embodiment, said chimeric RBP is a chimeric gpJ protein.

Designed Linker Region

By “designed linker region” is meant herein a region consisting of 1 to 70 amino acids, more particularly 1 to 65 amino acids, still particularly 1 to 60 amino acids, still particularly 1 to 55 amino acids, still particularly 1 to 50 amino acids, still particularly 1 to 45 amino acids, still particularly 1 to 40 amino acids, still particularly 1 to 35 amino acids, still particularly 1 to 30 amino acids, more particularly of 10 to 25 amino acids, or of 15 to 20 amino acids, in particular of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 or 70 amino acids, which links the N-terminal portion of the chimeric RBP and the C-terminal portion of the chimeric RBP.

In a particular embodiment, said designed linker region comprises the insertion site as defined above. In an alternative embodiment, said designed linker region is adjacent to the insertion site, as defined above. In a more particular embodiment, said designed linker region is at the C-terminal end of the insertion site as defined above. In other words, in that embodiment, the designed linker region starts at the amino acid directly following the last amino acid of the insertion site.

In a particular embodiment, said designed linker region is part of the N-terminal region or of the C-terminal region of the chimeric RBP. In a particular aspect of that embodiment, said N-terminal region or said C-terminal region of the chimeric RBP comprises the sequence of the linker region but said sequence has been specifically engineered (i.e. modified), compared to the corresponding wild-type sequence in the N-terminal region or C-terminal region of the RBP from which it is derived. Accordingly, in that particular aspect, when said designed linker region is part of the N-terminal region or of the C-terminal region of the chimeric RBP, the sequence of this designed linker region is not 100% identical to the sequence of the corresponding region in the N-terminal region of the RBP from which the N-terminal region of the chimeric RBP is derived or to the sequence of the corresponding region in the C-terminal region of the RBP from which the C-terminal region of the chimeric RBP is derived.

In a particular embodiment, said linker region is engineered in such a way as at least one amino acid of the linker region which is likely to be targeted by trypsin and/or chymotrypsin, as defined above, is mutated.

Accordingly, in a particular embodiment, at least one amino acid of the designed linker region, corresponding to an amino acid of the wildtype region sequence which is likely to be targeted by trypsin and/or chymotrypsin, is mutated compared to the wildtype region sequence.

In a particular embodiment said amino acid which is likely to be targeted to trypsin and/or chymotrypsin is selected from lysin (K), arginine (R), phenylalanine (F), tryptophan (W), tyrosine (Y) leucine (L) and methionine (M). In a particular embodiment, said amino acid is substituted by an alanine (A) or by any amino acid which is not lysin, arginine, phenylalanine, tryptophan, tyrosine, leucine or methionine, such as by an histidine (H).

In a particular embodiment, only one amino acid of the designed linker region is mutated. In an alternative embodiment, more than one amino acid of the designed linker region is mutated, in particular at least two or at least three amino acids of the designed linker region are mutated.

In a particular embodiment, said linker region is part of the C-terminal region of the chimeric RBP and said at least one amino acid is located within the 15 first amino acids of the linker region. In that embodiment, said at least one amino acid is in particular located within the 15 amino acids following the insertion site, as defined above.

In a particular embodiment, said chimeric RBP, typically including such designed linker region, comprises or consists of the sequence SEQ ID NO: 9 (herein called STF-V10-[FA]) or SEQ ID NO: 10 (herein called STF-V10-[AAH]).

In an alternative embodiment, said linker region is designed in such a way as it comprises a structure which is resistant to proteolytic digestion, and which thus typically restores the proteolytic digestion resistance of the chimeric RBP compared to a chimeric RBP which differs only by the absence of said linker region.

Therefore, In a particular aspect of the embodiment wherein said designed linker region is part of the N-terminal region or of the C-terminal region of the chimeric RBP, said N-terminal region or said C-terminal region of the chimeric RBP comprises the sequence of the linker region, preferably respectively at their C-terminal part or N-terminal part, said sequence being identical to the corresponding sequence in the N-terminal region or C-terminal region of the RBP from which it is derived, and said sequence restoring resistance to proteolytic digestion, as defined above, to said chimeric RBP compared to a chimeric RBP only differing by the absence of said linker region.

In other words, in that particular aspect, said designed linker region is part of the N-terminal region or of the C-terminal region of the chimeric RBP, and the sequence of this designed linker region has not been modified compared to the wild-type sequence in the N-terminal region or C-terminal region of the RBP from which it is derived, but has been specifically selected to be present, preferably at the C-terminal part of the N-terminal region or at the N-terminal part of the C-terminal region, compared to an N-terminal region or a C-terminal region not including it, because of its resistance to proteolytic digestion as defined above.

Alternatively, in a particular embodiment, said designed linker region comprises or consists of an heterologous amino acid sequence which is not derived from one of the RBP from which the N-terminal region and the C-terminal region of the chimeric RBP are derived. In a particular embodiment, said designed linker region comprises or consists of a sequence which is derived from a RBP which is not one of the RBP from which the N-terminal region and the C-terminal region of the chimeric RBP are derived.

In a particular embodiment, said designed linker region consists of 10 to 70 amino acids, in particular of 10 to 65 amino acids, of 10 to 64 amino acids, of 10 to 63 amino acids, of 10 to 62 amino acids, of 10 to 61 amino acids, of 10 to 60 amino acids, of 10 to 55 amino acids, of 10 to 50 amino acids, of 10 to 45 amino acids, of 10 to 40 amino acids, of 10 to 35 amino acids, of 10 to 30 amino acids, of 10 to 20 amino acids, in particular of 11 to 20 amino acids, or of 12 to 20 amino acids.

In a particular embodiment, said designed linker region comprises or consists of an amino acid sequence GSATDVMIQL (SEQ ID NO: 6) or GSATDVMIQLA (SEQ ID NO: 7), herein called helix sequence.

In a particular embodiment, said sequence is located within the 10 or 12 first amino acids of the designed linker region. In a more particular embodiment, said sequence is located directly after the insertion site, as defined above.

In a particular embodiment, said chimeric RBP, typically including such designed linker region, comprises or consists of the sequence SEQ ID NO: 11 (herein called STF-V10-[Helix]). In another embodiment, said chimeric RBP, typically including such designed linker region, comprises or consists of the sequence SEQ ID NO: 13 (herein called K5 5.0) or SEQ ID NO: 14 (herein called K5 5.1).

In a particular embodiment, said designed linker region comprises or consists of the amino acid sequence SEQ ID NO: 34 or SEQ ID NO: 36. In a particular embodiment, said sequence is located directly after the insertion site, as defined above. In a particular embodiment, said chimeric RBP, typically including such designed linker region, comprises or consists of the sequence SEQ ID NO: 38 (herein called K5 9.0) or SEQ ID NO: 40 (herein called K5 9.1).

In a particular embodiment, the designed linker region comprises a helix or helical bundle.

By “helical bundle” or “helix bundle” is meant herein a small protein fold composed of several alpha helices that are usually nearly parallel or antiparallel to each other.

By “helix” is meant herein a motif in the secondary structure of proteins.

The present disclosure also provides a nucleic acid encoding a chimeric RBP as defined above.

In a particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 9 and typically comprises or consists of the sequence SEQ ID NO: 17. In another particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 10 and typically comprises or consists of the sequence SEQ ID NO: 18. In another particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 11 and typically comprises or consists of the sequence SEQ ID NO: 19. In another particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 13 and typically comprises or consists of the sequence SEQ ID NO: 20. In another particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 14 and typically comprises or consists of the sequence SEQ ID NO: 21. In another particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 38 and typically comprises or consists of the sequence SEQ ID NO: 39. In another particular embodiment, said nucleic acid encodes a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 40 and typically comprises or consists of the sequence SEQ ID NO: 41.

Such nucleic acids may be included in vectors such as bacteriophages, plasmids, phagemids, phage-plasmids, viruses, and other vehicles which enable transfer and expression of the chimeric RBP encoding nucleic acids. The present disclosure thus also provides such a vector comprising a nucleic acid encoding a chimeric RBP as defined above, in particular comprising a nucleic acid encoding a chimeric RBP comprising or consisting of the sequence SEQ ID NO: 11 which typically comprises or consists of the sequence SEQ ID NO: 19.

Lambdoid Bacterial Delivery Vehicle

The present disclosure relates to a lambdoid bacterial delivery vehicle, typically for use in in vivo delivery of a DNA payload of interest into a targeted bacterial cell, wherein said lambdoid delivery vehicle comprises a chimeric RBP resistant to proteolytic digestion, in particular within the gastrointestinal tract, as defined in the section “Chimeric RBP” above.

The bacterial delivery vehicles provided herein enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell.

Delivery Vehicle

As used herein, the term “delivery vehicle” refers to any means that allows the transfer of a payload into a bacterium. There are several types of delivery vehicles encompassed by the present disclosure including, without limitation, bacteriophage scaffold, virus scaffold, chemical based delivery vehicle (e.g., cyclodextrin, calcium phosphate, cationic polymers, cationic liposomes), protein-based or peptide-based delivery vehicle, lipid-based delivery vehicle, nanoparticle-based delivery vehicles, non-chemical-based delivery vehicles (e.g., transformation, electroporation, sonoporation, optical transfection), particle-based delivery vehicles (e.g., gene gun, magnetofection, impalefection, particle bombardment, cell-penetrating peptides) or donor bacteria (conjugation). Any combination of delivery vehicles is also encompassed by the present disclosure. The delivery vehicle can refer to a bacteriophage derived scaffold and can be obtained from a natural, evolved or engineered capsid.

The bacterial delivery vehicles provided herein which enable transfer of a nucleic acid payload, encoding a protein or nucleic acid of interest, into a desired target bacterial host cell are characterized by having a chimeric RBP resistant to proteolytic digestion, in particular within the gastrointestinal tract, as defined in the section “Chimeric RBP” above.

In a particular embodiment, said chimeric RBP is a chimeric STF protein as defined in the section “Chimeric RBP” above. In a particular embodiment, said chimeric STF protein is a functional STF protein.

As used herein, a functional protein means in general a protein with a biological activity; more specifically a functional chimeric protein relates to a chimeric protein contributing to the efficient delivery of a DNA payload into a target strain. The efficiency threshold depends on a number of factors such as the type of protein, type of target strain and type of environment. For instance, STF and gpJ proteins allow for recognition, binding (and in some cases also degradation) of an extracellular epitope such as LPS, capsules and outer membrane proteins; gpH proteins allow for an efficient injection and hence successful passage of the DNA payload through the periplasm.

In some embodiments, the bacterial delivery vehicles disclosed herein further comprise the corresponding natural chaperone proteins (designated “accessory proteins” or “AP”) of the chimeric RBPs. Such AP proteins assist in the folding of the chimeric RBPs.

In a particular embodiment, the chimeric STF protein has enzyme activity such as depolymerase activity and the bacterial cell population of interest comprises encapsulated bacteria.

Bacterial delivery vehicles are also provided that further comprise recombinant gpJ proteins. Such gpJ proteins include recombinant gpJ proteins, including chimeric proteins as defined in the section “Chimeric RBP” above, that permit recognition of a bacterial cell receptor other than the LamB OMP receptor. It is known that receptor-recognition activity of gpJ lies in the C-terminal part of the protein, with a fragment as small as 249 amino acids conferring capability of binding to the LamB receptor [10]. In a particular embodiment, such chimeric gpJ protein may comprise a fusion between the N-terminal region of a gpJ protein from a lambdoid bacteriophage, in particular from a lambda or lambda-like bacteriophage, and the C-terminal region of a different gpJ protein.

By “N-terminal region” of a gpJ protein from a bacteriophage is meant herein an amino acid region of said gpJ protein starting at the N-terminal end of said gpJ protein and ending at positions 810-825 or 950-970 of said gpJ protein, said positions being with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22). By “C-terminal region” of a gpJ protein from a bacteriophage is meant herein an amino acid region of said gpJ protein starting at positions 810-825 or 950-970 of said gpJ protein, said positions being with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22), and ending at the C-terminal end of said gpJ protein.

For production of chimeric gpJ proteins, two insertion points, located respectively at positions corresponding to amino acids 814-821 and 958-966 of the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22) have previously been identified by the inventors. In non-limiting aspects, such insertion sites may be utilized for production of chimeric proteins. Both insertion points yield functional gpJ chimeras with altered receptor binding. In an embodiment, the bacterial delivery vehicles contain a chimeric gpJ protein comprising a fusion between an N-terminal region of a gpJ protein derived from a lambdoid bacteriophage, in particular from a lambda or lambda-like bacteriophage, and a C-terminal region of a different gpJ protein wherein said N-terminal region of the chimeric gpJ protein is fused to said C-terminal region of a different gpJ protein within one of the amino acids regions selected from positions 810-825, or 950-970 of the N-terminal region with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22).

In a specific embodiment, the chimeric gpJ protein comprises a fusion between the N-terminal region of a lambda bacteriophage gpJ protein and the C-terminal region of a gpJ protein from a different bacteriophage, which typically recognizes and binds OmpC, said N-terminal region being in particular fused to said C-terminal region within the amino acid region 950-970 of the N-terminal region with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22). In said embodiment, the chimeric gpJ variant may be H591 comprising or consisting of the amino acid sequence SEQ ID NO: 23 and typically encoded by the nucleotide sequence SEQ ID NO: 24, said H591 chimeric gpJ variant typically recognizing and binding OmpC. In another embodiment, the chimeric gpJ protein comprises a fusion between the N-terminal region of a lambda bacteriophage gpJ protein and the C-terminal region of a gpJ protein from a different bacteriophage, which typically recognizes a receptor present in O157 strains, said N-terminal region being in particular fused to said C-terminal region within the amino acid region 810-825 of the N-terminal region with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22). In said embodiment, the chimeric gpJ variant may be Z2145 comprising or consisting of the amino acid sequence SEQ ID NO: 25 and typically encoded by the nucleotide sequence SEQ ID NO: 26, said Z2145 chimeric gpJ variant typically recognizing a receptor present in 0157 strains. In still another embodiment, the chimeric gpJ protein comprises a fusion between the N-terminal region of a lambda bacteriophage gpJ protein and the C-terminal region of a gpJ protein from a different bacteriophage, which typically recognizes the OmpC receptor present in O157 strains, said N-terminal region being in particular fused to said C-terminal region within the amino acid region 950-970 of the N-terminal region with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22). In said embodiment, the chimeric gpJ variant may be the “1A2” variant comprising or consisting of the of amino acid sequence SEQ ID NO: 27 and typically encoded by the nucleotide sequence SEQ ID NO: 28, said 1A2 chimeric gpJ variant typically recognizing the OmpC receptor present in O157 strains. In still another embodiment, the chimeric gpJ protein comprises a fusion between the N-terminal region of a lambda bacteriophage gpJ protein and the C-terminal region of a gpJ protein from a different bacteriophage, which typically recognizes the OmpC receptor present in both 0157 and MG1655 strains, said N-terminal region being in particular fused to said C-terminal region within the amino acid region 950-970 of the N-terminal region with reference to the lambda bacteriophage gpJ protein sequence (SEQ ID NO: 22). In said embodiment, the chimeric gpJ variant may be the “A8” variant comprising or consisting of the amino acid sequence SEQ ID NO: 29 and typically encoded by the nucleotide sequence SEQ ID NO: 30, said A8 chimeric gpJ variant typically recognizing the OmpC receptor in both 0157 and MG1655 strains.

Bacterial delivery vehicles are also provided that further comprise recombinant gpH proteins. Such gpH proteins include recombinant gpH proteins that permit or allow improved entry of bacterial vectors in cells having deficiencies or alterations in permease complexes. One such variant is the “gpH-IAI” variant of amino acid sequence SEQ ID NO: 31.

In a particular embodiment, said bacterial delivery vehicle comprises chimeric STF of sequence SEQ ID NO: 11 and chimeric gpJ variant of sequence SEQ ID NO: 27.

In a particular embodiment, the lambdoid delivery vehicle as disclosed above further comprises a functional lambdoid bacteriophage gpJ protein, as defined above, and/or a functional lambdoid bacteriophage gpH protein, as defined above.

In aspects, the bacterial delivery vehicles provided herein, are vehicles wherein the one or more of the chimeric STF protein, the gpJ protein and/or the gpH protein are further engineered to increase the efficiency of transfer of the DNA payload into the targeted bacterial cell population. Such bacterial cell populations include for example E. coli. and other bacterial species of interest.

In a particular embodiment, the delivery vehicle is incapable of self-reproduction.

In the context of the present invention, “self-reproduction” is different from “self-replication”, “self-replication” referring to the capability of replicating a nucleic acid, whereas “self-reproduction” refers to the capability of having a progeny, in particular of producing new delivery vehicles, said delivery vehicles being either produced empty or with a nucleic acid of interest packaged.

By “delivery vehicle incapable of self-reproduction” is meant herein that at least one, several or all functional gene(s) necessary to produce said delivery vehicle is(are) absent from said delivery vehicle (and from said vector included in said delivery vehicle). In a preferred embodiment, said at least one, several or all functional gene(s) necessary to produce said delivery vehicle is(are) present in the donor cell as defined above, preferably in a plasmid, in the chromosome or in a helper phage present in the donor cell as defined below, enabling the production of said delivery vehicle in said donor cell.

In the context of the invention, said functional gene(s) necessary to produce said delivery vehicle may be absent through (i) the absence of the corresponding gene or (ii) the presence of the corresponding gene but in a non-functional form.

In an embodiment, the sequence of said gene necessary to produce said delivery vehicle is absent from said delivery vehicle. In a preferred embodiment, the sequence of said gene necessary to produce said delivery vehicle has been replaced by a nucleic acid sequence of interest.

Alternatively, said gene necessary to produce said delivery vehicle is present in said delivery vehicle in a non-functional form, for example in a mutant non-functional form, or in a non-expressible form, for example with deleted or mutated non-functional regulators. In a preferred embodiment, said gene necessary to produce said delivery vehicle is present in said delivery vehicle in a mutated form which renders it non-functional in the target cell, while remaining functional in the donor cell.

In the context of the invention, genes necessary to produce said delivery vehicle encompass any coding or non-coding nucleic acid required for the production of said delivery vehicle.

Examples of genes necessary to produce said delivery vehicle include genes encoding phage structural proteins; phage genes involved in the control of genetic expression; phage genes involved in transcription and/or translation regulation; phage genes involved in phage DNA replication; phage genes involved in production of phage proteins; phage genes involved in phage proteins folding; phage genes involved in phage DNA packaging; and phage genes encoding proteins involved in bacterial cell lysis.

Packaged Phagemids

Delivery vehicles include packaged phagemids, as well as bacteriophage, as disclosed herein. An eligobiotic® is a packaged phagemid, i.e a payload encapsidated in a phage-derived capsid. The engineering of such delivery vehicles is well known to those skilled in the art. Such engineering techniques may employ production cell lines engineered to express the STF, gpJ and gpH proteins disclosed herein. The present disclosure thus also provides a production cell line expressing the chimeric RBPs provided herein.

In one aspect, bacterial delivery vehicles with desired target host ranges are provided for use in transfer of a payload to the microbiome of a host. The bacterial delivery vehicles may be characterized by combinations of chimeric STF, and wild-type and engineered gpJ and gpH proteins.

Generation of packaged phagemids and bacteriophage particles are routine techniques well-known to one skilled in the art. In an embodiment, a satellite phage and/or helper phage may be used to promote the packaging of the payload in the delivery vehicles disclosed herein. Helper phages provide functions in trans and are well known to the man skilled in the art. The helper phage comprises all the genes coding for the structural and functional proteins that are indispensable for the payload to be packaged, (i.e. the helper phage provides all the necessary gene products for the assembly of the delivery vehicle). The helper phage may contain a defective origin of replication or packaging signal, or completely lack the latter, and hence it is incapable of self-packaging, thus only bacterial delivery particles carrying the payload or plasmid will be produced. Helper phages may be chosen so that they cannot induce lysis of the host used for the delivery particle production. One skilled in the art would understand that some bacteriophages are defective and need a helper phage for payload packaging. Thus, depending on the bacteriophage chosen to prepare the bacterial delivery particles, the person skilled in the art would know if a helper phage is required. Sequences coding for one or more proteins or regulatory processes necessary for the assembly or production of packaged payloads may be supplied in trans. For example, the STF, gpJ and gpH proteins of the present disclosure may be provided in a plasmid under the control of an inducible promoter or expressed constitutively. In this case, the phage wild-type sequence may or not contain a deletion of the gene or sequence supplied in trans. Additionally, chimeric or modified phage sequences encoding a new function, like an engineered STF, gpJ or gpH protein, may be directly inserted into the desired position in the genome of the helper phage, hence bypassing the necessity of providing the modified sequence in trans. Methods for both supplying a sequence or protein in trans in the form of a plasmid, as well as methods to generate direct genomic insertions, modifications and mutations are well known to those skilled in the art.

In a particular embodiment, said helper phage comprises a nucleic acid sequence encoding the chimeric RBP comprising or consisting of the sequence SEQ ID NO: 11, said nucleic acid sequence typically comprising or consisting of the sequence SEQ ID NO: 19, and said helper phage optionally further comprises a nucleic acid sequence encoding the chimeric gpJ variant comprising or consisting of the sequence SEQ ID NO: 27, said nucleic acid sequence typically comprising or consisting of the sequence SEQ ID NO: 28.

In a particular embodiment, said helper phage is a lambda prophage wherein (i) the nucleic acid encoding a wild-type STF protein has been replaced by a nucleic acid sequence encoding the chimeric RBP comprising or consisting of the sequence SEQ ID NO: 11, said nucleic acid sequence typically comprising or consisting of the sequence SEQ ID NO: 19, (ii) the nucleic acid encoding a wild-type gpJ protein has been replaced by a nucleic acid sequence encoding the chimeric gpJ variant comprising or consisting of the sequence SEQ ID NO: 27, said nucleic acid sequence typically comprising or consisting of the sequence SEQ ID NO: 28, and (iii) the Cos site has been removed, and wherein optionally (iv) the helper prophage contains a mutation which prevents spontaneous cell lysis, such as the Sam7 mutation and (v) the helper prophage contains a thermosensitive version of the master cI repressor, such as the cI857 version.

Another object of the disclosure thus also concerns providing a production cell line, as defined above, comprising a helper phage as defined above.

In a particular embodiment, said bacterial delivery vehicle comprises said DNA payload of interest.

Payload

As used herein, the term “payload” refers to any nucleic acid sequence or amino acid sequence, or a combination of both (such as, without limitation, peptide nucleic acid or peptide-oligonucleotide conjugate) transferred into a bacterium with a delivery vehicle. The term “payload” may also refer to a plasmid, a vector or a cargo. The payload can be a phagemid or phasmid obtained from natural, evolved or engineered bacteriophage genome. The payload can also be composed only in part of phagemid or phasmid obtained from natural, evolved or engineered bacteriophage genome.

In a particular embodiment, the payload has a size superior or equal to 4 kbp, and preferably inferior or equal to 51 kb.

In said embodiment, the payload may have a size, an integer multiple of which is between 36 kb and 51 kb. In other words, in that embodiment, there is at least an integer n, such as 36 kb ≤ n × size of the payload ≤ 51 kb .

As described herein it is more particularly demonstrated that it is possible to produce a more uniform population of bacterial delivery vehicles comprising an almost unique number of payload copies when said payload has a size of a specific range.

In a particular embodiment, the payload has a size strictly superior to 10.000 kb and strictly inferior to 12.000 kb. In an alternative embodiment, the payload has a size strictly superior to 12.500 kb and strictly inferior to 16.667 kb, in particular a size strictly superior to 12.500 kb and inferior to 13.000 kb.

In another particular embodiment, the payload has a size superior or equal to 18.000 kb and inferior or equal to 25.000 kb, in particular inferior or equal to 24.000 kb.

In a particular embodiment, said payload has a size of 11.6 kb.

The payload may be a nucleic acid plasmid that is able to circularize upon transfer into the target cell and then either replicate or integrate inside the chromosome. Replication of the vector DNA is dependent on the presence of a bacterial origin of replication. Once replicated, inheritance of the plasmid into each of the daughter cells can be mediated by the presence of an active partitioning mechanism and a plasmid addiction system such as toxin/anti-toxin system.

As used herein, the term “nucleic acid” refers to a sequence of at least two nucleotides covalently linked together which can be single-stranded or double-stranded or contains portion(s) of both single-stranded and double-stranded sequence. Nucleic acids can be naturally occurring, recombinant or synthetic. The nucleic acid can be in the form of a circular sequence or a linear sequence or a combination of both forms. The nucleic acid can be DNA, both genomic or cDNA, or RNA or a combination of both. The nucleic acid may contain any combination of deoxyribonucleotides and ribonucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, 5-hydroxymethylcytosine and isoguanine. Other examples of modified bases that can be used are detailed in Chemical Reviews 2016, 116 (20) 12655-12687. The term “nucleic acid” also encompasses any nucleic acid analogs which may contain other backbones comprising, without limitation, phosphoramide, phosphorothioate, phosphorodithioate, O-methylphosphoroamidite linkage and/or deoxyribonucleotides and ribonucleotides nucleic acids. Any combination of the above features of a nucleic acid is also encompassed by the present disclosure.

Origins of replication known in the art have been identified from species-specific plasmid DNAs (e.g. ColE1, R1, pT181, pSC101, pMB1, R6K, RK2, p15a and the like), from bacterial virus (e.g. φX174, M13, F1 and P4) and from bacterial chromosomal origins of replication (e.g. oriC). In one embodiment, the phagemid according to the disclosure comprises a bacterial origin of replication that is functional in the targeted bacteria.

Alternatively, the plasmid according to the disclosure does not comprise any functional bacterial origin of replication or contain an origin of replication that is inactive in the targeted bacteria. Thus, the plasmid of the disclosure cannot replicate by itself once it has been introduced into a bacterium by the bacterial virus particle.

In one embodiment, the origin of replication on the plasmid to be packaged is inactive in the targeted bacteria, meaning that this origin of replication is not functional in the bacteria targeted by the bacterial virus particles, thus preventing unwanted plasmid replication.

In one embodiment, the plasmid comprises a bacterial origin of replication that is functional in the bacteria used for the production of the bacterial virus particles.

Plasmid replication depends on host enzymes and on plasmid-controlled cis and trans determinants. For example, some plasmids have determinants that are recognized in almost all gram-negative bacteria and act correctly in each host during replication initiation and regulation. Other plasmids possess this ability only in some bacteria (Kues, U and Stahl, U 1989 Microbiol Rev 53:491-516).

Plasmids are replicated by three general mechanisms, namely theta type, strand displacement, and rolling circle (reviewed by Del Solar et al. 1998 Microhio and Molec Biol. Rev 62:434-464) that start at the origin of replication. These replication origins contain sites that are required for interactions of plasmid and/or host encoded proteins.

Origins of replication used on the plasmid of the disclosure may be of moderate copy number, such as colEl ori from pBR322 (15-20 copies per cell) or the R6K plasmid (15-20 copies per cell) or may be high copy number, e.g. pUC oris (500-700 copies per cell), pGEM oris (300-400 copies per cell), pTZ oris (>1000 copies per cell) or pBluescript oris (300-500 copies per cell).

In one embodiment, the bacterial origin of replication is selected in the group consisting of ColE1, pMB1 and variants (pBR322, pET, pUC, etc), p15a, ColA, ColE2, pOSAK, pSC101, R6K, IncW (pSa etc), IncFII, pT181, P1, F IncP, IncC, IncJ, IncN, IncP1, IncP4, IncQ, IncH11, RSF1010, CloDF13, NTP16, R1, f5, pPS10, pC194, pE194, BBR1, pBC1, pEP2, pWVO1, pLF1311, pAP1, pWKS1, pLS1, pLS11, pUB6060, pJD4, pIJ101, pSN22, pAMbeta1, pIP501, pIP407, ZM6100(Sa), pCU1, RA3, pMOL98, RK2/RP4/RP1/R68, pB10, R300B, pRO1614, pRO1600, pECB2, pCM1, pFA3, RepFIA, RepFIB, RepFIC, pYVE439-80, R387, phasyl, RA1, TF-FC2, pMV158 and pUB113.

In an embodiment, the bacterial origin of replication is a E.coli origin of replication selected in the group consisting of ColE1, pMB1 and variants (pBR322, pET, pUC, etc), p15a, ColA, ColE2, pOSAK, pSC101, R6K, IncW (pSaetc), IncFII, pT181, P1, F IncP, IncC, IncJ, IncN, IncP1, IncP4, IncQ, IncH11, RSF1010, CloDF13, NTP16, R1, f5 and pPS10.

In an embodiment, the bacterial origin of replication is selected in the group consisting of pC194, pE194, BBR1, pBC1, pEP2, pWVO1, pLF1311, pAP1, pWKS1, pLS1, pLS11, pUB6060, pJD4, pIJ101, pSN22, pAMbeta1, pIP501, pIP407, ZM6100(Sa), pCU1, RA3, pMOL98, RK2/RP4/RP1/R68, pB10, R300B, pRO1614, pRO1600, pECB2, pCM1, pFA3, RepFIA, RepFIB, RepFIC, pYVE439-80, R387, phasyl, RA1, TF-FC2, pMV158 and pUB113.

In an embodiment, the bacterial origin of replication is ColE1.

The delivered nucleic acid sequence according to the disclosure may comprise a phage replication origin which can initiate, with complementation of a complete phage genome, the replication of the delivered nucleic acid sequence for later encapsulation into the different capsids.

A phage origin of replication comprised in the delivered nucleic acid sequence of the disclosure can be any origin of replication found in a phage.

In an embodiment, the phage origin of replication can be the wild-type or non-wildtype sequence of the M13, fl, φX174, P4, lambda, P2, lambda-like, HK022, mEP237, HK97, HK629, HK630, mEP043, mEP213, mEP234, mEP390, mEP460, mEPx1, mEPx2, phi80, mEP234, T2, T4, T5, T7, RB49, phiX174, R17, PRD1 Pl-like, P2-like, P22, P22-like, N15 and N15-like bacteriophages.

In an embodiment, the phage origin of replication is selected in the group consisting of phage origins of replication of M13, fl, φX174, P4, and lambda.

In a particular embodiment, the phage origin of replication is the lambda or P4 origin of replication. In a particular embodiment, the phage origin of replication is from Propionibacterium phages: BW-like phages such as Doucette, B22, E6, G4, BV-like phages such as Anatole, E1, B3, BX-like phages such as PFR1 and PFR2, filamentous B5 phage, BU-like phages (Cutibacterium acnes phages).

In a particular embodiment, the payload or vector comprises a conditional origin of replication which is inactive in the targeted bacteria but is active in a donor bacterial cell.

In the context of the invention, a “conditional origin of replication” refers to an origin of replication whose functionality may be controlled by the presence of a specific molecule.

In a particular embodiment, the conditional origin of replication is an origin of replication, the replication of which depends upon the presence of one or more given protein, peptid, RNA, nucleic acid, molecule or any combination thereof.

In a particular embodiment, the replication of said origin of replication may further depend on a process, such as transcription, to activate said replication.

In the context of the invention, said conditional origin of replication is inactive in the targeted bacteria because of the absence of said given protein, peptid, RNA, nucleic acid, molecule or any combination thereof in said targeted bacteria.

In a particular embodiment, said conditional origin of replication is active in said donor bacterial cell because said donor bacterial cell expresses said given protein, peptid, RNA, nucleic acid, molecule or any combination thereof. In a particular embodiment, said protein, peptid, RNA nucleic acid, molecule or any combination thereof is expressed in trans in said donor bacterial cell.

By “in trans” is meant herein that said protein, peptid, RNA, nucleic acid, molecule or any combination thereof is not encoded on the same nucleic acid molecule as the one comprising the origin of replication. In a particular embodiment, said protein, peptid, RNA, nucleic acid, molecule or any combination thereof is encoded on a chromosome or on a vector, in particular a plasmid. In a particular embodiment, said vector comprises an antibiotic resistance marker. In an alternative embodiment, said vector is devoid of antibiotic resistance marker.

Since said conditional origin of replication is inactive in the targeted bacteria because of the absence of said given protein, peptid, RNA, nucleic acid, molecule or any combination thereof in said targeted bacteria, said conditional origin of replication may be selected depending on the specific bacteria to be targeted.

The conditional origin of replication disclosed herein may originate from plasmids, bacteriophages or PICIs which preferably share the following characteristics: they contain in their origin of replication repeat sequences, or iterons, and they code for at least one protein interacting with said origin of replication (i.e. Rep, protein O, protein P, pri) which is specific to them.

By way of example, mention may be made of the conditional replication systems of the following plasmids and bacteriophages: RK2, R1, pSC101, F, Rts1, RSF1010, P1, P4, lambda, phi82, phi80.

In a particular embodiment, said conditional origin of replication is selected from the group consisting of the R6Kλ, DNA replication origin and derivatives thereof, the IncPα oriV origin of replication and derivatives thereof, ColE1 origins of replication modified to be under an inducible promoter, and origins of replication from phage-inducible chromosomal islands (PICIs) and derivatives thereof.

In a particular embodiment, said conditional origin of replication is an origin of replication present in less than 50%, or less than 40%, less than 30%, less than 20%, less than 10% or less than 5% of the bacteria of the host microbiome.

In another particular embodiment, said conditional origin of replication comprises or consists of a sequence less than 80% identical, in particular less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5% or less than 1% identical to the sequences of the origins of replication of the bacteria of the host microbiome, in particular of the bacteria representing more than 50%, more particularly more than 60%, more than 70%, more than 80%, more than 90% or more than 95% of the host microbiome.

As used herein, the term “phage-inducible chromosomal islands” or “PICIs” refers to mobile genetic elements having a conserved gene organization, and encode a pair of divergent regulatory genes, including a PICI master repressor. Typically, in Gram-positive bacteria, left of rpr, and transcribed in the same direction, PICIs encode a small set of genes including an integrase (int) gene; right of rpr, and transcribed in the opposite direction, the PICIs encode an excision function (xis), and a replication module consisting of a primase homolog (pri) and optionally a replication initiator (rep), which are sometimes fused, followed by a replication origin (ori), next to these genes, and also transcribed in the same direction, PICIs encode genes involved in phage interference, and optionally, a terminase small subunit homolog (terS).

In a particular embodiment, said conditional origin of replication is an origin of replication derived from phage-inducible chromosomal islands (PICIs).

A particular conditional origin of replication has indeed been derived from PICIs.

It was shown that it is possible to derive novel conditionally replicative vectors or payloads, in particular based on the primase-helicase and origin of replication from PICIs. These origins may be relatively rare in target strains, and more advantageously the primase-ori pair may be unique for each PICI, significantly reducing the possibility of undesired recombination or payload spread events. They can further be modified to further limit recombination chances and remove restriction sites to bypass target bacteria defense systems.

In a particular embodiment, said conditional origin of replication is derived from the origin of replication from the PICI of the Escherichia coli strain CFT073, disclosed in Fillol-Salom et al. (2018) The ISME Journal 12:2114-2128.

In a particular embodiment, said conditional origin of replication is the primase ori from the PICI of the Escherichia coli strain CFT073, typically of sequence SEQ ID NO: 46.

In another particular embodiment, said conditional origin of replication is the primase ori from the PICI of the Escherichia coli strain CFT073, devoid of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 restriction site(s) selected from the group consisting of GAAABCC, GCCGGC, RCCGGY, GCNGC, TWCANNNNNNTGG (SEQ ID NO: 47), TGGCCA, ACCYAC, YGGCCR, AGACC, GCWGC, GGGANGC, GKAGATD, GCCGGYYD, GGCYAC, RGCCGGYYD, and VGCCGGYBD.

In a particular embodiment, said conditional origin of replication is the primase ori from the PICI of the Escherichia coli strain CFT073, devoid of the restriction site GAAABCC.

Preferably, said conditional origin of replication is of sequence SEQ ID NO: 48.

In another particular embodiment, said conditional origin of replication is the primase ori from the PICI of the Escherichia coli strain CFT073 devoid of the restriction sites GAAABCC, GCCGGC, RCCGGY, GCNGC, TWCANNNNNNTGG (SEQ ID NO: 47), TGGCCA, ACCYAC, YGGCCR, AGACC, GCWGC, GGGANGC, GKAGATD, GCCGGYYD, GGCYAC, RGCCGGYYD, and VGCCGGYBD. Preferably, said conditional origin of replication is of sequence SEQ ID NO: 49.

In a particular embodiment, wherein said origin of replication is derived from phage-inducible chromosomal islands (PICIs), said conditional origin of replication is active in said donor bacterial cell because said donor bacterial cell expresses a rep protein, in particular a primase-helicase, in particular a primase-helicase of sequence SEQ ID NO: 50, typically encoded by a nucleic acid comprising or consisting of the sequence SEQ ID NO: 51.

It was demonstrated that these specific conditional origins of replication were particularly compatible with lambda-based packaging, leading to sufficiently high titers (>10¹⁰ /mL) required for microbiota-related applications.

In a particular embodiment, when said payload or vector is a phagemid, said origin of replication may be derived from a microorganism which is different from the one that is used to encode the structural elements of the capsid packaging said phagemid.

By “donor bacterial cell” is meant herein a bacterium that is capable of hosting a payload or vector as defined above, of producing a payload or vector as defined above and/or which is capable of transferring said payload or vector as defined above to another bacterium. In a particular embodiment, said payload or vector may be a phagemid, and said donor bacterial cell may then be a bacterial cell able to produce said phagemid, more particularly in the form of a packaged phagemid.

Preferably, said donor bacterial cell stably comprises said payload or vector and is able to replicate said payload or vector.

In a particular embodiment, when the conditional origin of replication of said payload or vector is an origin of replication, the replication of which depends upon the presence of a given protein, peptid, nucleic acid, RNA, molecule or any combination thereof, said donor bacterial cell expresses said protein, peptid, nucleic acid, RNA, molecule or any combination thereof.

Preferably, said protein, peptid, nucleic acid, RNA, molecule or any combination thereof is expressed in trans, as defined above.

In a particular embodiment, said donor bacterial cell stably comprises a nucleic acid encoding said protein, peptid, nucleic acid, RNA, molecule or any combination thereof.

In a particular embodiment, when said origin of replication is derived from phage-inducible chromosomal islands (PICIs), said conditional origin of replication is active in said donor bacterial cell because said donor bacterial cell expresses a rep protein, in particular a primase-helicase, in particular a primase-helicase of sequence SEQ ID NO: 50.

In a particular embodiment, said donor bacterial cell stably comprises a nucleic acid encoding said rep protein, in particular said primase-helicase, said nucleic acid typically comprising or consisting of the sequence SEQ ID NO: 51.

In a particular embodiment, said donor bacterial cell is a production cell line, in particular a cell line producing packaged phagemids including the payload or vector of the invention.

The delivered nucleic acid of interest preferably comprises a nucleic acid sequence under the control of a promoter. In certain embodiments, the nucleic acid of interest is selected from the group consisting of a Cas nuclease gene, a Cas9 nuclease gene, a guide RNA, a CRISPR locus, a toxin gene, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, a gene expressing resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor, and a gene expressing a virulence protein or a virulence factor, and any of their combination. In an embodiment, the nucleic acid payload encodes a therapeutic protein. In another embodiment, the nucleic acid payload encodes an antisense nucleic acid molecule.

In one embodiment, the sequence of interest is a programmable nuclease circuit to be delivered to the targeted bacteria. This programmable nuclease circuit is able to mediate in vivo sequence-specific elimination of bacteria that contain a target gene of interest (e.g. a gene that is harmful to humans). Some embodiments of the present disclosure relate to engineered variants of the Type II CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated) system of Streptococcus pyogenes. Other programmable nucleases that can be used include other CRISPR-Cas systems, engineered TALEN (Transcription Activator-Like Effector Nuclease) variants, engineered zinc finger nuclease (ZFN) variants, natural, evolved or engineered meganuclease or recombinase variants, and any combination or hybrids of programmable nucleases. Thus, the engineered autonomously distributed nuclease circuits provided herein may be used to selectively cleave DNA encoding a gene of interest such as, for example, a toxin gene, a virulence factor gene, an antibiotic resistance gene, a remodeling gene or a modulatory gene (cf. WO2014124226).

Other sequences of interest, such as programmable sequences, can be added to the delivered nucleic acid sequence so as to be delivered to targeted bacteria. In an embodiment, the sequence of interest added to the delivered nucleic acid sequence leads to cell death of the targeted bacteria. For example, the nucleic acid sequence of interest added to the plasmid may encode holins or toxins.

Alternatively, the sequence of interest circuit added to the delivered nucleic acid sequence does not lead to bacteria death. For example, the sequence of interest may encode reporter genes leading to a luminescence or fluorescence signal. Alternatively, the sequence of interest may comprise proteins and enzymes achieving a useful function such as modifying the metabolism of the bacteria or the composition of its environment.

In a particular embodiment, the nucleic acid of interest is selected from the group consisting of Cas9, a single guide RNA (sgRNA), a CRISPR locus, a gene expressing an enzyme such as a nuclease or a kinase, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, resistance to an antibiotic or to a drug in general, a gene expressing a toxic protein or a toxic factor and a gene expressing a virulence protein or a virulence factor and any of their combination.

In a particular embodiment, the nucleic acid of interest is a gene expressing a nuclease. More particularly, the nuclease may target cleavage of a host bacterial cell chromosome or a host bacterial cell plasmid. In a more particular embodiment, the cleavage may occur in an antibiotic resistant gene.

In a particular embodiment, the delivered nucleic acid sequence according to the disclosure comprises a nucleic acid sequence of interest that encodes a bacteriocin, which can be a proteinaceous toxin produced by bacteria to kill or inhibit growth of other bacteria. Bacteriocins are categorized in several ways, including producing strain, common resistance mechanisms, and mechanism of killing. Such bacteriocin had been described from gram negative bacteria (e.g. microcins, colicin-like bacteriocins and tailocins) and from gram positive bacteria (e.g. Class I, Class II, Class III or Class IV bacteriocins).

In one embodiment, the delivered nucleic acid sequence according to the disclosure further comprises a sequence of interest encoding a toxin selected in the group consisting of microcins, colicin-like bacteriocins, tailocins, Class I, Class II, Class III and Class IV bacteriocins.

In a particular embodiment, the corresponding immunity polypeptide (i. e. anti-toxin) may be used to protect bacterial cells (see review by Cotter et al., Nature Reviews Microbiology 11: 95, 2013, which is hereby incorporated by reference in its entirety) for delivered nucleic acid sequence production and encapsidation purpose but is absent in the pharmaceutical composition and in the targeted bacteria in which the delivered nucleic acid sequence of the disclosure is delivered.

In one aspect of the disclosure, the CRISPR system is included in the delivered nucleic acid sequence. The CRISPR system contains two distinct elements, i.e. i) an endonuclease, in this case the CRISPR associated nuclease (Cas or “CRISPR associated protein”) and ii) a guide RNA. The guide RNA is in the form of a chimeric RNA which consists of the combination of a CRISPR (RNAcr) bacterial RNA and a RNAtracr (trans-activating RNA CRISPR) (Jinek et al., Science 2012). The guide RNA combines the targeting specificity of the RNAcr corresponding to the “spacing sequences” that serve as guides to the Cas proteins, and the conformational properties of the RNAtracr in a single transcript. When the guide RNA and the Cas protein are expressed simultaneously in the cell, the target genomic sequence can be permanently modified or interrupted. The modification is advantageously guided by a repair matrix. In general, the CRISPR system includes two main classes depending on the nuclease mechanism of action. Class 1 is made of multi-subunit effector complexes and includes type I, III and IV. Class 2 is made of single-unit effector modules, like Cas9 nuclease, and includes type II (II-A,II-B,II-C,II-C variant), V (V-A,V-B,V-C,V-D,V-E,V-U1,V-U2,V-U3,V-U4,V-U5) and VI (VI-A,VI-B1,VI-B2,VI-C,VI-D).

The sequence of interest according to the present disclosure comprises a nucleic acid sequence encoding Cas protein. A variety of CRISPR enzymes are available for use as a sequence of interest on the plasmid. In some embodiments, the CRISPR enzyme is a Type II CRISPR enzyme. In some embodiments, the CRISPR enzyme catalyzes DNA cleavage. In some other embodiments, the CRISPR enzyme catalyzes RNA cleavage. In one embodiment, the CRISPR enzymes may be coupled to a sgRNA. In certain embodiments, the sgRNA targets a gene selected in the group consisting of an antibiotic resistance gene, virulence protein or factor gene, toxin protein or factor gene, a bacterial receptor gene, a membrane protein gene, a structural protein gene, a secreted protein gene and a gene expressing resistance to a drug in general.

Non-limiting examples of Cas proteins as part of a multi-subunit effector or as a single-unit effector include Cas 1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Cas 11 (SS), Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), C2c4, C2c8, C2c5, C2c10, C2c9, Cas13a (C2c2), Cas13b (C2c6), Cas13c (C2c7), Cas13d, Csa5, Csc1, Csc2, Cse1, Cse2, Csy1, Csy2, Csy3, Csf1, Csf2, Csf3, Csf4, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csn2, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx13, Csx1, Csx15, SdCpf1, CmtCpf1, TsCpf1, CmaCpf1, PcCpf1, ErCpf1, FbCpf1, UbcCpf1, AsCpf1, LbCpf1, Mad4, Mad7, Cms1, homologues thereof, orthologues thereof, variants thereof, or modified versions thereof. In some embodiments, the CRISPR enzyme cleaves both strands of the target nucleic acid at the Protospacer Adj acent Motif (PAM) site. In a particular embodiment, said Cas protein is Cas12a (Cpf1).

In a particular embodiment, the CRISPR enzyme is any Cas9 protein, for instance any naturally occurring bacterial Cas9 as well as any variants, homologs or orthologs thereof.

By “Cas9” is meant a protein Cas9 (also called Csn1 or Csx12) or a functional protein, peptide or polypeptide fragment thereof, i.e. capable of interacting with the guide RNA(s) and of exerting the enzymatic activity (nuclease) which allows it to perform the double-strand cleavage of the DNA of the target genome. “Cas9” can thus denote a modified protein, for example truncated to remove domains of the protein that are not essential for the predefined functions of the protein, in particular the domains that are not necessary for interaction with the gRNA(s).

The sequence encoding Cas9 (the entire protein or a fragment thereof) as used in the context of the disclosure can be obtained from any known Cas9 protein (Fonfara et al., Nucleic Acids Res 42 (4), 2014; Koonin et al., Nat Rev Microbiol 15(3), 2017). Examples of Cas9 proteins useful in the present disclosure include, but are not limited to, Cas9 proteins of Streptococcus pyogenes (SpCas9), Streptococcus thermophiles (St1Cas9, St3Cas9), Streptococcus mutans, Staphylococcus aureus (SaCas9), Campylobacter jejuni (CjCas9), Francisella novicida (FnCas9) and Neisseria meningitides (NmCas9).

The sequence encoding Cpf1 (Cas12a) (the entire protein or a fragment thereof) as used in the context of the disclosure can be obtained from any known Cpf1 (Cas12a) protein (Koonin et al., 2017). Examples of Cpf1(Cas12a) proteins useful in the present disclosure include, but are not limited to, Cpf1(Cas12a) proteins of Acidaminococcus sp, Lachnospiraceae bacteriu and Francisella novicida.

The sequence encoding Cas13a (the entire protein or a fragment thereof) can be obtained from any known Cas13a (C2c2) protein (Abudayyeh et al., 2017). Examples of Cas13a (C2c2) proteins useful in the present disclosure include, but are not limited to, Cas13a (C2c2) proteins of Leptotrichia wadei (LwaCas13a).

The sequence encoding Cas13d (the entire protein or a fragment thereof) can be obtained from any known Cas13d protein (Yan et al., 2018). Examples of Cas13d proteins useful in the present disclosure include, but are not limited to, Cas13d proteins of Eubacterium siraeum and Ruminococcus sp.

The sequence encoding Mad4 (the entire protein or a fragment thereof) as used in the context of the invention is disclosed in international application WO2018/236548.

The sequence encoding Mad7 (the entire protein or a fragment thereof) as used in the context of the invention is disclosed in international application WO2018/236548.

The sequence encoding Cms1 (the entire protein or a fragment thereof) as used in the context of the invention is disclosed in international patent application WO2017/141173.

In a particular embodiment, the nucleic sequence of interest is a CRISPR/cas, in particular a CRISPR/Cas9, system for the reduction of gene expression or inactivation a gene selected in the group consisting of an antibiotic resistance gene, virulence factor or protein gene, toxin factor or protein gene, a gene expressing a bacterial receptor, a membrane protein, a structural protein, a secreted protein, and a gene expressing resistance to a drug in general.

In one embodiment, the CRISPR system is used to target and inactivate a virulence factor. A virulence factor can be any substance produced by a pathogen that alters host-pathogen interaction by increasing the degree of damage done to the host. Virulence factors are used by pathogens in many ways, including, for example, in cell adhesion or colonization of a niche in the host, to evade the host’s immune response, to facilitate entry to and egress from host cells, to obtain nutrition from the host, or to inhibit other physiological processes in the host. Virulence factors can include enzymes, endotoxins, adhesion factors, motility factors, factors involved in complement evasion, and factors that promote biofilm formation. For example, such targeted virulence factor gene can be E. coli virulence factor gene such as, without limitation, EHEC-HlyA, Stx1 (VT1), Stx2 (VT2), Stx2a (VT2a), Stx2b (VT2b), Stx2c (VT2c), Stx2d (VT2d), Stx2e (VT2e) and Stx2f (VT2f), Stx2h (VT2h), fimA, fimF, fimH, neuC, kpsE, sfa, foc, iroN, aer, iha, papC, papGI, papGII, papGIII, hlyC, cnf1, hra, sat, ireA, usp ompT, ibeA, malX, fyuA, irp2, traT, afaD, ipaH, eltB, estA, bfpA, eaeA, espA, aaiC, aatA, TEM, CTX, SHV, csgA, csgB, csgC, csgD, csgE, csgF, csgG, csgH, T1SS, T2SS, T3SS, T4SS, T5SS, T6SS (secretion systems). For example, such targeted virulence factor gene can be Shigella dysenteriae virulence factor gene such as, without limitation, stx1 and stx2. For example, such targeted virulence factor gene can be Yersinia pestis virulence factor gene such as, without limitation, yscF (plasmid-borne (pCDl) T3SS external needle subunit). For example, such targeted virulence factor gene can be Francisella tularensis virulence factor gene such as, without limitation, fslA. For example, such targeted virulence factor gene can be Bacillus anthracis virulence factor gene such as, without limitation, pag (Anthrax toxin, cell-binding protective antigen). For example, such targeted virulence factor gene can be Vibrio cholera virulence factor gene such as, without limitation, ctxA and ctxB (cholera toxin), tcpA (toxin co-regulated pilus), and toxT (master virulence regulator). For example, such targeted virulence factor gene can be Pseudomonas aeruginosa virulence factor genes such as, without limitation, pyoverdine (e.g., sigma factor pvdS, biosynthetic genes pvdL, pvdl, pvdJ, pvdH, pvdA, pvdF, pvdQ, pvdN, pvdM, pvdO, pvdP, transporter genes pvdE, pvdR, pvdT, opmQ), siderophore pyochelin (e.g., pchD, pchC, pchB, pchA, pchE, pchF and pchG, and toxins (e.g., exoU, exoS and exoT). For example, such targeted virulence factor gene can be Klebsiella pneumoniae virulence factor genes such as, without limitation, fimA (adherence, type I fimbriae major subunit), and cps (capsular polysaccharide). For example, such targeted virulence factor gene can be Acinetobacter baumannii virulence factor genes such as, without limitation, ptk (capsule polymerization) and epsA (assembly). For example, such targeted virulence factor gene can be Salmonella enterica Typhi virulence factor genes such as, without limitation, MIA (invasion, SPI-1 regulator), ssrB (SPI-2 regulator), and those associated with bile tolerance, including efflux pump genes acrA, acrB and tolC. For example, such targeted virulence factor gene can be Fusobacterium nucleatum virulence factor genes such as, without limitation, FadA and TIGIT. For example, such targeted virulence factor gene can be Bacteroides fragilis virulence factor genes such as, without limitation, bft.

In another embodiment, the CRISPR/Cas system is used to target and inactivate an antibiotic resistance gene such as, without limitation, GyrB, ParE, ParY, AAC(1), AAC(2′), AAC(3), AAC(6′), ANT(2″), ANT(3″), ANT(4′), ANT(6), ANT(9), APH(2″), APH(3″), APH(3′), APH(4), APH(6), APH(7″), APH(9), ArmA, RmtA, RmtB, RmtC, Sgm, AER, BLA1, CTX-M, KPC, SHV, TEM, BlaB, CcrA, IMP, NDM, VIM, ACT, AmpC, CMY, LAT, PDC, OXA β-lactamase, mecA, Omp36, OmpF, PIB, bla (blaI, blaR1) and mec (mecI, mecR1) operons, Chloramphenicol acetyltransferase (CAT), Chloramphenicol phosphotransferase, Ethambutol-resistant arabinosyltransferase (EmbB), MupA, MupB, Integral membrane protein MprF, Cfr 23S rRNA methyltransferase, Rifampin ADP-ribosyltransferase (Arr), Rifampin glycosyltransferase, Rifampin monooxygenase, Rifampin phosphotransferase, DnaA, RbpA, Rifampin-resistant beta-subunit of RNA polymerase (RpoB), Erm 23S rRNA methyltransferases, Lsa, MsrA, Vga, VgaB, Streptogramin Vgb lyase, Vat acetyltransferase, Fluoroquinolone acetyltransferase, Fluoroquinolone-resistant DNA topoisomerases, Fluoroquinolone-resistant GyrA, GyrB, ParC, Quinolone resistance protein (Qnr), FomA, FomB, FosC, FosA, FosB, FosX, VanA, VanB, VanD, VanR, VanS, Lincosamide nucleotidyltransferase (Lin), EreA, EreB, GimA, Mgt, Ole, Macrolide phosphotransferases (MPH), MefA, MefE, Mel, Streptothricin acetyltransferase (sat), Sull, Sul2, Sul3, sulfonamide-resistant FolP, Tetracycline inactivation enzyme TetX, TetA, TetB, TetC, Tet30, Tet31, TetM, TetO, TetQ, Tet32, Tet36, MacAB-TolC, MsbA, MsrA,VgaB, EmrD, EmrAB-TolC, NorB, GepA, MepA, AdeABC, AcrD, MexAB-OprM, mtrCDE, EmrE, adeR, acrR, baeSR, mexR, phoPQ, mtrR, or any antibiotic resistance gene described in the Comprehensive Antibiotic Resistance Database (CARD https://card.mcmaster.ca/).

In another embodiment, the CRISPR/Cas system is used to target and inactivate a bacterial toxin gene. Bacterial toxins can be classified as either exotoxins or endotoxins. Exotoxins are generated and actively secreted; endotoxins remain part of the bacteria. The response to a bacterial toxin can involve severe inflammation and can lead to sepsis. Such toxin can be for example Botulinum neurotoxin, Tetanus toxin, Staphylococus toxins, Diphteria toxin, Anthrax toxin, Alpha toxin, Pertussis toxin, Shiga toxin, Heat-stable enterotoxin ( E. coli ST), colibactin, BFT ( B. fragilis toxin) or any toxin described in Henkel et al., (Toxins from Bacteria in EXS. 2010; 100: 1-29). In a particular embodiment, said toxin is Shiga toxin.

In another embodiment, the nucleic acid of interest encodes a gene or group of genes encoding one or more exogenous enzyme(s) which result(s) in a genetic modification.

In a particular embodiment, said nucleic acid of interest is a gene encoding a base-editor or a prime-editor.

In some embodiments, the genetic modification is made with one or more of the following enzymes and systems.

Cytosine base editors (CBE) and Adenosine base editors (ABE), as described in Rees et al. (2018) Nat Rev Genet 19:770-788, which is hereby incorporated by reference.

So far there is seven types of DNA base editors described:

-   Cytosine Base Editor (CBE) that convert C:G into T:A (Komor et     al. (2016) Nature 533:420-424) -   Adenine Base Editor (ABE) that convert A:T into G:C (Gaudelli et     al. (2017) Nature 551:464-471) -   Cytosine Guanine Base Editor (CGBE) that convert C:G into G:C (Chen     et al. (2020) Biorxiv “Precise and programmable C:G to G:C base     editing in genomic DNA”; Kurt et al. (2020) Nat. Biotechnol. “CRISPR     C-to-G base editors for inducing targeted DNA transversions in human     cells”) -   Cytosine Adenine Base Editor (CABE) that convert C:G into A:T (Zhao     et al. (2020) Nature Biotechnol. “New base editors change C to A in     bacteria and C to G in mammalian cells”) -   Adenine Cytosine Base Editor (ACBE) that convert A:T into C:G     (WO2020181180) -   Adenine Thymine Base Editor (ATBE) that convert A:T into T:A     (WO2020181202) -   Thymine Adenine Base Editor (TABE) that convert T:A into A:T     (WO2020181193, WO2020181178, WO2020181195)

Base editors differ in the base modification enzymes. CBE rely on ssDNA cytidine deaminase among which: APOBEC1, rAPOBEC1, APOBEC1 mutant or evolved version (evoAPOBEC1), and APOBEC homologs (APOBEC3A (eA3A), Anc689), Cytidine deaminase 1 (CDA1), evoCDA1, FERNY, evoFERNY.

ABE rely on deoxyadenosine deaminase activity of a tandem fusion TadA-TadA* where TadA* is an evolved version of TadA, an E.coli tRNA adenosine deaminase enzyme, able to convert adenosine into Inosine on ssDNA.TadA* include TadA-8a-e and TadA-7.10.

Except from base modification enzyme there has been also modifications implemented to base editor to increase editing efficacy, precision and modularity:

-   the addition of one or two uracil DNA glycosylase inhibitor domain     (UGI) to prevent base excision repair mechanism to revert base     edition -   the addition of Mu-GAM that decrease insertion-deletion rate by     inhibiting Non-homologous end joining mechanism in the cell (NHEJ) -   the use of nickase active Cas9 (nCas9 D10A) that, by creating nicks     on the non-edited strand favor its repair and consequently the     fixation of the edited base -   the use of diverse Cas proteins from for example different     organisms, mutants with different PAM motifs or different fidelity     or different family (e.g. Cas12a).

Non-limiting examples of DNA based editor proteins include BE1, BE2, BE3, BE4, BE4-GAM, HF-BE3, Sniper-BE3, Target-AID, Target-AID-NG, ABE, EE-BE3, YE1-BE3, YE2-BE3, YEE-BE3, BE-PLUS, SaBE3, SaBE4, SaBE4-GAM, Sa(KKH)-BE3, VQR-BE3, VRER-BE3, EQR-BE3, xBE3, Cas12a-BE, Ea3A-BE3, A3A-BE3, TAM, CRISPR-X, ABE7.9, ABE7.10, ABE7.10*, xABE, ABESa, VQR-ABE, VRER-ABE, Sa(KKH)-ABE, ABE8e, SpRY-ABE, SpRY-CBE, SpG-CBE4, SpG-ABE, SpRY-CBE4, SpCas9-NG-ABE, SpCas9-NG-CBE4, enAsBE1.1, enAsBE1.2, enAsBE1.3, enAsBE1.4, AsBE1.1, AsBE1.4, CRISPR-Abest, CRISPR-Cbest, eA3A-BE3, AncBE4.

Cytosine Guanine Base Editors (CGBE) consist of a nickase CRISPR fused to:

-   [a] A cytosine deaminase (rAPOBEC) and base excision repair proteins     (e.g. rXRCC1) (Chen et al. (2020) Biorxiv “Precise and programmable     C:G to G:C base editing in genomic DNA”). -   [b] A rat APOBEC1 variant (R33A) protein and an E. coli-derived     uracil DNA N-glycosylase (eUNG) (Kurt et al. (2020) Nat. Biotechnol.     “CRISPR C-to-G base editors for inducing targeted DNA transversions     in human cells”).

Cytosine Adenine Base Editors (CABE) consist of a Cas9 nickase, a cytidine deaminase (e.g. AID), and a uracil-DNA glycosylase (Ung) (Zhao et al. (2020) Nature Biotechnol. “New base editors change C to A in bacteria and C to G in mammalian cells”).

ACBE include a nucleic acid programmable DNA-binding protein and an adenine oxidase (WO2020181180).

ATBE consist of a Cas9 nickase and one or more adenosine deaminase or an oxidase domain (WO2020181202).

TABE consist of a Cas9 nickase and an adenosine methyltransferase, a thymine alkyltransferase, or an adenosine deaminase domain (WO2020181193, WO2020181178, WO2020181195).

Base editor molecules can also consist of two or more of the above listed editor enzymes fused to a Cas protein (e.g. combination of an ABE and CBE). These biomolecules are named dual base editors and enable the editing of two different bases (Grunewald et al. (2020) Nature Biotechnol. “A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing”; Li et al. (2020) Nature Biotechnol. “Targeted, random mutagenesis of plant genes with dual cytosine and adenine base editors”).

Prime editors (PE), as described in Anzalone et al. (2019) Nature 576:149-157, which is hereby incorporated by reference, consist of nCas9 fused to a reverse transcriptase used in combination with a prime editing RNA (pegRNA, a guide RNA that includes a template region for reverse transcription).

Prime Editing allows introduction of insertions, deletions (indels) and 12 base-to-base conversions. Prime editing relies on the ability of a reverse transcriptase (RT), fused to a Cas nickase variant, to convert RNA sequence brought by a prime editing guide RNA (pegRNA) into DNA at the nick site generated by the Cas protein. The DNA flap generated from this process is then included or not in the targeted DNA sequence.

Prime editing systems include:

-   a Cas nickase variant such as Cas9-H840A fused to a reverse     transcriptase domain such as M-MLV RT or its mutant version (M-MLV     RT(D200N), M-MLV RT(D200N/L603W), M-MLV RT(D200N/L603W/T330P/     T306K/W313F) -   a prime editing guide RNA (pegRNA)

To favor editing the prime editing system can include the expression of an additional sgRNA targeting the Cas nickase activity towards the non-edited DNA strand ideally only after the resolution of the edited strand flap by designing the sgRNA to anneal with the edited strand but not with the original strand.

Non-limiting examples of prime editing systems include PE1, PE1-M1, PE1-M2, PE1-M3, PE1-M6, PE1-M15, PE1-M3inv, PE2, PE3, PE3b.

Cas9 Retron precISe Parallel Editing via homologY (‘CRISPEY’), a retron RNA fused to the sgRNA and expressed together with Cas9 and the retron proteins including at least the reverse transcriptase (Sharon etal. (2018) Cell 175:544-557.e16).

The SCRIBE strategy: a retron system expressed in combination with a recombinase promoting the recombination of single stranded DNA, also known as single stranded annealing proteins (SSAPs) (Farzadfard & Lu (2014) Science 346:1256272). Such recombinases include but are not limited to phage recombinases such as lambda red, recET, Sak, Sak4, and newly described SSAPs described in Wannier et al. (2020) Proc Natl Acad Sci USA 117(24):13689-13698 which is hereby incorporated by reference.

The targetron system based on group II introns described in Karberg et al. (2001) Nat Biotechnol 19:1162-7, which is hereby incorporated by reference, and which has been adapted to many bacterial species.

Other retron based gene targeting approaches are described in Simon et al. (2019) Nucleic Acids Res 47:11007-11019, which is hereby incorporated by reference.

In various embodiments, the nucleic acid of interest encodes fusion proteins comprising a Cas, in particular Cas9 (e.g., a Cas9 nickase), domain and a deaminase domain. In some embodiments, the fusion protein comprises a Cas, in particular Cas9, and a cytosine deaminase enzyme, such as APOBEC enzymes, or adenosine deaminase enzymes, such as ADAT enzymes, for example as disclosed in U.S. Pat. Publ. 2015/0166980, which is hereby incorporated by reference. In one embodiment, the deaminase is an ACF1/ASE deaminase.

In various embodiments, the APOBEC deaminase is selected from the group consisting of APOBEC1 deaminase, APOBEC2 deaminase, APOBEC3A deaminase, APOBEC3B deaminase, APOBEC3C deaminase, APOBEC3D deaminase, APOBEC3F deaminase, APOBEC3G deaminase, and APOBEC3H deaminase. In various embodiments, the fusion protein comprises a Cas9 domain, a cytosine deaminase domain, and a uracil glycosylase inhibitor (UGI) domain.

In one embodiment, the deaminase is an adenosine deaminase that deaminate adenosine in DNA, for example as disclosed in U.S. Pat. 10,113,163, which is hereby incorporated by reference. In some embodiments, the fusion proteins further comprise an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN), for example as disclosed in U.S. Pat. 10,113,163. In various embodiments, the nucleic acid of interest encodes fusion proteins comprising a catalytically impaired Cas, in particular Cas9, endonuclease fused to an engineered reverse transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the target site and encodes the desired edit, for example as described in Anzalone et al. (2019) Nature 576: 149-157, which is hereby incorporated by reference.

In some embodiments, the genetic modification is made at the RNA level. RNA base editing is based on the same principle as DNA base editing: an enzyme catalyzing the conversion of a RNA base into another must be brought close to the target base to perform its conversion locally. In one embodiment, the enzyme used for RNA editing is an adenosine deaminase from ADAR family that converts Adenosine into Inosine in dsRNA structure. Several seminal studies used this specificity for dsRNA and fused the ADAR deaminase domain (ADAR_(DD)) to an antisense oligo in order to program local RNA base editing. More recently the ability of some CRISPR-Cas systems to bind RNA molecules was repurposed into RNA editing. Using catalytically dead Cas13b enzyme (dPspCas13b) fused to a hyperactive mutant of ADAR2 deaminase domain (ADAR2DD-E488Q for REPAIRv1 and ADAR2_(DD)-E488Q-T375G for REPAIRv2) Cox et al improved specificity and efficiency compare to previous RNA editing strategies. Non-limiting examples of RNA based editor proteins include REPAIRv1, REPAIRv2.

In some embodiments, the nucleic acid of interest encodes other programmable nucleases. These include an engineered TALEN (Transcription Activator-Like Effector Nuclease) and variants, engineered zinc finger nuclease (ZFN) variants, natural, evolved or engineered meganuclease or recombinase variants, and any combination or hybrids of programmable nucleases. Thus, the programmable nucleases provided herein may be used to selectively modify DNA encoding a gene of interest such as, for example, a toxin gene, a virulence factor gene, an antibiotic resistance gene, a remodeling gene or a modulatory gene (cf. WO2014124226 and US2015/0064138).

In a particular embodiment, said payload comprises or consists of the nucleic acid sequence SEQ ID NO: 33. In an alternative embodiment, said payload comprises or consists of the nucleic acid sequence SEQ ID NO: 42.

In an alternative embodiment, the nucleic acid of interest encodes a therapeutic protein. In another embodiment, the nucleic acid of interest encodes an antisense nucleic acid molecule.

The present disclosure thus also provides a production cell line, as defined above, comprising a helper prophage as defined above, and further comprising a phagemid comprising or consisting of the payload as defined above, in particular of the nucleic acid sequence SEQ ID NO: 33 or of the nucleic acid sequence SEQ ID NO: 42.

In a particular embodiment, the bacterial delivery vehicle provided herein comprises chimeric STF of sequence SEQ ID NO: 11 and chimeric gpJ variant of sequence SEQ ID NO: 27, and further comprises a payload which comprises or consists of the nucleic acid sequence SEQ ID NO: 33.

In another particular embodiment, the bacterial delivery vehicle provided herein comprises chimeric STF of sequence SEQ ID NO: 11 and chimeric gpJ variant of sequence SEQ ID NO: 27, and further comprises a payload which comprises or consists of the nucleic acid sequence SEQ ID NO: 42.

Targeted Bacteria

The bacteria targeted by bacterial delivery vehicles disclosed herein can be any bacteria present in a mammal organism. In a certain aspect, the bacteria are targeted through interaction of the chimeric RBPs of the delivery vehicles with the bacterial cell. It can be any commensal, symbiotic or pathogenic bacteria of the microbiota or microbiome.

A microbiome may comprise a variety of endogenous bacterial species, any of which may be targeted in accordance with the present disclosure. In some embodiments, the genus and/or species of targeted endogenous bacterial cells may depend on the type of bacteriophages being used for preparing the bacterial delivery vehicles. For example, some bacteriophages exhibit tropism for, or preferentially target, specific host species of bacteria. Other bacteriophages do not exhibit such tropism and may be used to target a number of different genus and/or species of endogenous bacterial cells.

Examples of bacterial cells include, without limitation, cells from bacteria of the genus Yersinia spp., Escherichia spp., Klebsiella spp., Acinetobacter spp., Bordetella spp., Neisseria spp., Aeromonas spp., Franciesella spp., Corynebacterium spp., Citrobacter spp., Chlamydia spp., Hemophilus spp., Brucella spp., Mycobacterium spp., Legionella spp., Rhodococcus spp., Pseudomonas spp., Helicobacter spp., Vibrio spp., Bacillus spp., Erysipelothrix spp., Salmonella spp., Streptomyces spp., Streptococcus spp., Staphylococcus spp., Bacteroides spp., Prevotella spp., Clostridium spp., Bifidobacterium spp., Clostridium spp., Brevibacterium spp., Lactococcus spp., Leuconostoc spp., Actinobacillus spp., Selnomonas spp., Shigella spp., Zymonas spp., Mycoplasma spp., Treponema spp., Leuconostoc spp., Corynebacterium spp., Enterococcus spp., Enterobacter spp., Pyrococcus spp., Serratia spp., Morganella spp., Parvimonas spp., Fusobacterium spp., Actinomyces spp., Porphyromonas spp., Micrococcus spp., Bartonella spp., Borrelia spp., Brucelia spp., Campylobacter spp., Chlamydophilia spp., Cutibacterium (formerly Propionibacterium) spp., Ehrlichia spp., Haemophilus spp., Leptospira spp., Listeria spp., Mycoplasma spp., Nocardia spp., Rickettsia spp., Ureaplasma spp., and Lactobacillus spp, and a mixture thereof.

Thus, bacterial delivery vehicles may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus of bacteria to specifically deliver the payload of interest according to the disclosure.

In an embodiment, the targeted bacteria can be selected from the group consisting of Yersinia spp., Escherichia spp., Klebsiella spp., Acinetobacter spp., Pseudomonas spp., Helicobacter spp., Vibrio spp, Salmonella spp., Streptococcus spp., Staphylococcus spp., Bacteroides spp., Clostridium spp., Shigella spp., Enterococcus spp., Enterobacter spp., and Listeria spp.

In some embodiments, targeted bacterial cells of the present disclosure are anaerobic bacterial cells (e.g., cells that do not require oxygen for growth). Anaerobic bacterial cells include facultative anaerobic cells such as but not limited to Escherichia coli, Shewanella oneidensis and Listeria. Anaerobic bacterial cells also include obligate anaerobic cells such as, for example, Bacteroides and Clostridium species. In humans, anaerobic bacteria are most commonly found in the gastrointestinal tract. In some particular embodiment, the targeted bacteria are thus bacteria most commonly found in the gastrointestinal tract. Bacteriophages used for preparing the bacterial virus particles, and then the bacterial virus particles, may target (e.g., to specifically target) anaerobic bacterial cells according to their specific spectra known by the person skilled in the art to specifically deliver the plasmid.

In some embodiments, the targeted bacterial cells are, without limitation, Bacteroides thetaiotaomicron, Bacteroides fragilis, Bacteroides distasonis, Bacteroides vulgatus, Clostridium leptum, Clostridium coccoides, Staphylococcus aureus, Bacillus subtilis, Clostridium butyricum, Brevibacterium lactofermentum , Streptococcus agalactiae, Lactococcus lactis, Leuconostoc lactis, Actinobacillus actinomycetemcomitans, cyanobacteria, Escherichia coli, Helicobacter pylori, Selenomonas ruminatium, Shigella sonnei, Zymomonas mobilis, Mycoplasma mycoides, Treponema denticola, Bacillus thuringiensis, Staphylococcus lugdunensis, Leuconostoc oenos, Corynebacterium xerosis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus acidophilus, Enterococcus faecalis, Bacillus coagulans, Bacillus cereus, Bacillus popillae, Synechocystis strain PCC6803, Bacillus liquefaciens, Pyrococcus abyssi, Selenomonas nominantium, Lactobacillus hilgardii, Streptococcus ferus, Lactobacillus pentosus, Bacteroides fragilis, Staphylococcus epidermidis, Streptomyces phaechromogenes, Streptomyces ghanaenis, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, Parvimonas micra, Prevotella intermedia, Fusobacterium nucleatum, Prevotella nigrescens, Actinomyces israelii, Porphyromonas endodontalis, Porphyromonas gingivalis Micrococcus luteus, Bacillus megaterium, Aeromonas hydrophila, Aeromonas caviae, Bacillus anthracis, Bartonella henselae, Bartonella Quintana, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii, Borrelia afzelii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Campylobacter coli, Campylobacter fetus, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheria, Cutibacterium acnes (formerly Propionibacterium acnes), Ehrlichia canis, Ehrlichia chaffeensis, Enterococcus faecium, Francisella tularensis, Haemophilus influenza, Legionella pneumophila, Leptospira interrogans, Leptospira santarosai, Leptospira weilii, Leptospira noguchii, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumonia, Neisseria gonorrhoeae, Neisseria meningitides, Nocardia asteroids, Rickettsia rickettsia, Salmonella enteritidis, Salmonella typhi, Salmonella paratyphi, Salmonella typhimurium, Shigella flexnerii, Shigella dysenteriae, Staphylococcus saprophyticus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholera, Vibrio parahaemolyticus, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Actinobacter baumanii, Pseudomonas aeruginosa, and a mixture thereof. In an embodiment the targeted bacteria of interest are selected from the group consisting of Escherichia coli, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterobacter cloacae, and Enterobacter aerogenes, and a mixture thereof.

In some embodiments, the targeted bacterial cells are, without limitation, Anaerotruncus, Acetanaerobacterium, Acetitomaculum, Acetivibrio, Anaerococcus, Anaerofilum, Anaerosinus, Anaerostipes, Anaerovorax, Butyrivibrio, Clostridium, Capracoccus, Dehalobacter, Dialister, Dorea, Enterococcus, Ethanoligenens, Faecalibacterium, Fusobacterium, Gracilibacter, Guggenheimella, Hespellia, Lachnobacterium, Lachnospira, Lactobacillus, Leuconostoc, Megamonas, Moryella, Mitsuokella, Oribacterium, Oxobacter, Papillibacter, Proprionispira, Pseudobutyrivibrio, Pseudoramibacter, Roseburia, Ruminococcus, Sarcina, Seinonella, Shuttleworthia, Sporobacter, Sporobacterium, Streptococcus, Subdoligranulum, Syntrophococcus, Thermobacillus, Turibacter, Weisella, Clostridium, Bacteroides, Ruminococcus, Faecalibacterium, Treponema, Phascolarctobacterium, Megasphaera, Faecalibacterium, Bifidobacterium, Lactobacillus, Sutterella, and/or Prevotella.

In other embodiments, the targeted bacteria cells are, without limitation, Achromobacter xylosoxidans, Acidaminococcus fermentans, Acidaminococcus intestini, Acidaminococcus sp., Acinetobacter baumannii, Acinetobacter junii, Acinetobacter lwoffii, Actinobacillus capsulatus, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces radingae, Adlercreutzia equolifaciens, Aeromicrobium massiliense, Aggregatibacter actinomycetemcomitans, Akkermansia muciniphila, Aliagarivorans marinus, Alistipes finegoldii, Alistipes indistinctus, Alistipes inops, Alistipes onderdonkii, Alistipes putredinis, Alistipes senegalensis, Alistipes shahii, Alistipes timonensis, Alloscardovia omnicolens, Anaerobacter polyendosporus, Anaerobaculum hydrogeniformans, Anaerococcus hydrogenalis, Anaerococcus prevotii, Anaerococcus senegalensis, Anaerofustis stercorihominis, Anaerostipes caccae, Anaerostipes hadrus, Anaerotruncus colihominis, Aneurinibacillus aneurinilyticus, Bacillus licheniformis, Bacillus massilioanorexius, Bacillus massiliosenegalensis, Bacillus simplex, Bacillus smithii, Bacillus subtilis, Bacillus thuringiensis, Bacillus timonensis, Bacteroides xylanisolvens, Bacteroides acidifaciens, Bacteroides caccae, Bacteroides capillosus, Bacteroides cellulosilyticus, Bacteroides clarus, Bacteroides coprocola, Bacteroides coprophilus, Bacteroides dorei, Bacteroides eggerthii, Bacteroides faecis, Bacteroides finegoldii, Bacteroides fluxus, Bacteroides fragilis, Bacteroides gallinarum, Bacteroides intestinalis, Bacteroides nordii, Bacteroides oleiciplenus, Bacteroides ovatus, Bacteroides pectinophilus, Bacteroides plebeius, Bacteroides salanitronis, Bacteroides salyersiae, Bacteroides sp., Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Bacteroides pectinophilus ATCC, Barnesiella intestinihominis, Bavariicoccus seileri, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium gallicum, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium stercoris, Bilophila wadsworthia, Blautia faecis, Blautia hansenii, Blautia hydrogenotrophica, Blautia luti, Blautia obeum, Blautia producta, Blautia wexlerae, Brachymonas chironomi, Brevibacterium senegalense, Bryantella formatexigens, butyrate-producing bacterium, Butyricicoccus pullicaecorum, Butyricimonas virosa, Butyrivibrio crossotus, Butyrivibrio fibrisolvens, Caldicoprobacterfaecalis, Campylobacter concisus, Campylobacter jejuni, Campylobacter upsaliensis, Catenibacterium mitsuokai, Cedecea davisae, Cellulomonas massiliensis , Cetobacterium somerae, Citrobacter braakii, Citrobacter freundii, Citrobacter pasteurii, Citrobacter sp., Citrobacter youngae, Cloacibacillus evryensis, Clostridiales bacterium, Clostridioides difficile, Clostridium asparagiforme, Clostridium bartlettii, Clostridium boliviensis, Clostridium bolteae, Clostridium hathewayi, Clostridium hiranonis, Clostridium hylemonae, Clostridium leptum, Clostridium methylpentosum, Clostridium nexile, Clostridium orbiscindens, Clostridium ramosum, Clostridium scindens, Clostridium sp, Clostridium sp., Clostridium spiroforme, Clostridium sporogenes, Clostridium symbiosum, Collinsella aerofaciens, Collinsella intestinalis, Collinsella stercoris, Collinsella tanakaei, Coprobacillus cateniformis, Coprobacter fastidiosus, Coprococcus catus, Coprococcus comes, Coprococcus eutactus, Corynebacterium ammoniagenes, Corynebacterium amycolatum, Corynebacterium pseudodiphtheriticum, Cutibacterium acnes, Dermabacter hominis, Desulfitobacterium hafniense, Desulfovibrio fairfieldensis, Desulfovibrio piger, Dialister succinatiphilus, Dielma fastidiosa, Dorea formicigenerans, Dorea longicatena, Dysgonomonas capnocytophagoides, Dysgonomonas gadei, Dysgonomonas mossii, Edwardsiella tarda, Eggerthella lenta, Eisenbergiella tayi, Enorma massiliensis, Enterobacter aerogenes, Enterobacter asburiae, Enterobacter cancerogenus, Enterobacter cloacae, Enterobacter massiliensis, Enterococcus casseliflavus, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus sp., Enterovibrio nigricans, Erysipelatoclostridium ramosum, Escherichia coli, Escherichia sp., Eubacterium biforme, Eubacterium dolichum, Eubacterium hallii, Eubacterium limosum, Eubacterium ramulus, Eubacterium rectale, Eubacterium siraeum, Eubacterium ventriosum, Exiguobacterium marinum, Exiguobacterium undae, Faecalibacterium cf, Faecalibacterium prausnitzii, Faecalitalea cylindroides, Ferrimonas balearica, Finegoldia magna, Flavobacterium daejeonense, Flavonifractor plautii, Fusicatenibacter saccharivorans, Fusobacterium gonidiaformans, Fusobacterium mortiferum, Fusobacterium necrophorum, Fusobacterium nucleatum, Fusobacterium periodonticum, Fusobacterium sp., Fusobacterium ulcerans, Fusobacterium varium, Gallibacterium anatis, Gemmiger formicilis, Gordonibacter pamelaeae, Hafnia alvei, Helicobacter bilis, Helicobacter bills, Helicobacter canadensis, Helicobacter canis, Helicobacter cinaedi, Helicobacter macacae, Helicobacter pametensis, Helicobacter pullorum, Helicobacter pylori, Helicobacter rodentium, Helicobacter winghamensis, Herbaspirillum massiliense, Holdemanella biformis, Holdemania fdiformis, Holdemania filiformis, Holdemania massiliensis, Holdemania filiformis, Hungatella hathewayi, Intestinibacter bartlettii, Intestinimonas butyriciproducens, Klebsiella oxytoca, Klebsiella pneumoniae, Kurthia massiliensis, Lachnospira pectinoschiza, Lactobacillus acidophilus, Lactobacillus amylolyticus, Lactobacillus animalis, Lactobacillus antri, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus iners, Lactobacillus intestinalis, Lactobacillus johnsonii, Lactobacillus murinus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri , Lactobacillus rhamnosus, Lactobacillus ruminis, Lactobacillus sakei, Lactobacillus salivarius, Lactobacillus ultunensis, Lactobacillus vaginalis, Lactobacillus plantarum subsp., Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Listeria grayi, Listeria innocua, Mannheimia granulomatis, Marvinbryantia formatexigens, Megamonas funiformis, Megamonas hypermegale, Methanobrevibacter smithii, Methanobrevibacter smithii, Micrococcus luteus, Microvirgula aerodenitrificans, Mitsuokella jalaludinii, Mitsuokella multacida, Mollicutes bacterium, Murimonas intestini, Neisseria macacae, Nitriliruptor alkaliphilus, Oceanobacillus massiliensis, Odoribacter laneus, Odoribacter splanchnicus, Ornithobacterium rhinotracheale, Oxalobacter formigenes, Paenibacillus barengoltzii, Paenibacillus chitinolyticus, Paenibacillus lautus, Paenibacillus motobuensis, Paenibacillus senegalensis, Paenisporosarcina quisquiliarum, Parabacteroides distasonis, Parabacteroides goldsteinii, Parabacteroides gordonii, Parabacteroides johnsonii, Parabacteroides merdae, Paraprevotella xylaniphila, Parasutterella excrementihominis, Parvimonas micra, Pediococcus acidilactici, Peptoclostridium difficile, Peptoniphilus harei, Peptoniphilus obesi, Peptoniphilus senegalensis, Peptoniphilus timonensis, Phascolarctobacterium succinatutens, Porphyromonas asaccharolytica, Porphyromonas uenonis, Prevotella baroniae, Prevotella bivia, Prevotella copri, Prevotella dentalis, Prevotella micans, Prevotella multisaccharivorax, Prevotella oralis, Prevotella salivae, Prevotella stercorea, Prevotella veroralis, Propionibacterium acnes, Propionibacterium avidum, Propionibacterium freudenreichii, Propionimicrobium lymphophilum, Proteus mirabilis, Proteus penneri ATCC, Providencia alcalifaciens, Providencia rettgeri, Providencia rustigianii, Providencia stuartii, Pseudoflavonifractor capillosus, Pseudomonas aeruginosa, Pseudomonas luteola, Ralstonia pickettii, Rheinheimera perlucida, Rheinheimera texasensis, Riemerella columbina, Romboutsia lituseburensis, Roseburia faecis, Roseburia intestinalis, Roseburia inulinivorans, Ruminococcus bicirculans, Ruminococcus bromii, Ruminococcus callidus, Ruminococcus champanellensis, Ruminococcus faecis, Ruminococcus gnavus, Ruminococcus lactaris, Ruminococcus obeum, Ruminococcus sp, Ruminococcus sp., Ruminococcus torques, Sarcina ventriculi, Sellimonas intestinalis, Senegalimassilia anaerobia, Shigella sonnei, Slackia piriformis, Staphylococcus epidermidis, Staphylococcus lentus, Staphylococcus nepalensis, Staphylococcus pseudintermedius, Staphylococcus xylosus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus australis, Streptococcus caballi, Streptococcus castoreus, Streptococcus didelphis, Streptococcus equinus, Streptococcus gordonii, Streptococcus henryi, Streptococcus hyovaginalis, Streptococcus infantarius, Streptococcus infantis, Streptococcus lutetiensis, Streptococcus merionis, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus ovis, Streptococcus parasanguinis, Streptococcus plurextorum, Streptococcus porci, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sobrinus, Streptococcus thermophilus, Streptococcus thoraltensis, Streptomyces albus, Subdoligranulum variabile, Succinatimonas hippei, Sutterella parvirubra, Sutterella wadsworthensis, Terrisporobacter glycolicus, Terrisporobacter mayombei, Thalassobacillus devorans, Timonella senegalensis, Turicibacter sanguinis, unknown sp, unknown sp., Varibaculum cambriense, Veillonella atypica, Veillonella dispar, Veillonella parvula, Vibrio cincinnatiensis, Virgibacillus salexigens or Weissella paramesenteroides.

In other embodiments, the targeted bacteria cells are those commonly found on the skin microbiota and are without limitation Acetobacter farinalis, Acetobacter malorum, Acetobacter orleanensis, Acetobacter sicerae, Achromobacter anxifer, Achromobacter denitrificans, Achromobacter marplatensis, Achromobacter spanius, Achromobacter xylosoxidans subsp. xylosoxidans, Acidovorax konjaci, Acidovorax radicis, Acinetobacter johnsonii, Actinomadura citrea, Actinomadura coerulea, Actinomadura fibrosa, Actinomadura fulvescens, Actinomadura jiaoheensis, Actinomadura luteofluorescens, Actinomadura mexicana, Actinomadura nitritigenes, Actinomadura verrucosospora, Actinomadura yumaensis, Actinomyces odontolyticus, Actinomycetospora atypica, Actinomycetospora corticicola, Actinomycetospora rhizophila, Actinomycetospora rishiriensis, Aeromonas australiensis, Aeromonas bestiarum, Aeromonas bivalvium, Aeromonas encheleia, Aeromonas eucrenophila, Aeromonas hydrophila subsp. hydrophila, Aeromonas piscicola, Aeromonas popoffii, Aeromonas rivuli, Aeromonas salmonicida subsp. pectinolytica, Aeromonas salmonicida subsp. smithia, Amaricoccus kaplicensis, Amaricoccus veronensis, Aminobacter aganoensis, Aminobacter ciceronei, Aminobacter lissarensis, Aminobacter niigataensis, Ancylobacter polymorphus, Anoxybacillus flavithermus subsp. yunnanensis, Aquamicrobium aerolatum, Archangium gephyra, Archangium gephyra, Archangium minus, Archangium violaceum, Arthrobacter viscosus, Bacillus anthracis, Bacillus australimaris, Bacillus drentensis, Bacillus mycoides, Bacillus pseudomycoides, Bacillus pumilus, Bacillus safensis, Bacillus vallismortis, Bosea thiooxidans, Bradyrhizobium huanghuaihaiense, Bradyrhizobium japonicum, Brevundimonas aurantiaca, Brevundimonas intermedia, Burkholderia aspalathi, Burkholderia choica, Burkholderia cordobensis, Burkholderia diffusa, Burkholderia insulsa, Burkholderia rhynchosiae, Burkholderia terrestris, Burkholderia udeis, Buttiauxella gaviniae, Caenimonas terrae, Capnocytophaga gingivalis, Chitinophaga dinghuensis, Chryseobacterium gleum, Chryseobacterium greenlandense, Chryseobacterium jejuense, Chryseobacterium piscium, Chryseobacterium sediminis, Chryseobacterium tructae, Chryseobacterium ureilyticum, Chryseobacterium vietnamense, Corynebacterium accolens, Corynebacterium afermentans subsp. lipophilum, Corynebacterium minutissimum, Corynebacterium sundsvallense, Cupriavidus metallidurans, Cupriavidus nantongensis, Cupriavidus necator, Cupriavidus pampae, Cupriavidus yeoncheonensis, Curtobacterium flaccumfaciens, Devosia epidermidihirudinis, Devosia riboflavina, Devosia riboflavina, Diaphorobacter oryzae, Dietzia psychralcaliphila, Ensifer adhaerens, Ensifer americanus, Enterococcus malodoratus, Enterococcus pseudoavium, Enterococcus viikkiensis, Enterococcus xiangfangensis, Erwinia rhapontici, Falsirhodobacter halotolerans, Flavobacterium araucananum, Flavobacterium frigidimaris, Gluconobacter frateurii, Gluconobacter thailandicus, Gordonia alkanivorans, Halomonas aquamarina, Halomonas axialensis, Halomonas meridiana , Halomonas olivaria, Halomonas songnenensis, Halomonas variabilis, Herbaspirillum chlorophenolicum, Herbaspirillum frisingense, Herbaspirillum hiltneri, Herbaspirillum huttiense subsp. putei, Herbaspirillum lusitanum, Herminiimonas fonticola, Hydrogenophaga intermedia, Hydrogenophaga pseudoflava, Klebsiella oxytoca, Kosakonia sacchari, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus modestisalitolerans, Lactobacillus plantarum subsp. argentoratensis, Lactobacillus xiangfangensis, Lechevalieria roselyniae, Lentzea albida, Lentzea californiensis, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc gelidum subsp. gasicomitatum, Leuconostoc mesenteroides subsp. suionicum, Luteimonas aestuarii, Lysobacter antibioticus, Lysobacter koreensis, Lysobacter oryzae, Magnetospirillum moscoviense, Marinomonas alcarazii, Marinomonas primoryensis, Massilia aurea, Massilia jejuensis, Massilia kyonggiensis, Massilia timonae, Mesorhizobium acaciae, Mesorhizobium qingshengii, Mesorhizobium shonense, Methylobacterium haplocladii, Methylobacterium platani, Methylobacterium pseudosasicola, Methylobacterium zatmanii, Microbacterium oxydan, Micromonospora chaiyaphumensis, Micromonospora chalcea, Micromonospora citrea, Micromonospora coxensis, Micromonospora echinofusca, Micromonospora halophytica, Micromonospora kangleipakensis, Micromonospora maritima, Micromonospora nigra, Micromonospora purpureochromogene, Micromonospora rhizosphaerae, Micromonospora saelicesensis, Microvirga subterranea, Microvirga zambiensis, Mycobacterium alvei, Mycobacterium avium subsp. silvaticum, Mycobacterium colombiense, Mycobacterium conceptionense, Mycobacterium conceptionense, Mycobacterium farcinogenes, Mycobacterium fortuitum subsp. fortuitum, Mycobacterium goodii, Mycobacterium insubricum, Mycobacterium llatzerense, Mycobacterium neoaurum, Mycobacterium neworleansense, Mycobacterium obuense, Mycobacterium peregrinum, Mycobacterium saopaulense, Mycobacterium septicum, Mycobacterium setense, Mycobacterium smegmatis, Neisseria subflava, Nocardia lijiangensis, Nocardia thailandica, Novosphingobium barchaimii, Novosphingobium lindaniclasticum, Novosphingobium lindaniclasticum, Novosphingobium mathurense, Ochrobactrum pseudogrignonense, Oxalicibacterium solurbis, Paraburkholderia glathei, Paraburkholderia humi, Paraburkholderia phenazinium, Paraburkholderia phytofirmans, Paraburkholderia sordidicola, Paraburkholderia terricola, Paraburkholderia xenovorans, Paracoccus laeviglucosivorans, Patulibacter ginsengiterrae, Polymorphospora rubra, Porphyrobacter colymbi, Prevotella jejuni, Prevotella melaninogenica, Propionibacterium acnes subsp. elongatum, Proteus vulgaris, Providencia rustigianii, Pseudoalteromonas agarivorans, Pseudoalteromonas atlantica, Pseudoalteromonas paragorgicola, Pseudomonas asplenii, Pseudomonas asuensis, Pseudomonas benzenivorans, Pseudomonas cannabina, Pseudomonas cissicola, Pseudomonas congelans, Pseudomonas costantinii, Pseudomonas ficuserectae, Pseudomonas frederiksbergensis, Pseudomonas graminis, Pseudomonas jessenii, Pseudomonas koreensis, Pseudomonas koreensis, Pseudomonas kunmingensis, Pseudomonas marginalis, Pseudomonas mucidolens, Pseudomonas panacis, Pseudomonas plecoglossicida, Pseudomonas poae, Pseudomonas pseudoalcaligenes , Pseudomonas putida, Pseudomonas reinekei, Pseudomonas rhizosphaerae, Pseudomonas seleniipraecipitans, Pseudomonas umsongensis, Pseudomonas zhaodongensis, Pseudonocardia alaniniphila, Pseudonocardia ammonioxydans, Pseudonocardia autotrophica, Pseudonocardia kongjuensis, Pseudonocardia yunnanensis, Pseudorhodoferax soli, Pseudoxanthomonas daejeonensis, Pseudoxanthomonas indica, Pseudoxanthomonas kaohsiungensis, Psychrobacter aquaticus, Psychrobacter arcticus, Psychrobacter celer, Psychrobacter marincola, Psychrobacter nivimaris, Psychrobacter okhotskensis, Psychrobacter okhotskensis, Psychrobacter piscatorii, Psychrobacter pulmonis, Ramlibacter ginsenosidimutans, Rheinheimera japonica, Rheinheimera muenzenbergensis, Rheinheimera soli, Rheinheimera tangshanensis, Rheinheimera texasensis, Rheinheimera tilapiae, Rhizobium alamii, Rhizobium azibense, Rhizobium binae, Rhizobium daejeonense, Rhizobium endophyticum, Rhizobium etli, Rhizobium fabae, Rhizobium freirei, Rhizobium gallicum, Rhizobium loessense, Rhizobium sophoriradicis, Rhizobium taibaishanense, Rhizobium vallis, Rhizobium vignae, Rhizobium vignae, Rhizobium yanglingense, Rhodococcus baikonurensis, Rhodococcus enclensis, Rhodoferax saidenbachensis, Rickettsia canadensis, Rickettsia heilongjiangensis, Rickettsia honei, Rickettsia raoultii, Roseateles aquatilis, Roseateles aquatilis, Salmonella enterica subsp. salamae, Serratia ficaria, Serratia myotis, Serratia vespertilionis, Shewanella aestuarii, Shewanella decolorationis, Sphingobium amiense, Sphingobium baderi, Sphingobium barthaii, Sphingobium chlorophenolicum, Sphingobium cupriresistens, Sphingobium czechense, Sphingobium fuliginis, Sphingobium indicum, Sphingobium indicum, Sphingobium japonicum, Sphingobium lactosutens, Sphingomonas dokdonensis, Sphingomonas pseudosanguinis, Sphingopyxis chilensis, Sphingopyxis fribergensis, Sphingopyxis granuli, Sphingopyxis indica, Sphingopyxis witflariensis, Staphylococcus agnetis, Staphylococcus aureus subsp. aureus, Staphylococcus epidermidis, Staphylococcus hominis subsp. novobiosepticus, Staphylococcus nepalensis, Staphylococcus saprophyticus subsp. bovis, Staphylococcus sciuri subsp. carnaticus, Streptomyces caeruleatus, Streptomyces canarius, Streptomyces capoamus, Streptomyces ciscaucasicus, Streptomyces griseorubiginosus, Streptomyces olivaceoviridis, Streptomyces panaciradicis, Streptomyces phaeopurpureus, Streptomyces pseudovenezuelae, Streptomyces resistomycificus, Tianweitania sediminis, Tsukamurella paurometabola, Variovorax guangxiensis, Vogesella alkaliphila, Xanthomonas arboricola, Xanthomonas axonopodis, Xanthomonas cassavae, Xanthomonas cucurbitae, Xanthomonas cynarae, Xanthomonas euvesicatoria, Xanthomonas fragariae, Xanthomonas gardneri, Xanthomonas perforans, Xanthomonas pisi, Xanthomonas populi, Xanthomonas vasicola, Xenophilus aerolatus, Yersinia nurmii, Abiotrophia defectiva, Acidocella aminolytica, Acinetobacter guangdongensis, Acinetobacter parvus, Acinetobacter radioresistens, Acinetobacter soli, Acinetobacter variabilis, Actinomyces cardiffensis, Actinomyces dentalis, Actinomyces europaeus, Actinomyces gerencseriae, Actinomyces graevenitzii, Actinomyces haliotis, Actinomyces johnsonii, Actinomyces massiliensis, Actinomyces meyeri, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii subsp. anitratus, Actinomyces odontolyticus, Actinomyces oris, Actinomyces turicensis, Actinomycetospora corticicola, Actinotignum schaalii, Aerococcus christensenii, Aerococcus urinae, Aeromicrobium flavum, Aeromicrobium massiliense, Aeromicrobium tamlense, Aeromonas sharmana, Aggregatibacter aphrophilus, Aggregatibacter segnis, Agrococcus baldri, Albibacter methylovorans, Alcaligenes faecalis subsp. faecalis, Algoriphagus ratkowskyi, Alkalibacterium olivapovliticus, Alkalibacterium pelagium, Alkalibacterium pelagium, Alloprevotella rava, Alsobacter metallidurans, Amaricoccus kaplicensis, Amaricoccus veronensis, Anaerococcus hydrogenalis, Anaerococcus lactolyticus, Anaerococcus murdochii, Anaerococcus octavius, Anaerococcus prevotii, Anaerococcus vaginalis, Aquabacterium citratiphilum, Aquabacterium olei, Aquabacterium olei, Aquabacterium parvum, Aquincola tertiaricarbonis, Arcobacter venerupis, Arsenicicoccus bolidensis, Arthrobacter russicus, Asticcacaulis excentricus, Atopobium deltae, Atopobium parvulum, Atopobium rimae, Atopobium vaginae, Aureimonas altamirensis, Aureimonas rubiginis, Azospira oryzae, Azospirillum oryzae, Bacillus circulans, Bacillus drentensis, Bacillus fastidiosus, Bacillus lehensis, Bacillus oceanisediminis, Bacillus rhizosphaerae, Bacteriovorax stolpii, Bacteroides coagulans, Bacteroides dorei, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus, Bdellovibrio bacteriovorus, Bdellovibrio exovorus, Belnapia moabensis, Belnapia soli, Blautia hansenii, Blautia obeum, Blautia wexlerae, Bosea lathyri, Brachybacterium fresconis, Brachybacterium muris, Brevibacterium ammoniilyticum, Brevibacterium casei, Brevibacterium epidermidis, Brevibacterium iodinum, Brevibacterium luteolum, Brevibacterium paucivorans, Brevibacterium pityocampae, Brevibacterium sanguinis, Brevundimonas albigilva, Brevundimonas diminuta, Brevundimonas vancanneytii, Caenimonas terrae, Calidifontibacter indicus, Campylobacter concisus, Campylobacter gracilis, Campylobacter hominis, Campylobacter rectus, Campylobacter showae, Campylobacter ureolyticus, Capnocytophaga gingivalis, Capnocytophaga leadbetteri, Capnocytophaga ochracea, Capnocytophaga sputigena, Cardiobacterium hominis, Cardiobacterium valvarum, Carnobacterium divergens, Catonella morbi, Caulobacter henricii, Cavicella subterranea, Cellulomonas xylanilytica, Cellvibrio vulgaris, Chitinimonas taiwanensis, Chryseobacterium arachidis, Chryseobacterium daecheongense, Chryseobacterium formosense, Chryseobacterium formosense, Chryseobacterium greenlandense, Chryseobacterium indologenes, Chryseobacterium piscium, Chryseobacterium rigui, Chryseobacterium solani, Chryseobacterium taklimakanense, Chryseobacterium ureilyticum, Chryseobacterium ureilyticum, Chryseobacterium zeae, Chryseomicrobium aureum, Cloacibacterium haliotis, Cloacibacterium normanense, Cloacibacterium normanense, Collinsella aerofaciens, Comamonas denitrificans, Comamonas terrigena, Corynebacterium accolens, Corynebacterium afermentans subsp. lipophilum, Corynebacterium ammoniagenes, Corynebacterium amycolatum, Corynebacterium aurimucosum, Corynebacterium aurimucosum, Corynebacterium coyleae, Corynebacterium durum, Corynebacterium freiburgense, Corynebacterium glaucum, Corynebacterium glyciniphilum, Corynebacterium imitans, Corynebacterium jeikeium, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium massiliense, Corynebacterium mastitidis, Corynebacterium matruchotii, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium mustelae, Corynebacterium mycetoides, Corynebacterium pyruviciproducens, Corynebacterium simulans, Corynebacterium singulare, Corynebacterium sputi, Corynebacterium suicordis, Corynebacterium tuberculostearicum, Corynebacterium tuberculostearicum, Corynebacterium ureicelerivorans, Corynebacterium variabile, Couchioplanes caeruleus subsp. caeruleus, Cupriavidus metallidurans, Curtobacterium herbarum, Dechloromonas agitata, Deinococcus actinosclerus, Deinococcus antarcticus, Deinococcus caeni, Deinococcus ficus, Deinococcus geothermalis, Deinococcus radiodurans, Deinococcus wulumuqiensis, Deinococcus xinjiangensis, Dermabacter hominis, Dermabacter vaginalis, Dermacoccus nishinomiyaensis, Desemzia incerta, Desertibacter roseus, Dialister invisus, Dialister micraerophilus, Dialister propionicifaciens, Dietzia aurantiaca, Dietzia cercidiphylli, Dietzia timorensis, Dietzia timorensis, Dokdonella koreensis, Dokdonella koreensis, Dolosigranulum pigrum, Eikenella corrodens, Elizabethkingia miricola, Elstera litoralis, Empedobacter brevis, Enhydrobacter aerosaccus, Enterobacter xiangfangensis, Enterococcus aquimarinus, Enterococcus faecalis, Enterococcus olivae, Erwinia rhapontici, Eubacterium eligens, Eubacterium infirmum, Eubacterium rectale, Eubacterium saphenum, Eubacterium sulci, Exiguobacterium mexicanum, Facklamia tabacinasalis, Falsirhodobacter halotolerans, Finegoldia magna, Flavobacterium cutihirudinis, Flavobacterium lindanitolerans, Flavobacterium resistens, Friedmanniella capsulata, Fusobacterium nucleatum subsp. polymorphum, Gemella haemolysans, Gemella morbillorum, Gemella palaticanis, Gemella sanguinis, Gemmobacter aquaticus, Gemmobacter caeni, Gordonia jinhuaensis, Gordonia kroppenstedtii, Gordonia polyisoprenivorans, Gordonia polyisoprenivorans, Granulicatella adiacens, Granulicatella elegans, Haemophilus parainfluenzae, Haemophilus sputorum, Halomonas sulfidaeris, Herpetosiphon aurantiacus, Hydrocarboniphaga effusa, Idiomarina maris, Janibacter anophelis, Janibacter hoylei, Janibacter indicus, Janibacter limosus, Janibacter melonis, Jeotgalicoccus halophilus, Jonquetella anthropi, Kaistia geumhonensis, Kingella denitrificans, Kingella oralis, Klebsiella oxytoca, Knoellia aerolata, Knoellia locipacati, Kocuria atrinae, Kocuria carniphila, Kocuria kristinae, Kocuria palustris, Kocuria turfanensis, Lachnoanaerobaculum saburreum, Lachnoanaerobaculum saburreum, Lactobacillus crispatus, Lactobacillus iners, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. lactis, Lactococcus piscium, Lapillicoccus jejuensis, Lautropia mirabilis, Legionella beliardensis, Leptotrichia buccalis, Leptotrichia goodfellowii, Leptotrichia hofstadii, Leptotrichia hongkongensis, Leptotrichia shahii, Leptotrichia trevisanii, Leptotrichia wadei, Luteimonas terricola, Lysinibacillus fusiformis, Lysobacter spongiicola, Lysobacter xinjiangensis, Macrococcus caseolyticus, Marmoricola pocheonensis, Marmoricola scoriae, Massilia alkalitolerans, Massilia alkalitolerans, Massilia aurea, Massilia plicata, Massilia timonae, Megamonas rupellensis, Meiothermus silvanus, Methylobacterium dankookense, Methylobacterium goesingense, Methylobacterium goesingense, Methylobacterium isbiliense, Methylobacterium jeotgali, Methylobacterium oxalidis, Methylobacterium platani, Methylobacterium pseudosasicola, Methyloversatilis universalis, Microbacterium foliorum, Microbacterium hydrothermale, Microbacterium hydrothermale, Microbacterium lacticum, Microbacterium lacticum, Microbacterium laevaniformans, Microbacterium paludicola, Microbacterium petrolearium, Microbacterium phyllosphaerae, Microbacterium resistens, Micrococcus antarcticus, Micrococcus cohnii, Micrococcus flavus, Micrococcus lylae, Micrococcus terreus, Microlunatus aurantiacus, Micropruina glycogenica, Microvirga aerilata, Microvirga aerilata, Microvirga subterranea, Microvirga vignae, Microvirga zambiensis, Microvirgula aerodenitrificans, Mogibacterium timidum, Moraxella atlantae, Moraxella catarrhalis, Morganella morganii subsp. morganii, Morganella psychrotolerans, Murdochiella asaccharolytica, Mycobacterium asiaticum, Mycobacterium chubuense, Mycobacterium crocinum, Mycobacterium gadium, Mycobacterium holsaticum, Mycobacterium iranicum, Mycobacterium longobardum, Mycobacterium neoaurum, Mycobacterium neoaurum, Mycobacterium obuense, Negativicoccus succinicivorans, Neisseria bacilliformis, Neisseria oralis, Neisseria sicca, Neisseria subflava, Nesterenkonia lacusekhoensis, Nesterenkonia rhizosphaerae, Nevskia persephonica, Nevskia ramosa, Niabella yanshanensis, Niveibacterium umoris, Nocardia niwae, Nocardia thailandica, Nocardioides agariphilus, Nocardioides dilutus, Nocardioides ganghwensis, Nocardioides hwasunensis, Nocardioides nanhaiensis, Nocardioides sediminis, Nosocomiicoccus ampullae, Noviherbaspirillum malthae, Novosphingobium lindaniclasticum, Novosphingobium rosa, Ochrobactrum rhizosphaerae, Olsenella uli, Ornithinimicrobium murale, Ornithinimicrobium tianjinense, Oryzobacter terrae, Ottowia beijingensis, Paenalcaligenes suwonensis, Paenibacillus agaridevorans, Paenibacillus phoenicis, Paenibacillus xylanexedens, Paludibacterium yongneupense, Pantoea cypripedii, Parabacteroides distasonis, Paraburkholderia andropogonis, Paracoccus alcaliphilus, Paracoccus angustae, Paracoccus kocurii, Paracoccus laeviglucosivorans, Paracoccus sediminis, Paracoccus sphaerophysae, Paracoccus yeei, Parvimonas micra, Parviterribacter multiflagellatus, Patulibacter ginsengiterrae, Pedobacter aquatilis, Pedobacter ginsengisoli, Pedobacter xixiisoli, Peptococcus niger, Peptoniphilus coxii, Peptoniphilus gorbachii, Peptoniphilus harei, Peptoniphilus koenoeneniae, Peptoniphilus lacrimalis, Peptostreptococcus anaerobius, Peptostreptococcus stomatis, Phascolarctobacterium faecium, Phenylobacterium haematophilum, Phenylobacterium kunshanense, Pluralibacter gergoviae, Polymorphobacter multimanifer, Porphyromonas bennonis, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas gingivicanis, Porphyromonas pasteri, Porphyromonas pogonae, Porphyromonas somerae, Povalibacter uvarum, Prevotella aurantiaca, Prevotella baroniae, Prevotella bivia, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella corporis, Prevotella denticola , Prevotella enoeca, Prevotella histicola, Prevotella intermedia, Prevotella jejuni, Prevotella jejuni, Prevotella maculosa, Prevotella melaninogenica, Prevotella melaninogenica, Prevotella micans, Prevotella multiformis, Prevotella nanceiensis, Prevotella nigrescens, Prevotella oris, Prevotella oulorum, Prevotella pallens, Prevotella pleuritidis, Prevotella saccharolytica, Prevotella salivae, Prevotella shahii, Prevotella timonensis, Prevotella veroralis, Propionibacterium acidifaciens, Propionibacterium acnes subsp. acnes, Propionibacterium acnes subsp. acnes, Propionibacterium acnes subsp. elongatum, Propionibacterium granulosum, Propionimicrobium lymphophilum, Propionispira arcuata, Pseudokineococcus lusitanus, Pseudomonas aeruginosa, Pseudomonas chengduensis, Pseudonocardia benzenivorans, Pseudorhodoplanes sinuspersici, Psychrobacter sanguinis, Ramlibacter ginsenosidimutans, Rheinheimera aquimaris, Rhizobium alvei, Rhizobium daejeonense, Rhizobium larrymoorei, Rhizobium rhizoryzae, Rhizobium soli, Rhizobium taibaishanense, Rhizobium vignae, Rhodanobacter glycinis, Rhodobacter veldkampii, Rhodococcus enclensis, Rhodococcus fascians, Rhodococcus fascians, Rhodovarius lipocyclicus, Rivicola pingtungensis, Roseburia inulinivorans, Rosenbergiella nectarea, Roseomonas aerilata, Roseomonas aquatica, Roseomonas mucosa, Roseomonas rosea, Roseomonas vinacea, Rothia aeria, Rothia amarae, Rothia dentocariosa, Rothia endophytica, Rothia mucilaginosa, Rothia nasimurium, Rubellimicrobium mesophilum, Rubellimicrobium roseum, Rubrobacter bracarensis, Rudaea cellulosilytica, Ruminococcus gnavus, Runella zeae, Saccharopolyspora rectivirgula, Salinicoccus qingdaonensis, Scardovia wiggsiae, Sediminibacterium ginsengisoli, Selenomonas artemidis, Selenomonas infelix, Selenomonas noxia, Selenomonas sputigena, Shewanella aestuarii, Shuttleworthia satelles, Simonsiella muelleri, Skermanella aerolata, Skermanella stibiiresistens, Slackia exigua, Smaragdicoccus niigatensis, Sneathia sanguinegens, Solirubrobacter soli, Sphingobacterium caeni, Sphingobacterium daejeonense, Sphingobacterium hotanense, Sphingobacterium kyonggiense, Sphingobacterium multivorum, Sphingobacterium nematocida, Sphingobacterium spiritivorum, Sphingobium amiense, Sphingobium indicum, Sphingobium lactosutens, Sphingobium subterraneum, Sphingomonas abaci, Sphingomonas aestuarii, Sphingomonas canadensis, Sphingomonas daechungensis, Sphingomonas dokdonensis, Sphingomonas echinoides, Sphingomonas fonticola, Sphingomonas fonticola, Sphingomonas formosensis, Sphingomonas gei, Sphingomonas hankookensis, Sphingomonas hankookensis, Sphingomonas koreensis, Sphingomonas kyeonggiensis, Sphingomonas laterariae, Sphingomonas mucosissima, Sphingomonas oligophenolica, Sphingomonas pseudosanguinis, Sphingomonas sediminicola, Sphingomonas yantingensis, Sphingomonas yunnanensis, Sphingopyxis indica, Spirosoma rigui, Sporacetigenium mesophilum, Sporocytophaga myxococcoides, Staphylococcus auricularis, Staphylococcus epidermidis, Staphylococcus epidermidis, Staphylococcus hominis subsp. novobiosepticus, Staphylococcus lugdunensis, Staphylococcus pettenkoferi, Stenotrophomonas koreensis, Stenotrophomonas rhizophila, Stenotrophomonas rhizophila, Streptococcus agalactiae, Streptococcus canis, Streptococcus cristatus, Streptococcus gordonii, Streptococcus infantis, Streptococcus intermedius, Streptococcus mutans, Streptococcus oligofermentans, Streptococcus oralis, Streptococcus sanguinis, Streptomyces iconiensis, Streptomyces yanglinensis, Tabrizicola aquatica, Tahibacter caeni, Tannerella forsythia, Tepidicella xavieri, Tepidimonas fonticaldi, Terracoccus luteus, Tessaracoccus flavescens, Thermus thermophilus, Tianweitania sediminis, Tianweitania sediminis, Treponema amylovorum, Treponema denticola, Treponema lecithinolyticum, Treponema medium, Turicella otitidis, Turicibacter sanguinis, Undibacterium oligocarboniphilum, Undibacterium squillarum, Vagococcus salmoninarum, Varibaculum cambriense, Vibrio metschnikovii, Xanthobacter tagetidis, Xenophilus aerolatus, Xenophilus arseniciresistens, Yimella lutea, Zimmermannella alba, Zimmermannella bifida or Zoogloea caeni.

In other embodiments, the targeted bacteria cells are those commonly found in the vaginal microbiota and are, without limitation, Acinetobacter antiviralis, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Actinobaculum massiliense, Actinobaculum schaalii, Actinomyces europaeus, Actinomyces graevenitzii, Actinomyces israelii, Actinomyces meyeri, Actinomyces naeslundii, Actinomyces neuii, Actinomyces odontolyticus, Actinomyces turicensis, Actinomyces urogenitalis, Actinomyces viscosus, Aerococcus christensenii, Aerococcus urinae, Aerococcus viridans, Aeromonas encheleia, Aeromonas salmonicida, Afipia massiliensis, Agrobacterium tumefaciens, Algoriphagus aquatilis, Aliivibrio wodanis, Alistipes finegoldii, Alloiococcus otitis, Alloprevotella tannerae, Alloscardovia omnicolens, Altererythrobacter epoxidivorans, Ammoniphilus oxalaticus, Amnibacterium kyonggiense, Anaerococcus hydrogenalis, Anaerococcus lactolyticus, Anaerococcus murdochii, Anaerococcus obesiensis, Anaerococcus prevotii, Anaerococcus tetradius, Anaerococcus vaginalis, Anaeroglobus geminatus, Anoxybacillus pushchinoensis, Aquabacterium parvum, Arcanobacterium phocae, Arthrobacter aurescens, Asticcacaulis excentricus, Atopobium minutum, Atopobium parvulum, Atopobium rimae, Atopobium vaginae, Avibacterium gallinarum, Bacillus acidicola, Bacillus atrophaeus, Bacillus cereus, Bacillus cibi, Bacillus coahuilensis, Bacillus gaemokensis, Bacillus methanolicus, Bacillus oleronius, Bacillus pumilus, Bacillus shackletonii, Bacillus sporothermodurans, Bacillus subtilis, Bacillus wakoensis, Bacillus weihenstephanensis, Bacteroides barnesiae, Bacteroides coagulans, Bacteroides dorei, Bacteroides faecis, Bacteroides forsythus, Bacteroides fragilis, Bacteroides nordii, Bacteroides ovatus, Bacteroides salyersiae, Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus, Bacteroides xylanisolvens, Bacteroides zoogleoformans, Barnesiella viscericola, Bhargavaea cecembensis, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium dentium, Bifidobacterium logum subsp. infantis, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium scardovii, Bilophila wadsworthia, Blautia hydrogenotrophica, Blautia obeum, Blautia producta, Brachybacterium faecium, Bradyrhizobium japonicum, Brevibacterium mcbrellneri, Brevibacterium otitidis, Brevibacterium paucivorans, Bulleidia extructa, Burkholderia fungorum, Burkholderia phenoliruptix, Caldicellulosiruptor saccharolyticus, Caldimonas taiwanensis, Campylobacter gracilis, Campylobacter hominis, Campylobacter sputorum, Campylobacter ureolyticus, Capnocytophaga ochracea, Cardiobacterium hominis, Catonella morbi, Chlamydia trachomatis, Chlamydophila abortus, Chondromyces robustus, Chryseobacterium aquaticum, Citrobacter youngae, Cloacibacterium normanense, Clostridium cavendishii, Clostridium colicanis, Clostridium jejuense, Clostridium perfringens, Clostridium ramosum, Clostridium sordellii, Clostridium viride, Comamonas terrigena, Corynebacterium accolens, Corynebacterium appendicis, Corynebacterium coyleae, Corynebacterium glucuronolyticum, Corynebacterium glutamicum, Corynebacterium jeikeium, Corynebacterium kroppenstedtii, Corynebacterium lipophiloflavum, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium nuruki, Corynebacterium pseudogenitalium, Corynebacterium pyruviciproducens, Corynebacterium singulare, Corynebacterium striatum, Corynebacterium tuberculostearicum, Corynebacterium xerosis, Cryobacterium psychrophilum, Curtobacterium flaccumfaciens, Cutibacterium acnes, Cutibacterium avidum, Cytophaga xylanolytica, Deinococcus radiophilus, Delftia tsuruhatensis, Desulfovibrio desulfuricans, Dialister invisus, Dialister micraerophilus, Dialister pneumosintes, Dialister propionicifaciens, Dickeya chrysanthemi, Dorea longicatena, Eggerthella lenta, Eggerthia catenaformis, Eikenella corrodens, Enhydrobacter aerosaccus, Enterobacter asburiae, Enterobacter cloacae, Enterococcus avium, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus hirae, Erwinia persicina, Erwinia rhapontici, Erwinia toletana, Escherichia coli, Escherichia fergusonii, Eubacterium brachy, Eubacterium eligens, Eubacterium nodatum, Eubacterium rectale, Eubacterium saphenum, Eubacterium siraeum, Eubacterium sulci, Eubacterium yurii, Exiguobacterium acetylicum, Facklamia ignava, Faecalibacterium prausnitzii, Filifactor alocis, Finegoldia magna, Fusobacterium gonidiaformans, Fusobacterium nucleatum, Fusobacterium periodonticum, Gardnerella vaginalis, Gemella asaccharolytica, Gemella bergeri, Gemella haemolysans, Gemella sanguinis, Geobacillus stearothermophilus, Geobacillus thermocatenulatus, Geobacillus thermoglucosidasius, Geobacter grbiciae, Granulicatella elegans, Haemophilus ducreyi, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus parainfluenzae, Hafnia alvei, Halomonas meridiana, Halomonas phoceae, Halomonas venusta, Herbaspirillum seropedicae, Janthinobacterium lividum, Jonquetella anthropi, Klebsiella granulomatis, Klebsiella oxytoca, Klebsiella pneumoniae, Lactobacillus acidophilus, Lactobacillus amylovorus, Lactobacillus brevis, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kalixensis, Lactobacillus kefiranofaciens, Lactobacillus kimchicus, Lactobacillus kitasatonis, Lactobacillus mucosae, Lactobacillus panis, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus ultunensis, Lactobacillus vaginalis, Lactococcus lactis, Leptotrichia buccalis, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc garlicum, Leuconostoc lactis, Leuconostoc mesenteroides, Lysinimonas kribbensis, Mageeibacillus indolicus, Maribacter orientalis, Marinomonas protea, Marinospirillum insulare, Massilia timonae, Megasphaera elsdenii, Megasphaera micronuciformis, Mesorhizobium amorphae, Methylobacterium radiotolerans, Methylotenera versatilis, Microbacterium halophilum, Micrococcus luteus, Microterricola viridarii, Mobiluncus curtisii, Mobiluncus mulieris, Mogibacterium timidum, Moorella glycerini, Moraxella osloensis, Morganella morganii, Moryella indoligenes, Murdochiella asaccharolytica, Mycoplasma alvi, Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma muris, Mycoplasma salivarium, Negativicoccus succinicivorans, Neisseria flava, Neisseria gonorrhoeae, Neisseria mucosa, Neisseria subflava, Nevskia ramosa, Nevskia soli, Nitriliruptor alkaliphilus, Odoribacter splanchnicus, Oligella urethralis, Olsenella uli, Paenibacillus amylolyticus, Paenibacillus humicus, Paenibacillus pabuli, Paenibacillus pasadenensis, Paenibacillus pini, Paenibacillus validus, Pantoea agglomerans, Parabacteroides merdae, Paraburkholderia caryophylli, Paracoccus yeei, Parastreptomyces abscessus, Parvimonas micra, Pectobacterium betavasculorum, Pectobacterium carotovorum, Pediococcus acidilactici, Pediococcus ethanolidurans, Pedobacter alluvionis, Pedobacter wanjuense, Pelomonas aquatica, Peptococcus niger, Peptoniphilus asaccharolyticus, Peptoniphilus gorbachii, Peptoniphilus harei, Peptoniphilus indolicus, Peptoniphilus lacrimalis, Peptoniphilus massiliensis, Peptostreptococcus anaerobius, Peptostreptococcus massiliae, Peptostreptococcus stomatis, Photobacterium angustum, Photobacterium frigidiphilum, Photobacterium phosphoreum, Porphyromonas asaccharolytica, Porphyromonas bennonis, Porphyromonas catoniae, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas somerae, Porphyromonas uenonis, Prevotella amnii, Prevotella baroniae, Prevotella bergensis, Prevotella bivia, Prevotella buccae, Prevotella buccalis, Prevotella colorans, Prevotella copri, Prevotella corporis, Prevotella dentalis, Prevotella denticola, Prevotella disiens, Prevotella intermedia, Prevotella loescheii, Prevotella marshii, Prevotella melaninogenica, Prevotella micans, Prevotella nigrescens, Prevotella oris, Prevotella pleuritidis, Prevotella ruminicola, Prevotella shahii, Prevotella stercorea, Prevotella timonensis, Prevotella veroralis, Propionimicrobium lymphophilum, Proteus mirabilis, Pseudomonas abietaniphila, Pseudomonas aeruginosa, Pseudomonas amygdali, Pseudomonas azotoformans, Pseudomonas chlororaphis, Pseudomonas cuatrocienegasensis, Pseudomonas fluorescens, Pseudomonas fulva, Pseudomonas lutea, Pseudomonas mucidolens, Pseudomonas oleovorans, Pseudomonas orientalis, Pseudomonas pseudoalcaligenes, Pseudomonas psychrophila, Pseudomonas putida, Pseudomonas synxantha, Pseudomonas syringae, Pseudomonas tolaasii, Pseudopropionibacterium propionicum, Rahnella aquatilis, Ralstonia pickettii, Ralstonia solanacearum, Raoultella planticola, Rhizobacter dauci, Rhizobium etli, Rhodococcus fascians, Rhodopseudomonas palustris, Roseburia intestinalis, Roseburia inulinivorans, Rothia mucilaginosa, Ruminococcus bromii, Ruminococcus gnavus, Ruminococcus torques , Sanguibacter keddieii, Sediminibacterium salmoneum, Selenomonas bovis, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Shewanella algae, Shewanella amazonensis, Shigella boydii, Shigella sonnei, Slackia exigua, Sneathia amnii, Sneathia sanguinegens, Solobacterium moorei, Sorangium cellulosum, Sphingobium amiense, Sphingobium japonicum, Sphingobium yanoikuyae, Sphingomonas wittichii, Sporosarcina aquimarina, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Staphylococcus schleiferi, Staphylococcus simiae, Staphylococcus simulans, Staphylococcus warneri, Stenotrophomonas maltophilia, Stenoxybacter acetivorans, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus australis, Streptococcus equinus, Streptococcus gallolyticus, Streptococcus infantis, Streptococcus intermedius, Streptococcus lutetiensis, Streptococcus marimammalium, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus phocae, Streptococcus pseudopneumoniae, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus thermophilus, Sutterella wadsworthensis, Tannerella forsythia, Terrahaemophilus aromaticivorans, Treponema denticola, Treponema maltophilum, Treponema parvum, Treponema vincentii, Trueperella bernardiae, Turicella otitidis, Ureaplasma parvum, Ureaplasma urealyticum, Varibaculum cambriense, Variovorax paradoxus, Veillonella atypica, Veillonella dispar, Veillonella montpellierensis, Veillonella parvula, Virgibacillus proomii, Viridibacillus arenosi, Viridibacillus arvi, Weissella cibaria, Weissella soli, Xanthomonas campestris, Xanthomonas vesicatoria, Zobellia laminariae or Zoogloea ramigera.

In one embodiment, the targeted bacteria are Escherichia coli.

Thus, bacteriophages used for preparing the bacterial delivery vehicles, and then the bacterial delivery vehicles, may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus and/or species of bacteria to specifically deliver the payload of interest.

In one embodiment, the targeted bacteria are pathogenic bacteria. The targeted bacteria can be virulent bacteria.

The targeted bacteria can be antibacterial resistance bacteria, including those selected from the group consisting of extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli, ESBL Klebsiella pneumoniae, vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) Acinetobacter baumannii, MDR Enterobacter spp., and a combination thereof. The targeted bacteria can be selected from the group consisting of extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli strains. In a particular embodiment, said targeted bacteria are ESBL Escherichia coli and/or ESBL Klebsiella pneumoniae.

Alternatively, the targeted bacterium can be a bacterium of the microbiome of a given species, including a bacterium of the human microbiota.

The present disclosure is directed to a bacterial delivery vehicle containing the payload as described herein. The bacterial delivery vehicles are typically prepared from bacterial virus. The bacterial delivery vehicles are typically chosen in order to be able to introduce the payload into the targeted bacteria.

Bacterial viruses, from which the bacterial delivery vehicles disclosed herein may be derived, include bacteriophages. Optionally, the bacteriophage is selected from the Order Caudovirales consisting of, based on the taxonomy of Krupovic et al, Arch Virol, 2015, the family Myoviridae, the family Podoviridae, the family Siphoviridae, and the family Ackermannviridae.

Bacteriophages may be selected from the family Myoviridae (such as, without limitation, genus Cp220virus, Cp8virus, Ea214virus, Felixolvirus, Mooglevirus, Suspvirus, Hp1virus, P2virus, Kayvirus, P100virus, Silviavirus, Spolvirus, Tsarbombavirus, Twortvirus, Cc31virus, Jd18virus, Js98virus, Kp15virus, Moonvirus, Rb49virus, Rb69virus, S16virus, Schizot4virus, Sp18virus, T4virus, Cr3virus, Selvirus, V5virus, Abouovirus, Agatevirus, Agrican357virus, Ap22virus, Arv1virus, B4virus, Bastillevirus, Bc431virus, Bcep78virus, Bcepmuvirus, Biquartavirus, Bxzlvirus, Cd119virus, Cp51virus, Cvm10virus, Eah2virus, Elvirus, Hapunavirus, Jimmervirus, Kpp10virus, M12virus, Machinavirus, Marthavirus, Msw3virus, Muvirus, Myohalovirus, Nit1virus, P1virus, Pakpunavirus, Pbunavirus, Phikzvirus, Rheph4virus, Rs12virus, Rslunavirus, Secunda5virus, Sep1virus, Spn3virus, Svunavirus, Tg1virus, Vhmlvirus and Wphvirus).

Bacteriophages may be selected from the family Podoviridae (such as, without limitation, genus Fri1virus, Kp32virus, Kp34virus, Phikmvvirus, Pradovirus, Sp6virus, T7virus, Cp1virus, P68virus, Phi29virus, Nona33virus, Pocjvirus, T12011virus, Bcep22virus, Bpplvirus, Cba41virus, Dfl12virus, Ea92virus, Epsilon15virus, F116virus, G7cvirus, Jwalphavirus, Kf1virus, Kpp25virus, Lit1virus, Luz24virus, Luz7virus, N4virus, Nonanavirus, P22virus, Pagevirus, Phieco32virus, Prtbvirus, Sp58virus, Una961virus and Vp5virus).

Bacteriophages may be selected from the family Siphoviridae (such as, without limitation, genus Camvirus, Likavirus, R4virus, Acadianvirus, Coopervirus, Pg1virus, Pipefishvirus, Rosebushvirus, Brujitavirus, Che9cvirus, Hawkeyevirus, Plotvirus, Jerseyvirus, K1gvirus, Sp31virus, Lmd1virus, Una4virus, Bongovirus, Reyvirus, Buttersvirus, Charlievirus, Redivirus, Baxtervirus, Nymphadoravirus, Bignuzvirus, Fishbumevirus, Phayoncevirus, Kp36virus, Rogue1virus, Rtpvirus, T1virus, Tlsvirus, Ab18virus, Amigovirus, Anatolevirus, Andromedavirus, Attisvirus, Barnyardvirus, Bernal 13virus, Biseptimavirus, Bronvirus, C2virus, C5virus, Cba181virus, Cbastvirus, Cecivirus, Che8virus, Chivirus, Cjw1virus, Corndogvirus, Cronusvirus, D3112virus, D3virus, Decurrovirus, Demosthenesvirus, Doucettevirus, E125virus, Eiauvirus, Ff47virus, Gaiavirus, Gilesvirus, Gordonvirus, Gordtnkvirus, Harrisonvirus, Hk578virus, Hk97virus, Jenstvirus, Jwxvirus, Kelleziovirus, Korravirus, L5virus, lambdavirus, Laroyevirus, Liefievirus, Marvinvirus, Mudcatvirus, N15virus, Nonagvirus, Np1virus, Omegavirus, P12002virus, P12024virus, P23virus, P70virus, Pa6virus, Pamx74virus, Patiencevirus, Pbi1virus, Pepy6virus, Pfr1virus, Phic31virus, Phicbkvirus, Phietavirus, Phifelvirus, Phijl1virus, Pis4avirus, Psavirus, Psimunavirus, Rdjlvirus, Rer2virus, Sap6virus, Send513virus, Septima3virus, Seuratvirus, Sextaecvirus, Sfi11virus, Sfi21dtlvirus, Sitaravirus, Sklvirus, Slashvirus, Smoothievirus, Soupsvirus, Spbetavirus, Ssp2virus, T5virus, Tankvirus, Tin2virus, Titanvirus, Tm4virus, Tp21virus, Tp84virus, Triavirus, Trigintaduovirus, Vegasvirus, Vendettavirus, Wbetavirus, Wildcatvirus, Wizardvirus, Woesvirus, Xp10virus, Ydn12virus and Yuavirus).

Bacteriophages may be selected from the family Ackermannviridae (such as, without limitation, genus Ag3virus, Limestonevirus, Cba120virus and Vi1virus).

Optionally, the bacteriophage is not part of the order Caudovirales but from families with unassigned order such as, without limitation, family Tectiviridae (such as genus Alphatectivirus, Betatectivirus), family Corticoviridae (such as genus Corticovirus), family Inoviridae (such as genus Fibrovirus, Habenivirus, Inovirus, Lineavirus, Plectrovirus, Saetivirus, Vespertiliovirus), family Cystoviridae (such as genus Cystovirus), family Leviviridae (such as genus Allolevivirus, Levivirus), family Microviridae (such as genus Alpha3microvirus, G4microvirus, Phix174microvirus, Bdellomicrovirus, Chlamydiamicrovirus, Spiromicrovirus) and family Plasmaviridae (such as genus Plasmavirus).

Optionally, the bacteriophage is targeting Archea not part of the Order Caudovirales but from families with unassigned order such as, without limitation, Ampullaviridae, FuselloViridae, Globuloviridae, Guttaviridae, Lipothrixviridae, Pleolipoviridae, Rudiviridae, Salterprovirus and Bicaudaviridae.

A non-exhaustive listing of bacterial genera and their known host-specific bacteria viruses is presented in the following paragraphs. The chimeric RBPs and/or the recombinant gpJ proteins and/or the recombinant gpH proteins, and the bacterial delivery vehicles disclosed herein may be engineered, as non-limiting examples, from the following phages. Synonyms and spelling variants are indicated in parentheses. Homonyms are repeated as often as they occur (e.g., D, D, d). Unnamed phages are indicated by “NN” beside their genus and their numbers are given in parentheses.

Bacteria of the genus Actinomyces can be infected by the following phages: Av-I, Av-2, Av-3, BF307, CT1, CT2, CT3, CT4, CT6, CT7, CT8 and 1281.

Bacteria of the genus Aeromonas can be infected by the following phages: AA-I, Aeh2, N, PM1, TP446, 3, 4, 11, 13, 29, 31, 32, 37, 43, 43-10T, 51, 54, 55R.1, 56, 56RR2, 57, 58, 59.1, 60, 63, Aehl, F, PM2, 1, 25, 31, 40RR2.8t, (syn= 44R), (syn= 44RR2.8t), 65, PM3, PM4, PM5 and PM6.

Bacteria of the genus Bacillus can be infected by the following phages: A, aizl, Al-K-I, B, BCJA1, BC1, BC2, BLL1, BL1, BP142, BSL1, BSL2, BS1, BS3, BS8, BS15, BS18, BS22, BS26, BS28, BS31, BS104, BS105, BS106, BTB, B1715V1, C, CK-I, Coll, Corl, CP-53, CS-I, CSi, D, D, D, D5, entl, FP8, FP9, FSi, FS2, FS3, FS5, FS8, FS9, G, GH8, GT8, GV-I, GV-2, GT-4, g3, g12, gl3, gl4, gl6, g17, g21, g23, g24, g29, H2, kenl, KK-88, Kuml, Kyul, J7W-1, LP52, (syn= LP-52), L7, Mexl, MJ-I, mor2, MP-7, MP1O, MP12, MP14, MP15, Neol, N°2, N5, N6P, PBC1, PBLA, PBP1, P2, S-a, SF2, SF6, Shal, Sill, SP02, (syn= ΦSPP1), SPβ, STI, STi, SU-I1, t, TbI, Tb2, Tb5, TbIO, Tb26, Tb51, Tb53, Tb55, Tb77, Tb97, Tb99, Tb560, Tb595, Td8, Td6, Tdl5, TgI, Tg4, Tg6, Tg7, Tg9, TgIO, TgI1, Tgl3, Tgl5, Tg21, Tinl, Tin7, Tin8, Tinl3, Tm3, Tocl, Togl, toll, TP-I, TP-10vir, TP-15c, TP-16c, TP-17c, TP-19, TP35, TP51, TP-84, Tt4, Tt6, type A, type B, type C, type D, type E, Tφ3, VA-9, W, wx23, wx26, Yunl, α, γ, pl l,, φmed-2, φT, φµ-4, φ3T, φ75, φ1O5, (syn= φ1O5), IA, IB, 1-97A, 1-97B, 2, 2, 3, 3, 3, 5, 12, 14, 20, 30, 35, 36, 37, 38, 41C, 51, 63, 64, 138D, I, II, IV, NN-Bacillus (13), alel, AR1, AR2, AR3, AR7, AR9, Bace-11, (syn= 11), Bastille, BL1, BL2, BL3, BL4, BL5, BL6, BL8, BL9, BP124, BS28, BS80, Ch, CP-51, CP-54, D-5, darl, denl, DP-7, entl, FoSi, FoS2, FS4, FS6, FS7, G, gall, gamma, GE1, GF-2, GSi, GT-I, GT-2, GT-3, GT-4, GT-5, GT-6, GT-7, GV-6, gl5, 19, 110, ISi, K, MP9, MP13, MP21, MP23, MP24, MP28, MP29, MP30, MP32, MP34, MP36, MP37, MP39, MP40, MP41, MP43, MP44, MP45, MP47, MP50, NLP-I, No.1, N17, N19, PBS1, PK1, PMB1, PMB12, PMJ1, S, SPO1, SP3, SP5, SP6, SP7, SP8, SP9, SP1O, SP-15, SP50, (syn= SP-50), SP82, SST, subl, SW, Tg8, Tg12, Tgl3, Tgl4, thul, thuA, thuS, Tin4, Tin23, TP-13, TP33, TP50, TSP-I, type V, type VI, V, Vx, β22, φe, φNR2, φ25, φ63, 1, 1, 2, 2C, 3NT, 4, 5, 6, 7, 8, 9, 10, 12, 12, 17, 18, 19, 21, 138, III, 4 (B. megateriwn), 4 (B. sphaericus), AR13, BPP-IO, BS32, BS107, B1, B2, GA-I, GP-IO, GV-3, GV-5, g8, MP20, MP27, MP49, Nf, PP5, PP6, SF5, Tgl8, TP-I, Versailles, φ15, φ29, 1-97, 837/IV, mi-Bacillus (1), BatlO, BSL1O, BSLI1, BS6, BSI1, BS16, BS23, BS1O1, BS102, gl8, morl, PBL1, SN45, thu2, thu3, TmI, Tm2, TP-20, TP21, TP52, type F, type G, type IV, HN-BacMus (3), BLE, (syn= θc), BS2, BS4, BS5, BS7, B1O, B12, BS20, BS21, F, MJ-4, PBA12, AP50, AP50-04, AP50-11, AP50-23, AP50-26, AP50-27 and Bam35. The following Bacillus-specific phages are defective: DLP10716, DLP-11946, DPB5, DPB12, DPB21, DPB22, DPB23, GA-2, M, No. IM, PBLB, PBSH, PBSV, PBSW, PBSX, PBSY, PBSZ, phi, SPa, type 1 and µ.

Bacteria of the genus Bacteroides can be infected by the following phages: ad I2, Baf-44, Baf-48B, Baf-64, Bf-I, Bf-52, B40-8, F1, β1, φA1, φBrO1, φBrO2, 11, 67.1, 67.3, 68.1, mt-Bacteroides (3), Bf42, Bf71, HN-Bdellovibrio (1) and BF-41.

Bacteria of the genus Bordetella can be infected by the following phages: 134 and NN-Bordetella (3).

Bacteria of the genus Borrelia can be infected by the following phages: NN-Borrelia (1) and NN-Borrelia (2).

Bacteria of the genus Brucella can be infected by the following phages: A422, Bk, (syn= Berkeley), BM29, FOi, (syn= FO1), (syn= FQ1), D, FP2, (syn= FP2), (syn= FD2), Fz, (syn= Fz75/13), (syn= Firenze 75/13), (syn= Fi), Fi, (syn= F1), Fim, (syn= FIm), (syn= Fim), FiU, (syn= F1U), (syn= FiU), F2, (syn= F2), F3, (syn= F3), F4, (syn= F4), F5, (syn= F5), F6, F7, (syn= F7), F25, (syn= F25), (syn= £25), F25U, (syn= F25u), (syn= F25U), (syn= F25V), F44, (syn- F44), F45, (syn= F45), F48, (syn= F48), I, Im, M, MC/75, M51, (syn= M85), P, (syn= D), S708, R, Tb, (syn= TB), (syn= Tbilisi), W, (syn= Wb), (syn= Weybridge), X, 3, 6, 7, 10/1, (syn= 10), (syn= F8), (syn= F8), 12m, 24/11, (syn= 24), (syn= F9), (syn= F9), 45/111, (syn= 45), 75, 84, 212/XV, (syn= 212), (syn= Fi0), (syn= F1O), 371/XXIX, (syn= 371), (syn= Fn), (syn= F11) and 513.

Bacteria of the genus Burkholderia can be infected by the following phages: CP75, NN-Burkholderia (1) and 42.

Bacteria of the genus Campylobacter can be infected by the following phages: C type, NTCC12669, NTCC12670, NTCC12671, NTCC12672, NTCC12673, NTCC12674, NTCC12675, NTCC12676, NTCC12677, NTCC12678, NTCC12679, NTCC12680, NTCC12681, NTCC12682, NTCC12683, NTCC12684, 32f, 111c, 191, NN-Campylobacter (2), Vfi-6, (syn= V19), VfV-3, V2, V3, V8, V16, (syn= Vfi-1), V19, V20(V45), V45, (syn= V-45) and NN-Campylobacter (1).

Bacteria of the genus Chlamydia can be infected by the following phages: Chpl.

Bacteria of the genus Clostridium can be infected by the following phages: CAK1, CA5, Ca7, CEβ, (syn= 1C), CEy, Cldl, c-n71, c-203 Tox-, DEβ, (syn= ID), (syn= 1Dt0X+), HM3, KM1, KT, Ms, NA1, (syn= Naltox+), PA135Oe, Pfó, PL73, PL78, PL81, P1, P50, P5771, P19402, 1Ct0X+, 2Ct0X\ 2D3 (syn= 2Dt0X+), 3C, (syn= 3Ctox+), 4C, (syn= 4Ct0X+), 56, III-l, NN-Clostridium (61), NBlt0X+, αl, CAl, HMT, HM2, PFl5 P-23, P-46, Q-05, Q-oe, Q-16, Q-21, Q-26, Q-40, Q-46, S111, SA02, WA01, WA03, Wm, W523, 80, C, CA2, CA3, CPT1, CPT4, c1, c4, c5, HM7, H11/A1, H18/Ax, FWS23, Hi58ZA1, K2ZA1, K21ZS23, ML, NA2t0X; Pf2, Pf3, Pf4, S9ZS3, S41ZA1, S44ZS23, α2, 41, 112ZS23, 214/S23, 233/Ai, 234/S23, 235/S23, II-1, II-2, II-3, NN-Clostridium (12), CA1, F1, K, S2, 1, 5 and NN-Clostridium (8).

Bacteria of the genus Corynebacterium can be infected by the following phages: CGK1 (defective), A, A2, A3, A1O1, A128, A133, A137, A139, A155, A182, B, BF, B17, B18, B51, B271, B275, B276, B277, B279, B282, C, capi, CC1, CG1, CG2, CG33, CL31, Cog, (syn= CG5), D, E, F, H, H-I, hqi, hq2, 11ZH33, Ii/31, J, K, K, (syn= Ktox″), L, L, (syn= Ltox+), M, MC-I, MC-2, MC-3, MC-4, MLMa, N, O, ovi, ov2, ov3, P, P, R, RP6, RS29, S, T, U, UB1, ub2, UH1, UH3, uh3, uh5, uh6, β, (syn= βtox+), βhv64, βvir, γ, (syn= γtoχ-), γ19, δ, (syn= 8'ox+), p, (syn= ptoχ-), Φ9, φ984, ω, IA, 1/1180, 2, 2/1180, 5/1180, 5ad/9717, 7/4465, 8/4465, 8ad/10269, 10/9253, 13Z9253, 15/3148, 21/9253, 28, 29, 55, 2747, 2893, 4498 and 5848.

Bacteria of the genus Enterococcus can be infected by the following phages: DF78, F1, F2, 1, 2, 4, 14, 41, 867, D1, SB24, 2BV, 182, 225, C2, C2F, E3, E62, DS96, H24, M35, P3, P9, SB1O1, S2, 2BII, 5, 182a, 705, 873, 881, 940, 1051, 1057, 21096C, NN-Enterococcus (1), PE1, F1, F3, F4, VD13, 1, 200, 235 and 341.

Bacteria of the genus Erysipelothrix can be infected by the following phage: NN-Eiysipelothrix (1).

Bacteria of the genus Escherichia can be infected by the following phages: BW73, B278, D6, D108, E, E1, E24, E41, FI-2, FI-4, FI-5, HI8A, Ffl8B, i, MM, Mu, (syn= mu), (syn= MuI), (syn= Mu-I), (syn= MU-I), (syn= MuI), (syn= µ), 025, PhI-5, Pk, PSP3, P1, P1D, P2, P4 (defective), S1, Wφ, φK13, cpR73 (defective), φ1, φ2, φ7, φ92, ψ (defective), 7 A, 8φ, 9φ, 15 (defective), 18, 28-1, 186, 299, HH-Escherichia (2), AB48, CM, C4, C16, DD-VI, (syn= Dd-Vi), (syn= DDVI), (syn= DDVi), E4, E7, E28, FI1, FI3, H, H1, H3, H8, K3, M, N, ND-2, ND-3, ND4, ND-5, ND6, ND-7, Ox-I (syn= OX1), (syn= HF), Ox-2 (syn= 0x2), (syn= 0X2), Ox-3, Ox-4, Ox-5, (syn= 0X5), Ox-6, (syn= 66F), (syn= φ66t), (syn= φ66t-)5 0111, PhI-I, RB42, RB43, RB49, RB69, S, SaI-I, Sal-2, Sal-3, Sal-4, Sal-5, Sal-6, TC23, TC45, TuII^(∗)-6, (syn= TuII^(∗)), TuIP-24, TuII^(∗)46, TuIP-60, T2, (syn= ganuTia), (syn= γ), (syn= PC), (syn= P.C.), (syn= T-2), (syn= T2), (syn= P4), T4, (syn= T-4), (syn= T4), T6, T35, α1, 1, IA, 3, (syn= Ac3), 3A, 3T+, (syn= 3), (syn= Ml), 5φ, (syn= φ5), 9266Q, CFO103, HK620, J, K, K1F, m59, no. A, no. E, no. 3, no. 9, N4, sd, (syn= Sd), (syn= SD), (syn= Sa)3 (syn= sd), (syn= SD), (syn= CD), T3, (syn= T-3), (syn= T3), T7, (syn= T-7), (syn= T7), WPK, W31, ΔH, φC3888, φK3, φK7, φK12, φV-1, Φ04-CF, Φ05, Φ06, Φ07, φ1, φ1.2, φ20, φ95, φ263, φ1O92, φ1, φ11, (syn=φW), Ω8, 1, 3, 7, 8, 26, 27, 28-2, 29, 30, 31, 32, 38, 39, 42, 933W, NN-Escherichia (1), Esc-7-11, AC30, CVX-5, C1, DDUP, EC1, EC2, E21, E29, F1, F26S, F27S, Hi, HK022, HK97, (syn= ΦHK97), HK139, HK253, HK256, K7, ND-I, no.D, PA-2, q, S2, T1, (syn= α), (syn= P28), (syn= T-I), (syn= Tx), T3C, T5, (syn= T-5), (syn= T5), UC-I, w, β4, γ2, λ (syn= lambda), (syn= Φλ), ΦD326, φγ, Φ06, Φ7, Φ10, φ80, χ, (syn= χi), (syn= φχ), (syn= φχi), 2, 4, 4A, 6, 8A, 102, 150, 168, 174, 3000, AC6, AC7, AC28, AC43, AC50, AC57, AC81, AC95, HK243, K1O, ZG/3A, 5, 5A, 21EL, H19-J and 933H.

Bacteria of the genus Fusobacterium can be infected by the following phages: NN-Fusobacterium (2), fv83-554/3, fv88-531/2, 227, fv2377, fv2527 and fv8501.

Bacteria of the genus Haemophilus can be infected by the following phages: HP1, S2 and N3.

Bacteria of the genus Helicobacter can be infected by the following phages: HP1 and ^^-Helicobacter (1).

Bacteria of the genus Klebsiella can be infected by the following phages: AIO-2, KI4B, Kl6B, Kl9, (syn= Kl9), K114, K115, Kl21, Kl28, Kl29, KI32, Kl33, Kl35, Kl106B, Kl171B, Kl181B, Kl832B, AIO-I, AO-I, AO-2, AO-3, FC3-10, K, Kl1, (syn= KIl), Kl2, (syn= Kl2), Kl3, (syn= Kl3), (syn= Kl 70/11), Kl4, (syn= Kl4), Kl5, (syn= K15), Kl6, (syn= Kl6), Kl7, (syn= Kl7), Kl18, (syn= Kl8), Kl19, (syn= K19), Kl27, (syn= K127), Kl31, (syn= K131), Kl35, K1171B, II, VI, IX, CI-I, Kl4B, Kl8, Kl11, Kl12, Kl13, Kl16, Kl17, Kl18, Kl20, Kl22, Kl23, Kl24, Kl26, Kl30, Kl34, Kl106B, KIi65B, Kl328B, KLXI, K328, P5046, 11, 380, III, IV, VII, VIII, FC3-11, Kl2B, (syn= Kl2B), Kl25, (syn= Kl25), Kl42B, (syn= K142), (syn= K142B), K1181B, (syn= KI 81), (syn= K1181B), K1765/!, (syn= K1765/1), K1842B, (syn= K1832B), K1937B, (syn= K1937B), L1, φ28, 7, 231, 483, 490, 632 and 864/100.

Bacteria of the genus Lepitospira can be infected by the following phages: LEI, LE3, LE4 and ~NN-Leptospira (1).

Bacteria of the genus Listeria can be infected by the following phages: A511, 01761, 4211, 4286, (syn= BO54), A005, A006, A020, A500, A502, A511, Al 18, A620, A640, B012, B021, B024, B025, B035, B051, B053, B054, B055, B056, BlOl, BI lO, B545, B604, B653, C707, D441, HSO47, HlOG, H8/73, H19, H21, H43, H46, H107, H108, HI lO, H163/84, H312, H340, H387, H391/73, H684/74, H924A, PSA, U153, φMLUP5, (syn= P35), 00241, 00611, 02971A, 02971C, 5/476, 5/911, 5/939, 5/11302, 5/11605, 5/11704, 184, 575, 633, 699/694, 744, 900, 1090, 1317, 1444, 1652, 1806, 1807, 1921/959, 1921/11367, 1921/11500, 1921/11566, 1921/12460, 1921/12582, 1967, 2389, 2425, 2671, 2685, 3274, 3550, 3551, 3552, 4276, 4277, 4292, 4477, 5337, 5348/11363, 5348/11646, 5348/12430, 5348/12434, 10072, 11355C, 11711A, 12029, 12981, 13441, 90666, 90816, 93253, 907515, 910716 and NN-Listeria (15).

Bacteria of the genus Morganella can be infected by the following phage: 47.

Bacteria of the genus Mycobacterium can be infected by the following phages: 13, AGl, ALi, ATCC 11759, A2, B.C3, BG2, BKl, BK5, butyricum, B-I, B5, B7, B30, B35, Clark, Cl, C2, DNAIII, DSP1, D4, D29, GS4E, (syn= GS4E), GS7, (syn= GS-7), (syn= GS7), IPa, lacticola, Legendre, Leo, L5, (syn= ΦL-5), MC-I, MC-3, MC-4, minetti, MTPHI l, Mx4, MyF3P/59a, phlei, (syn= phlei 1), phlei 4, Polonus II, rabinovitschi, smegmatis, TM4, TM9, TMlO, TM20, Y7, YlO, φ630, IB, IF, IH, 1/1, 67, 106, 1430, Bl, (syn= Bol), B24, D, D29, F-K, F-S, HP, Polonus I, Roy, Rl, (syn= Rl-Myb), (syn= Ri), 11, 31, 40, 50, 103a, 103b, 128, 3111-D, 3215-D and NN-Mycobacterium (1).

Bacteria of the genus Neisseria can be infected by the following phages: Group I, group II and NPl.

Bacteria of the genus Nocardia can be infected by the following phages: MNP8, NJ-L, NS-8, N5 and TtiN-Nocardia.

Bacteria of the genus Proteus can be infected by the following phages: Pm5, 13vir, 2/44, 4/545, 6/1004, 13/807, 20/826, 57, 67b, 78, 107/69, 121, 9/0, 22/608, 30/680, PmI, Pm3, Pm4, Pm6, Pm7, Pm9, PmIO, PmI l, Pv2, πl, φm, 7/549, 9B/2, 10A/31, 12/55, 14, 15, 16/789, 17/971, 19A/653, 23/532, 25/909, 26/219, 27/953, 32A/909, 33/971, 34/13, 65, 5006M, 7480b, VI, 13/3a, Clichy 12, π2600, φχ7, 1/1004, 5/742, 9, 12, 14, 22, 24/860, 2600/D52, Pm8 and 24/2514.

Bacteria of the genus Providencia can be infected by the following phages: PL25, PL26, PL37, 9211/9295, 9213/921 Ib, 9248, 7/R49, 7476/322, 7478/325, 7479, 7480, 9000/9402 and 9213/921 Ia.

Bacteria of the genus Pseudomonas can be infected by the following phages: Pfl, (syn= Pf-I), Pf2, Pf3, PP7, PRRl, 7s, im-Pseudomonas (1), AI-I, AI-2, B 17, B89, CB3, Col 2, Col 11, Col 18, Col 21, C154, C163, C167, C2121, E79, F8, ga, gb, H22, K1, M4, N2, Nu, PB-I, (syn= PBl), pfl6, PMN17, PPl, PP8, Psal, PsPl, PsP2, PsP3, PsP4, PsP5, PS3, PS17, PTB80, PX4, PX7, PYOl, PYO2, PYO5, PYO6, PYO9, PYOlO, PYO13, PYO14, PYO16, PYO18, PYO19, PYO20, PYO29, PYO32, PYO33, PYO35, PYO36, PYO37, PYO38, PYO39, PYO41, PYO42, PYO45, PYO47, PYO48, PYO64, PYO69, PYO103, PlK, SLPl, SL2, S2, UNL-I, wy, Yai, Ya4, Yan, φBE, φCTX, φC17, φKZ, (syn=ΦKZ), φ-LT, Φmu78, φNZ, φPLS-1, φST-1, φW-14, φ-2, 1/72, 2/79, 3, 3/DO, 4/237, 5/406, 6C, 6/6660, 7, 7v, 7/184, 8/280, 9/95, 10/502, 11/DE, 12/100, 12S, 16, 21, 24, 25F, 27, 31, 44, 68, 71, 95, 109, 188, 337, 352, 1214, HN-Pseudomonas (23), A856, B26, CI-I, CI-2, C5, D, gh-1, Fl 16, HF, H90, K5, K6, Kl 04, K109, K166, K267, N4, N5, O6N-25P, PE69, Pf, PPN25, PPN35, PPN89, PPN91, PP2, PP3, PP4, PP6, PP7, PP8, PP56, PP87, PPl 14, PP206, PP207, PP306, PP651, Psp231a, Pssy401, Pssy9220, psi, PTB2, PTB20, PTB42, PXl, PX3, PXlO, PX12, PX14, PYO70, PYO71, R, SH6, SH133, tf, Ya5, Ya7, φBS, ΦKf77, φ-MC, ΦmnF82, φPLS27, φPLS743, φS-1, 1, 2, 2, 3, 4, 5, 6, 7, 7, 8, 9, 10, 11, 12, 12B, 13, 14, 15, 14, 15, 16, 17, 18, 19, 20, 20, 21, 21, 22, 23, 23, 24, 25, 31, 53, 73, 119x, 145, 147, 170, 267, 284, 308, 525, NN-Pseudomonas (5), af, A7, B3, B33, B39, BI-I, C22, D3, D37, D40, D62, D3112, F7, FlO, g, gd, ge, gξ Hwl2, Jb 19, KFl, L°, OXN-32P, O6N-52P, PCH-I, PC13-1, PC35-1, PH2, PH51, PH93, PH132, PMW, PM13, PM57, PM61, PM62, PM63, PM69, PM105, PMl 13, PM681, PM682, PO4, PPl, PP4, PP5, PP64, PP65, PP66, PP71, PP86, PP88, PP92, PP401, PP711, PP891, Pssy41, Pssy42, Pssy403, Pssy404, Pssy420, Pssy923, PS4, PS-IO, Pz, SDl, SLl, SL3, SL5, SM, φC5, φCl l, φCl l-1, φC13, φC15, φMO, φX, φO4, φl l, φ240, 2, 2F, 5, 7m, 11, 13, 13/441, 14, 20, 24, 40, 45, 49, 61, 73, 148, 160, 198, 218, 222, 236, 242, 246, 249, 258, 269, 295, 297, 309, 318, 342, 350, 351, 357-1, 400-1, HN-Pseudomonas (6), GlOl, M6, M6a, Ll, PB2, Pssyl5, Pssy4210, Pssy4220, PYO12, PYO34, PYO49, PYO50, PYO51, PYO52, PYO53, PYO57, PYO59, PYO200, PX2, PX5, SL4, φO3, φO6 and 1214.

Bacteria of the genus Rickettsia can be infected by the following phage: NN-Rickettsia.

Bacteria of the genus Salmonella can be infected by the following phages: b, Beccles, CT, d, Dundee, f, FeIs 2, GI, GUI, GVI, GVIII, k, K, i, j, L, 01, (syn= 0-1), (syn= O1), (syn= O-I), (syn= 7), 02, 03, P3, P9a, PlO, Sab3, Sab5, SanlS, Sanl7, SI, Taunton, ViI, (syn= ViI), 9, imSalmonella (1), N-I, N-5, N-IO, N-17, N-22, 11, 12, 16-19, 20.2, 36, 449C/C178, 966A/C259, a, B.A.O.R., e, G4, GUI, L, LP7, M, MG40, N-18, PSA68, P4, P9c, P22, (syn= P22), (syn= PLT22), (syn= PLT22), P22al, P22-4, P22-7, P22-11, SNT-I, SNT-2, SP6, Villi, ViIV, ViV, ViVI, ViVII, Worksop, Sj5, s34, 1,37, 1(40), (syn= φl[40]), 1,422, 2, 2.5, 3b, 4, 5, 6,14(18), 8, 14(6,7), 10, 27, 28B, 30, 31, 32, 33, 34, 36, 37, 39, 1412, SNT-3, 7-11, 40.3, c, C236, C557, C625, C966N, g, GV, G5, Gl 73, h, IRA, Jersey, MB78, P22-1, P22-3, P22-12, Sabl, Sab2, Sab2, Sab4, Sanl, San2, San3, San4, San6, San7, San8, San9, Sanl3, Sanl4, Sanl6, Sanl8, Sanl9, San20, San21, San22, San23, San24, San25, San26, SasLl, SasL2, SasL3, SasL4, SasL5, SlBL, SII, ViII, φl, 1, 2, 3a, 3al, 1010, Ym-Salmonella (1), N-4, SasL6 and 27.

Bacteria of the genus Serratia can be infected by the following phages: A2P, PS20, SMB3, SMP, SMP5, SM2, V40, V56, ic, ΦCP-3, ΦCP-6, 3M, 10/la, 20A, 34CC, 34H, 38T, 345G, 345P, 501B, SMB2, SMP2, BC, BT, CW2, CW3, CW4, CW5, Lt232, L2232, L34, L.228, SLP, SMPA, V.43, σ, φCWl, ΦCP6-1, ΦCP6-2, ΦCP6-5, 3T, 5, 8, 9F, 10/1, 2OE, 32/6, 34B, 34CT, 34P, 37, 41, 56, 56D, 56P, 6OP, 61/6, 74/6, 76/4, 101/8900, 226, 227, 228, 229F, 286, 289, 290F, 512, 764a, 2847/10, 2847/1Oa, L.359 and SMBl.

Bacteria of the genus Shigella can be infected by the following phages: Fsa, (syn=a), FSD2d, (syn= D2d), (syn= W2d), FSD2E, (syn= W2e), fv, F6, f7.8, H-Sh, PE5, P90, SfII, Sh, SHm, SHrv, (syn= HIV), SHvi, (syn= HVI), SHVvm, (syn= HVIII), SKy66, (syn= gamma 66), (syn= yββ), (syn= y66b), SKm, (syn= SIIIb)5 (syn= UI), SKw, (syn= Siva), (syn= IV), SIC™, (syn= SIVA.), (syn= IVA), SKvi, (syn= KVI), (syn= Svi), (syn= VI), SKvm, (syn= Svm), (syn= VIII), SKVΠIA, (syn= SvmA), (syn= VIIIA), STvi, STK, STx1, STxn, S66, W2, (syn= D2c), (syn= D20), φl, φIVb 3-SO-R, 8368-SO-R, F7, (syn= FS7), (syn= K29), FlO, (syn= FSlO), (syn= K31), I1, (syn= alfa), (syn= FSa), (syn= K1 8), (syn= α), I2, (syn= a), (syn= K19), SG33, (syn= G35), (syn= SO-35/G), SG35, (syn= SO-55/G), SG3201, (syn= SO-3201/G), SHn, (syn= HII), SHv, (syn= SHV), SHx, SHX, SKn, (syn= K2), (syn= KII), (syn= Sn), (syn= SsII), (syn= II), SKrv, (syn= Sm), (syn= SsIV), (syn= IV), SK1Va, (syn= Swab), (syn= SsIVa), (syn= IVa), SKV, (syn= K4), (syn= KV), (syn= SV), (syn= SsV), (syn= V), SKx, (syn= K9), (syn= KX), (syn= SX), (syn= SsX), (syn= X), STV, (syn= T35), (syn= 35-50-R), STvm, (syn= T8345), (syn= 8345-SO-S-R), W1, (syn= D8), (syn= FSD8), W2a, (syn= D2A), (syn= FS2a), DD-2, Sf6, FSi, (syn= Fl), SF6, (syn= F6), SG42, (syn= SO-42/G), SG3203, (syn= SO-3203/G), SKF12, (syn= SsF12), (syn= F12), (syn= F12), STn, (syn= 1881-SO-R), y66, (syn= gamma 66a), (syn= Ssy66), φ2, BIl, DDVII, (syn= DD7), FSD2b, (syn= W2B), FS2, (syn= F2), (syn= F2), FS4, (syn= F4), (syn= F4), FS5, (syn= F5), (syn= F5), FS9, (syn= F9), (syn= F9), FI l, P2-S0-S, SG36, (syn= SO-36/G), (syn= G36), SG3204, (syn= SO-3204/G), SG3244, (syn= SO-3244/G), SHi, (syn= HI), SHvπ, (syn= HVII), SHK, (syn= HIX), SHx1, SHxπ, (syn= HXn), SKI, KI, (syn= S1), (syn= SsI), SKVII, (syn= KVII), (syn= Svπ), (syn= SsVII), SKIX, (syn= KIX), (syn= S1x), (syn= SsIX), SKXII, (syn= KXII), (syn= Sxn), (syn= SsXII), STi, STffl, STrv, STVi, STvπ, S70, S206, U2-S0-S, 3210-SO-S, 3859-SO-S, 4020-SO-S, φ3, φ5, φ7, φ8, φ9, φlO, φl l, φl3, φl4, φl8, SHm, (syn= Hπi), SHχi, (syn= HXt) and SKxI, (syn= KXI), (syn= Sχi), (syn= SsXI), (syn= XI).

Bacteria of the genus Staphylococcus can be infected by the following phages: A, EW, K, Ph5, Ph9, PhIO, Phl3, Pl, P2, P3, P4, P8, P9, PlO, RG, SB-i, (syn= Sb-I), S3K, Twort, ΦSK311, φ812, 06, 40, 58, 119, 130, 131,200, 1623, STCl, (syn=stcl), STC2, (syn=stc2), 44AHJD, 68, ACl, AC2, A6”C″, A9”C″, b581, CA-I, CA-2, CA-3, CA-4, CA-5, DI l, L39x35, L54a, M42, Nl, N2, N3, N4, N5, N7, N8, NlO, Ni l, N12, N13, N14, N16, Ph6, Phl2, Phl4, UC-18, U4, U15, Sl, S2, S3, S4, S5, X2, Z1, φB5-2, φD, ω, 11, (syn= φl l), (syn= P11-M15), 15, 28, 28A, 29, 31, 31B, 37, 42D, (syn= P42D), 44A, 48, 51, 52, 52A, (syn= P52A), 52B, 53, 55, 69, 71, (syn= P71), 71A, 72, 75, 76, 77, 79, 80, 80α, 82, 82A, 83 A, 84, 85, 86, 88, 88A, 89, 90, 92, 95, 96, 102, 107, 108, 111, 129-26, 130, 130A, 155, 157, 157A, 165, 187, 275, 275A, 275B, 356, 456, 459, 471, 471A, 489, 581, 676, 898, 1139, 1154A, 1259, 1314, 1380, 1405, 1563, 2148, 2638A, 2638B, 2638C, 2731, 2792A, 2792B, 2818, 2835, 2848A, 3619, 5841, 12100, AC3, A8, AlO, A13, b594n, D, HK2, N9, N15, P52, P87, Sl, S6, Z4, φRE, 3A, 3B, 3C, 6, 7, 16, 21, 42B, 42C, 42E, 44, 47, 47A5 47C, 51, 54, 54x1, 70, 73, 75, 78, 81, 82, 88, 93, 94, 101, 105, 110, 115, 129/16, 174, 594n, 1363/14, 2460 and mS-Staphylococcus (1).

Bacteria of the genus Streptococcus can be infected by the following phages: EJ-I, NN-Streptococais (1), a, Cl, FL0Ths, H39, Cp-I, Cρ-5, Cp-7, Cp-9, Cp-IO, AT298, A5, alO/Jl, alO/J2, alO/J5, alO/J9, A25, BTI l, b6, CAl, c20-l, c20-2, DP-I, Dp-4, DTl, ET42, elO, FA101, FEThs, Fκ, FKKIOI, FKLIO, FKP74, FKH, FLOThs, FyIOl, fl, F10, F20140/76, g, GT-234, HB3, (syn= HB-3), HB-623, HB-746, M102, 01205, φO1205, PST, PO, Pl, P2, P3, P5, P6, P8, P9, P9, P12, P13, P14, P49, P50, P51, P52, P53, P54, P55, P56, P57, P58, P59, P64, P67, P69, P71, P73, P75, P76, P77, P82, P83, P88, sc, sch, sf, Sfll 1, (syn= SFiI l), (syn= cpSFill), (syn= ΦSfil l), (syn= φSfil l), sfil9, (syn= SFil9), (syn= φSFil9), (syn= φSfil9), Sfi21, (syn= SFi21), (syn= φSFi21), (syn= cpSfi21), ST0, STX, st2, ST2, ST4, S3, (syn= φS3), s265, Φ17, φ42, Φ57, φ80, φ81, φ82, φ83, φ84, φ85, φ86, φ87, φ88, φ89, φ90, φ91, φ92, φ93, φ94, φ95, φ96, φ97, φ98, φ99, φlOO, φlOl, φlO2, φ227, Φ7201, ωl, ω2, ω3, ω4, ω5, ω6, ω8, ωlO, 1, 6, 9, 1OF, 12/12, 14, 17SR, 19S, 24, 50/33, 50/34, 55/14, 55/15, 70/35, 70/36, 71/ST15, 71/45, 71/46, 74F, 79/37, 79/38, 80/J4, 80/J9, 80/ST16, 80/15, 80/47, 80/48, 101, 103/39, 103/40, 121/41, 121/42, 123/43, 123/44, 124/44, 337/ST17 and mStreptococcus (34).

Bacteria of the genus Treponema can be infected by the following phage: NN-Treponema (1).

Bacteria of the genus Vibrio can be infected by the following phages: CTXΦ, fs, (syn= si), fs2, Ivpf5, Vfl2, Vf33, VPIΦ, VSK, v6, 493, CP-Tl, ET25, kappa, K139, Labol, )XN-69P, OXN-86, O6N-21P, PB-I, P147, rp-1, SE3, VA-I, (syn= VcA-I), VcA-2, VPl, VP2, VP4, VP7, VP8, VP9, VPlO, VP17, VP18, VP19, X29, (syn= 29 d'Herelle), t, ΦHAWI-1, ΦHAWI-2, ΦHAWI-3, ΦHAWI-4, ΦHAWI-5, ΦHAWI-6, ΦHAWI-7, XHAWI-8, ΦHAWI-9, ΦHAWI-10, ΦHCl-1, ΦHC1-2, ΦHC1-3, ΦHC1-4, ΦHC2-1, >HC2-2, ΦHC2-3, ΦHC2-4, ΦHC3-1, ΦHC3-2, ΦHC3-3, ΦHD1S-1, ΦHD1S-2, ΦHD2S-1, ΦHD2S-2, ΦHD2S-3, ΦHD2S-4, ΦHD2S-5, ΦHDO-1, ΦHDO-2, ΦHDO-3, ΦHDO-4, ΦHDO-5, ΦHDO-6, ΦKL-33, ΦKL-34, ΦKL-35, ΦKL-36, ΦKWH-2, ΦKWH-3, ΦKWH-4, ΦMARQ-1, ΦMARQ-2, ΦMARQ-3, ΦMOAT-1, ΦO139, ΦPEL1A-1, ΦPEL1A-2, ΦPEL8A-1, ΦPEL8A-2, ΦPEL8A-3, ΦPEL8C-1, ΦPEL8C-2, ΦPEL13A-1, ΦPEL13B-1, ΦPEL13B-2, ΦPEL13B-3, ΦPEL13B-4, ΦPEL13B-5, ΦPEL13B-6, ΦPEL13B-7, ΦPEL13B-8, ΦPEL13B-9, ΦPEL13B-10, φVP143, φVP253, Φ16, φl38, 1-II, 5, 13, 14, 16, 24, 32, 493, 6214, 7050, 7227, II, (syn= group II), (syn== φ2), V, VIII, ~m-Vibrio (13), KVP20, KVP40, nt-1, O6N-22P, P68, el, e2, e3, e4, e5, FK, G, I, K, nt-6, Nl, N2, N3, N4, N5, O6N-34P, OXN-72P, OXN-85P, OXN-100P, P, Ph-I, PL163/10, Q, S, T, φ92, 1-9, 37, 51, 57, 70A-8, 72A-4, 72A-10, 110A-4, 333, 4996, I (syn= group I), III (syn= group III), VI, (syn= A-Saratov), VII, IX, X, HN-Vibrio (6), pAl, 7, 7-8, 70A-2, 71A-6, 72A-5, 72A-8, 108A-10, 109A-6, 109A-8, l lOA-1, 110A-5, 110A-7, hv-1, OXN-52P, P13, P38, P53, P65, P108, Pill, TPl3 VP3, VP6, VP12, VP13, 70A-3, 70A-4, 70A-10, 72A-1, 108A-3, 109-B1, 110A-2, 149, (syn= φl49), IV, (syn= group IV), NN-Vibrio (22), VP5, VPIl, VP15, VP16, αl, α2, α3a, α3b, 353B and HN-Vibrio (7).

Bacteria of the genus Yersinia can be infected by the following phages: H, H-I, H-2, H-3, H-4, Lucas 110, Lucas 303, Lucas 404, YerA3, YerA7, YerA20, YerA41, 3/M64-76, 5/G394-76, 6/C753-76, 8/C239-76, 9/F18167, 1701, 1710, PST, ⅟F2852-76, D'Herelle, EV, H, Kotljarova, PTB, R, Y, YerA41, φYerO3-12, 3, 4/C1324-76, 7/F783-76, 903, ⅟M6176 and Yer2AT.

In an embodiment, the bacteriophage is selected in the group consisting of Salmonella virus SKML39, Shigella virus AG3, Dickeya virus Limestone, Dickeya virus RC2014, Escherichia virus CBA120, Escherichia virus PhaxI, Salmonella virus 38, Salmonella virus Det7, Salmonella virus GG32, Salmonella virus PM10, Salmonella virus SFP10, Salmonella virus SH19, Salmonella virus SJ3, Escherichia virus ECML4, Salmonella virus Marshall, Salmonella virus Maynard, Salmonella virus SJ2, Salmonella virus STML131, Salmonella virus ViI, Erwinia virus Ea2809, Klebsiella virus 0507KN21, Serratia virus IME250, Serratia virus MAM1, Campylobacter virus CP21, Campylobacter virus CP220, Campylobacter virus CPt10, Campylobacter virus IBB35, Campylobacter virus CP81, Campylobacter virus CP30A, Campylobacter virus CPX, Campylobacter virus NCTC12673, Erwinia virus Ea214, Erwinia virus M7, Escherichia virus AYO145A, Escherichia virus EC6, Escherichia virus HY02, Escherichia virus JH2, Escherichia virus TP1, Escherichia virus VpaE1, Escherichia virus wV8, Salmonella virus FelixO1, Salmonella virus HB2014, Salmonella virus Mushroom, Salmonella virus UAB87, Citrobacter virus Moogle, Citrobacter virus Mordin, Escherichia virus SUSP1, Escherichia virus SUSP2, Aeromonas virus phiO18P, Haemophilus virus HP1, Haemophilus virus HP2, Pasteurella virus F108, Vibrio virus K139, Vibrio virus Kappa, Burkholderia virus phi52237, Burkholderia virus phiE122, Burkholderia virus phiE202, Escherichia virus 186, Escherichia virus P4, Escherichia virus P2, Escherichia virus Wphi, Mannheimia virus PHL101, Pseudomonas virus phiCTX, Ralstonia virus RSA1, Salmonella virus Fels2, Salmonella virus PsP3, Salmonella virus SopEphi, Yersinia virus L413C, Staphylococcus virus G1, Staphylococcus virus G15, Staphylococcus virus JD7, Staphylococcus virus K, Staphylococcus virus MCE2014, Staphylococcus virus P108, Staphylococcus virus Rodi, Staphylococcus virus S253, Staphylococcus virus S25-4, Staphylococcus virus SA12, Listeria virus A511, Listeria virus P100, Staphylococcus virus Remus, Staphylococcus virus SA11, Staphylococcus virus Stau2, Bacillus virus Camphawk, Bacillus virus SPO1, Bacillus virus BCP78, Bacillus virus TsarBomba, Staphylococcus virus Twort, Enterococcus virus phiEC24C, Lactobacillus virus Lb338-1, Lactobacillus virus LP65, Enterobacter virus PG7, Escherichia virus CC31, Klebsiella virus JD18, Klebsiella virus PKO111, Escherichia virus Bp7, Escherichia virus IME08, Escherichia virus JS10, Escherichia virus JS98, Escherichia virus QL01, Escherichia virus VR5, Enterobacter virus Eap3, Klebsiella virus KP15, Klebsiella virus KP27, Klebsiella virus Matisse, Klebsiella virus Miro, Citrobacter virus Merlin, Citrobacter virus Moon, Escherichia virus JSE, Escherichia virus phi1, Escherichia virus RB49, Escherichia virus HX01, Escherichia virus JS09, Escherichia virus RB69, Shigella virus UTAM, Salmonella virus S16, Salmonella virus STML198, Vibrio virus KVP40, Vibrio virus nt1, Vibrio virus ValKK3, Escherichia virus VR7, Escherichia virus VR20, Escherichia virus VR25, Escherichia virus VR26, Shigella virus SP18, Escherichia virus AR1, Escherichia virus C40, Escherichia virus E112, Escherichia virus ECML134, Escherichia virus HY01, Escherichia virus Ime09, Escherichia virus RB3, Escherichia virus RB14, Escherichia virus T4, Shigella virus Pss1, Shigella virus Shfl2, Yersinia virus D1, Yersinia virus PST, Acinetobacter virus 133, Aeromonas virus 65, Aeromonas virus Aeh1, Escherichia virus RB16, Escherichia virus RB32, Escherichia virus RB43, Pseudomonas virus 42, Cronobacter virus CR3, Cronobacter virus CR8, Cronobacter virus CR9, Cronobacter virus PBES02, Pectobacterium virus phiTE, Cronobacter virus GAP31, Escherichia virus 4MG, Salmonella virus SE1, Salmonella virus SSE121, Escherichia virus FFH2, Escherichia virus FV3, Escherichia virus JES2013, Escherichia virus V5, Brevibacillus virus Abouo, Brevibacillus virus Davies, Bacillus virus Agate, Bacillus virus Bobb, Bacillus virus Bp8pC, Erwinia virus Deimos, Erwinia virus Ea35-70, Erwinia virus RAY, Erwinia virus Simmy50, Erwinia virus SpecialG, Acinetobacter virus AB1, Acinetobacter virus AB2, Acinetobacter virus AbC62, Acinetobacter virus AP22, Arthrobacter virus ArV1, Arthrobacter virus Trina, Bacillus virus AvesoBmore, Bacillus virus B4, Bacillus virus Bigbertha, Bacillus virus Riley, Bacillus virus Spock, Bacillus virus Troll, Bacillus virus Bastille, Bacillus virus CAM003, Bacillus virus Bc431, Bacillus virus Bcp1, Bacillus virus BCP82, Bacillus virus BM15, Bacillus virus Deepblue, Bacillus virus JBP901, Burkholderia virus Bcep1, Burkholderia virus Bcep43, Burkholderia virus Bcep781, Burkholderia virus BcepNY3, Xanthomonas virus OP2, Burkholderia virus BcepMu, Burkholderia virus phiE255, Aeromonas virus 44RR2, Mycobacterium virus Alice, Mycobacterium virus Bxz1, Mycobacterium virus Dandelion, Mycobacterium virus HyRo, Mycobacterium virus I3, Mycobacterium virus Nappy, Mycobacterium virus Sebata, Clostridium virus phiC2, Clostridium virus phiCD27, Clostridium virus phiCD119, Bacillus virus CP51, Bacillus virus JL, Bacillus virus Shanette, Escherichia virus CVM10, Escherichia virus ep3, Erwinia virus Asesino, Erwinia virus EaH2, Pseudomonas virus EL, Halomonas virus HAP1, Vibrio virus VP882, Brevibacillus virus Jimmer, Brevibacillus virus Osiris, Pseudomonas virus Ab03, Pseudomonas virus KPP10, Pseudomonas virus PAKP3, Sinorhizobium virus M7, Sinorhizobium virus M12, Sinorhizobium virus N3, Erwinia virus Machina, Arthrobacter virus Brent, Arthrobacter virus Jawnski, Arthrobacter virus Martha, Arthrobacter virus Sonny, Edwardsiella virus MSW3, Edwardsiella virus PEi21, Escherichia virus Mu, Shigella virus SfMu, Halobacterium virus phiH, Bacillus virus Grass, Bacillus virus NIT1, Bacillus virus SPG24, Aeromonas virus 43, Escherichia virus P1, Pseudomonas virus CAb1, Pseudomonas virus CAb02, Pseudomonas virus JG004, Pseudomonas virus PAKP1, Pseudomonas virus PAKP4, Pseudomonas virus PaP1, Burkholderia virus BcepF1, Pseudomonas virus 141, Pseudomonas virus Ab28, Pseudomonas virus DL60, Pseudomonas virus DL68, Pseudomonas virus F8, Pseudomonas virus JG024, Pseudomonas virus KPP12, Pseudomonas virus LBL3, Pseudomonas virus LMA2, Pseudomonas virus PB1, Pseudomonas virus SN, Pseudomonas virus PA7, Pseudomonas virus phiKZ, Rhizobium virus RHEph4, Ralstonia virus RSF1, Ralstonia virus RSL2, Ralstonia virus RSL1, Aeromonas virus 25, Aeromonas virus 31, Aeromonas virus Aes12, Aeromonas virus Aes508, Aeromonas virus AS4, Stenotrophomonas virus IME13, Staphylococcus virus IPLAC1C, Staphylococcus virus SEP1, Salmonella virus SPN3US, Bacillus virus 1, Geobacillus virus GBSV1, Yersinia virus R1RT, Yersinia virus TG1, Bacillus virus G, Bacillus virus PBS1, Microcystis virus Ma-LMM01, Vibrio virus MAR, Vibrio virus VHML, Vibrio virus VP585, Bacillus virus BPS 13, Bacillus virus Hakuna, Bacillus virus Megatron, Bacillus virus WPh, Acinetobacter virus AB3, Acinetobacter virus Abp1, Acinetobacter virus Fri1, Acinetobacter virus IME200, Acinetobacter virus PD6A3, Acinetobacter virus PDAB9, Acinetobacter virus phiAB1, Escherichia virus K30, Klebsiella virus K5, Klebsiella virus K11, Klebsiella virus Kp1, Klebsiella virus KP32, Klebsiella virus KpV289, Klebsiella virus F19, Klebsiella virus K244, Klebsiella virus Kp2, Klebsiella virus KP34, Klebsiella virus KpV41, Klebsiella virus KpV71, Klebsiella virus KpV475, Klebsiella virus SU503, Klebsiella virus SU552A, Pantoea virus Limelight, Pantoea virus Limezero, Pseudomonas virus LKA1, Pseudomonas virus phiKMV, Xanthomonas virus f20, Xanthomonas virus f30, Xylella virus Prado, Erwinia virus Era103, Escherichia virus K5, Escherichia virus K1-5, Escherichia virus K1E, Salmonella virus SP6, Escherichia virus T7, Kluyvera virus Kvp1, Pseudomonas virus gh1, Prochlorococcus virus PSSP7, Synechococcus virus P60, Synechococcus virus Syn5, Streptococcus virus Cp1, Streptococcus virus Cp7, Staphylococcus virus 44AHJD, Streptococcus virus C1, Bacillus virus B103, Bacillus virus GA1, Bacillus virus phi29, Kurthia virus 6, Actinomyces virus Av1, Mycoplasma virus P1, Escherichia virus 24B, Escherichia virus 933W, Escherichia virus Min27, Escherichia virus PA28, Escherichia virus Stx2 II, Shigella virus 7502Stx, Shigella virus POCJ13, Escherichia virus 191, Escherichia virus PA2, Escherichia virus TL2011, Shigella virus VASD, Burkholderia virus Bcep22, Burkholderia virus Bcepil02, Burkholderia virus Bcepmigl, Burkholderia virus DC1, Bordetella virus BPP1, Burkholderia virus BcepC6B, Cellulophaga virus Cba41, Cellulophaga virus Cba172, Dinoroseobacter virus DFL12, Erwinia virus Ea9-2, Erwinia virus Frozen, Escherichia virus phiV10, Salmonella virus Epsilon15, Salmonella virus SPN1S, Pseudomonas virus F116, Pseudomonas virus H66, Escherichia virus APEC5, Escherichia virus APEC7, Escherichia virus Bp4, Escherichia virus EC1UPM, Escherichia virus ECBP1, Escherichia virus G7C, Escherichia virus IME11, Shigella virus Sb1, Achromobacter virus Axp3, Achromobacter virus JWAlpha, Edwardsiella virus KF1, Pseudomonas virus KPP25, Pseudomonas virus R18, Pseudomonas virus Ab09, Pseudomonas virus LIT1, Pseudomonas virus PA26, Pseudomonas virus Ab22, Pseudomonas virus CHU, Pseudomonas virus LUZ24, Pseudomonas virus PAA2, Pseudomonas virus PaP3, Pseudomonas virus PaP4, Pseudomonas virus TL, Pseudomonas virus KPP21, Pseudomonas virus LUZ7, Escherichia virus N4, Salmonella virus 9NA, Salmonella virus SP069, Salmonella virus BTP1, Salmonella virus HK620, Salmonella virus P22, Salmonella virus ST64T, Shigella virus Sf6, Bacillus virus Page, Bacillus virus Palmer, Bacillus virus Pascal, Bacillus virus Pony, Bacillus virus Pookie, Escherichia virus 172-1, Escherichia virus ECB2, Escherichia virus NJ01, Escherichia virus phiEco32, Escherichia virus Septima11, Escherichia virus SU10, Brucella virus Pr, Brucella virus Tb, Escherichia virus Pollock, Salmonella virus FSL SP-058, Salmonella virus FSL SP-076, Helicobacter virus 1961P, Helicobacter virus KHP30, Helicobacter virus KHP40, Hamiltonella virus APSE1, Lactococcus virus KSY1, Phormidium virus WMP3, Phormidium virus WMP4, Pseudomonas virus 119X, Roseobacter virus SIO1, Vibrio virus VpV262, Vibrio virus VC8, Vibrio virus VP2, Vibrio virus VP5, Streptomyces virus Amela, Streptomyces virus phiCAM, Streptomyces virus Aaronocolus, Streptomyces virus Calibum, Streptomyces virus Danzina, Streptomyces virus Hydra, Streptomyces virus Izzy, Streptomyces virus Lannister, Streptomyces virus Lika, Streptomyces virus Sujidade, Streptomyces virus Zemlya, Streptomyces virus ELB20, Streptomyces virus R4, Streptomyces virus phiHau3, Mycobacterium virus Acadian, Mycobacterium virus Baee, Mycobacterium virus Reprobate, Mycobacterium virus Adawi, Mycobacterium virus Bane1, Mycobacterium virus BrownCNA, Mycobacterium virus Chrisnmich, Mycobacterium virus Cooper, Mycobacterium virus JAMaL, Mycobacterium virus Nigel, Mycobacterium virus Stinger, Mycobacterium virus Vincenzo, Mycobacterium virus Zemanar, Mycobacterium virus Apizium, Mycobacterium virus Manad, Mycobacterium virus Oline, Mycobacterium virus Osmaximus, Mycobacterium virus Pg1, Mycobacterium virus Soto, Mycobacterium virus Suffolk, Mycobacterium virus Athena, Mycobacterium virus Bernardo, Mycobacterium virus Gadjet, Mycobacterium virus Pipefish, Mycobacterium virus Godines, Mycobacterium virus Rosebush, Mycobacterium virus Babsiella, Mycobacterium virus Brujita, Mycobacterium virus Che9c, Mycobacterium virus Sbash, Mycobacterium virus Hawkeye, Mycobacterium virus Plot, Salmonella virus AG11, Salmonella virus Ent1, Salmonella virus f18SE, Salmonella virus Jersey, Salmonella virus L13, Salmonella virus LSPA1, Salmonella virus SE2, Salmonella virus SETP3, Salmonella virus SETP7, Salmonella virus SETP13, Salmonella virus SP101, Salmonella virus SS3e, Salmonella virus wksl3, Escherichia virus K1G, Escherichia virus K1H, Escherichia virus K1ind1, Escherichia virus K1ind2, Salmonella virus SP31, Leuconostoc virus Lmd1, Leuconostoc virus LN03, Leuconostoc virus LN04, Leuconostoc virus LN12, Leuconostoc virus LN6B, Leuconostoc virus P793, Leuconostoc virus 1A4, Leuconostoc virus Ln8, Leuconostoc virus Ln9, Leuconostoc virus LN25, Leuconostoc virus LN34, Leuconostoc virus LNTR3, Mycobacterium virus Bongo, Mycobacterium virus Rey, Mycobacterium virus Butters, Mycobacterium virus Michelle, Mycobacterium virus Charlie, Mycobacterium virus Pipsqueaks, Mycobacterium virus Xeno, Mycobacterium virus Panchino, Mycobacterium virus Phrann, Mycobacterium virus Redi, Mycobacterium virus Skinnyp, Gordonia virus BaxterFox, Gordonia virus Yeezy, Gordonia virus Kita, Gordonia virus Zirinka, Gorrdonia virus Nymphadora, Mycobacterium virus Bignuz, Mycobacterium virus Brusacoram, Mycobacterium virus Donovan, Mycobacterium virus Fishburne, Mycobacterium virus Jebeks, Mycobacterium virus Malithi, Mycobacterium virus Phayonce, Enterobacter virus F20, Klebsiella virus 1513, Klebsiella virus KLPN1, Klebsiella virus KP36, Klebsiella virus PKP126, Klebsiella virus Sushi, Escherichia virus AHP42, Escherichia virus AHS24, Escherichia virus AKS96, Escherichia virus C119, Escherichia virus E41c, Escherichia virus Eb49, Escherichia virus Jk06, Escherichia virus KP26, Escherichia virus Rogue 1, Escherichia virus ACGM12, Escherichia virus Rtp, Escherichia virus ADB2, Escherichia virus JMPW1, Escherichia virus JMPW2, Escherichia virus T1, Shigella virus PSf2, Shigella virus Shfl 1, Citrobacter virus Stevie, Escherichia virus TLS, Salmonella virus SP126, Cronobacter virus Esp2949-1, Pseudomonas virus Ab18, Pseudomonas virus Ab19, Pseudomonas virus PaMx11, Arthrobacter virus Amigo, Propionibacterium virus Anatole, Propionibacterium virus B3, Bacillus virus Andromeda, Bacillus virus Blastoid, Bacillus virus Curly, Bacillus virus Eoghan, Bacillus virus Finn, Bacillus virus Glittering, Bacillus virus Riggi, Bacillus virus Taylor, Gordonia virus Attis, Mycobacterium virus Barnyard, Mycobacterium virus Konstantine, Mycobacterium virus Predator, Mycobacterium virus Bernal13, Staphylococcus virus 13, Staphylococcus virus 77, Staphylococcus virus 108PVL, Mycobacterium virus Bron, Mycobacterium virus Faith1, Mycobacterium virus Joedirt, Mycobacterium virus Rumpelstiltskin, Lactococcus virus bIL67, Lactococcus virus c2, Lactobacillus virus c5, Lactobacillus virus Ld3, Lactobacillus virus Ld17, Lactobacillus virus Ld25A, Lactobacillus virus LLKu, Lactobacillus virus phiLdb, Cellulophaga virus Cba121, Cellulophaga virus Cba171, Cellulophaga virus Cba181, Cellulophaga virus ST, Bacillus virus 250, Bacillus virus IEBH, Mycobacterium virus Ardmore, Mycobacterium virus Avani, Mycobacterium virus Boomer, Mycobacterium virus Che8, Mycobacterium virus Che9d, Mycobacterium virus Deadp, Mycobacterium virus Dlane, Mycobacterium virus Dorothy, Mycobacterium virus Dotproduct, Mycobacterium virus Drago, Mycobacterium virus Fruitloop, Mycobacterium virus Gumbie, Mycobacterium virus Ibhubesi, Mycobacterium virus Llij, Mycobacterium virus Mozy, Mycobacterium virus Mutaforma13, Mycobacterium virus Pacc40, Mycobacterium virus PMC, Mycobacterium virus Ramsey, Mycobacterium virus Rockyhorror, Mycobacterium virus SG4, Mycobacterium virus Shauna1, Mycobacterium virus Shilan, Mycobacterium virus Spartacus, Mycobacterium virus Taj, Mycobacterium virus Tweety, Mycobacterium virus Wee, Mycobacterium virus Yoshi, Salmonella virus Chi, Salmonella virus FSLSP030, Salmonella virus FSLSP088, Salmonella virus iEPS5, Salmonella virus SPN19, Mycobacterium virus 244, Mycobacterium virus Bask21, Mycobacterium virus CJW1, Mycobacterium virus Eureka, Mycobacterium virus Kostya, Mycobacterium virus Porky, Mycobacterium virus Pumpkin, Mycobacterium virus Sirduracell, Mycobacterium virus Toto, Mycobacterium virus Comdog, Mycobacterium virus Firecracker, Rhodobacter virus RcCronus, Pseudomonas virus D3112, Pseudomonas virus DMS3, Pseudomonas virus FHA0480, Pseudomonas virus LPB1, Pseudomonas virus MP22, Pseudomonas virus MP29, Pseudomonas virus MP38, Pseudomonas virus PA1KOR, Pseudomonas virus D3, Pseudomonas virus PMG1, Arthrobacter virus Decurro, Gordonia virus Demosthenes, Gordonia virus Katyusha, Gordonia virus Kvothe, Propionibacterium virus B22, Propionibacterium virus Doucette, Propionibacterium virus E6, Propionibacterium virus G4, Burkholderia virus phi6442, Burkholderia virus phi1026b, Burkholderia virus phiE125, Edwardsiella virus eiAU, Mycobacterium virus Ff47, Mycobacterium virus Muddy, Mycobacterium virus Gaia, Mycobacterium virus Giles, Arthrobacter virus Captnmurica, Arthrobacter virus Gordon, Gordonia virus GordTnk2, Paenibacillus virus Harrison, Escherichia virus EK99P1, Escherichia virus HK578, Escherichia virus JL1, Escherichia virus SSL2009a, Escherichia virus YD2008s, Shigella virus EP23, Sodalis virus SO1, Escherichia virus HK022, Escherichia virus HK75, Escherichia virus HK97, Escherichia virus HK106, Escherichia virus HK446, Escherichia virus HK542, Escherichia virus HK544, Escherichia virus HK633, Escherichia virus mEp234, Escherichia virus mEp235, Escherichia virus mEpX1, Escherichia virus mEpX2, Escherichia virus mEp043, Escherichia virus mEp213, Escherichia virus mEp237, Escherichia virus mEp390, Escherichia virus mEp460, Escherichia virus mEp505, Escherichia virus mEp506, Brevibacillus virus Jenst, Achromobacter virus 83-24, Achromobacter virus JWX, Arthrobacter virus Kellezzio, Arthrobacter virus Kitkat, Arthrobacter virus Bennie, Arthrobacter virus DrRobert, Arthrobacter virus Glenn, Arthrobacter virus HunterDalle, Arthrobacter virus Joann, Arthrobacter virus Korra, Arthrobacter virus Preamble, Arthrobacter virus Pumancara, Arthrobacter virus Wayne, Mycobacterium virus Alma, Mycobacterium virus Arturo, Mycobacterium virus Astro, Mycobacterium virus Backyardigan, Mycobacterium virus BBPiebs31, Mycobacterium virus Benedict, Mycobacterium virus Bethlehem, Mycobacterium virus Billknuckles, Mycobacterium virus Bruns, Mycobacterium virus Bxb1, Mycobacterium virus Bxz2, Mycobacterium virus Che12, Mycobacterium virus Cuco, Mycobacterium virus D29, Mycobacterium virus Doom, Mycobacterium virus Ericb, Mycobacterium virus Euphoria, Mycobacterium virus George, Mycobacterium virus Gladiator, Mycobacterium virus Goose, Mycobacterium virus Hammer, Mycobacterium virus Heldan, Mycobacterium virus Jasper, Mycobacterium virus JC27, Mycobacterium virus Jeffabunny, Mycobacterium virus JHC117, Mycobacterium virus KBG, Mycobacterium virus Kssjeb, Mycobacterium virus Kugel, Mycobacterium virus L5, Mycobacterium virus Lesedi, Mycobacterium virus LHTSCC, Mycobacterium virus lockley, Mycobacterium virus Marcell, Mycobacterium virus Microwolf, Mycobacterium virus Mrgordo, Mycobacterium virus Museum, Mycobacterium virus Nepal, Mycobacterium virus Packman, Mycobacterium virus Peaches, Mycobacterium virus Perseus, Mycobacterium virus Pukovnik, Mycobacterium virus Rebeuca, Mycobacterium virus Redrock, Mycobacterium virus Ridgecb, Mycobacterium virus Rockstar, Mycobacterium virus Saintus, Mycobacterium virus Skipole, Mycobacterium virus Solon, Mycobacterium virus Switzer, Mycobacterium virus SWU1, Mycobacterium virus Ta17a, Mycobacterium virus Tiger, Mycobacterium virus Timshel, Mycobacterium virus Trixie, Mycobacterium virus Turbido, Mycobacterium virus Twister, Mycobacterium virus U2, Mycobacterium virus Violet, Mycobacterium virus Wonder, Escherichia virus DE3, Escherichia virus HK629, Escherichia virus HK630, Escherichia virus lambda, Arthrobacter virus Laroye, Mycobacterium virus Halo, Mycobacterium virus Liefie, Mycobacterium virus Marvin, Mycobacterium virus Mosmoris, Arthrobacter virus Circum, Arthrobacter virus Mudcat, Escherichia virus N15, Escherichia virus 9g, Escherichia virus JenK1, Escherichia virus JenP1, Escherichia virus JenP2, Pseudomonas virus NP1, Pseudomonas virus PaMx25, Mycobacterium virus Baka, Mycobacterium virus Courthouse, Mycobacterium virus Littlee, Mycobacterium virus Omega, Mycobacterium virus Optimus, Mycobacterium virus Thibault, Polaribacter virus P12002L, Polaribacter virus P12002S, Nonlabens virus P12024L, Nonlabens virus P12024S, Thermus virus P23-45, Thermus virus P74-26, Listeria virus LP26, Listeria virus LP37, Listeria virus LP110, Listeria virus LP114, Listeria virus P70, Propionibacterium virus ATCC29399BC, Propionibacterium virus ATCC29399BT, Propionibacterium virus Attacne, Propionibacterium virus Keiki, Propionibacterium virus Kubed, Propionibacterium virus Lauchelly, Propionibacterium virus MrAK, Propionibacterium virus Ouroboros, Propionibacterium virus P91, Propionibacterium virus P105, Propionibacterium virus P144, Propionibacterium virus P1001, Propionibacterium virus P1.1, Propionibacterium virus P100A, Propionibacterium virus P100D, Propionibacterium virus P101A, Propionibacterium virus P104A, Propionibacterium virus PA6, Propionibacterium virus Pacnes201215, Propionibacterium virus PAD20, Propionibacterium virus PAS50, Propionibacterium virus PHL009M11, Propionibacterium virus PHL025M00, Propionibacterium virus PHL037M02, Propionibacterium virus PHL041M10, Propionibacterium virus PHL060L00, Propionibacterium virus PHL067M01, Propionibacterium virus PHL070N00, Propionibacterium virus PHL071N05, Propionibacterium virus PHL082M03, Propionibacterium virus PHL092M00, Propionibacterium virus PHL095N00, Propionibacterium virus PHL111M01, Propionibacterium virus PHL112N00, Propionibacterium virus PHL113M01, Propionibacterium virus PHL114L00, Propionibacterium virus PHL116M00, Propionibacterium virus PHL117M00, Propionibacterium virus PHL117M01, Propionibacterium virus PHL132N00, Propionibacterium virus PHL141N00, Propionibacterium virus PHL151M00, Propionibacterium virus PHL151N00, Propionibacterium virus PHL152M00, Propionibacterium virus PHL163M00, Propionibacterium virus PHL171M01, Propionibacterium virus PHL179M00, Propionibacterium virus PHL194M00, Propionibacterium virus PHL199M00, Propionibacterium virus PHL301M00, Propionibacterium virus PHL308M00, Propionibacterium virus Pirate, Propionibacterium virus Procrass1, Propionibacterium virus SKKY, Propionibacterium virus Solid, Propionibacterium virus Stormbom, Propionibacterium virus Wizzo, Pseudomonas virus PaMx28, Pseudomonas virus PaMx74, Mycobacterium virus Patience, Mycobacterium virus PBI1, Rhodococcus virus Pepy6, Rhodococcus virus Poco6, Propionibacterium virus PFR1, Streptomyces virus phiBT1, Streptomyces virus phiC31, Streptomyces virus TG1, Caulobacter virus Karma, Caulobacter virus Magneto, Caulobacter virus phiCbK, Caulobacter virus Rogue, Caulobacter virus Swift, Staphylococcus virus 11, Staphylococcus virus 29, Staphylococcus virus 37, Staphylococcus virus 53, Staphylococcus virus 55, Staphylococcus virus 69, Staphylococcus virus 71, Staphylococcus virus 80, Staphylococcus virus 85, Staphylococcus virus 88, Staphylococcus virus 92, Staphylococcus virus 96, Staphylococcus virus 187, Staphylococcus virus 52a, Staphylococcus virus 80alpha, Staphylococcus virus CNPH82, Staphylococcus virus EW, Staphylococcus virus IPLA5, Staphylococcus virus IPLA7, Staphylococcus virus IPLA88, Staphylococcus virus PH15, Staphylococcus virus phiETA, Staphylococcus virus phiETA2, Staphylococcus virus phiETA3, Staphylococcus virus phiMR11, Staphylococcus virus phiMR25, Staphylococcus virus phiNM1, Staphylococcus virus phiNM2, Staphylococcus virus phiNM4, Staphylococcus virus SAP26, Staphylococcus virus X2, Enterococcus virus FL1, Enterococcus virus FL2, Enterococcus virus FL3, Lactobacillus virus ATCC8014, Lactobacillus virus phiJL1, Pediococcus virus cIP1, Aeromonas virus pIS4A, Listeria virus LP302, Listeria virus PSA, Methanobacterium virus psiM1, Roseobacter virus RDJL1, Roseobacter virus RDJL2, Rhodococcus virus RER2, Enterococcus virus BC611, Enterococcus virus IMEEF1, Enterococcus virus SAP6, Enterococcus virus VD13, Streptococcus virus SPQS1, Mycobacterium virus Papyrus, Mycobacterium virus Send513, Burkholderia virus KL1, Pseudomonas virus 73, Pseudomonas virus Ab26, Pseudomonas virus Kakheti25, Escherichia virus Cajan, Escherichia virus Seurat, Staphylococcus virus SEP9, Staphylococcus virus Sextaec, Streptococcus virus 858, Streptococcus virus 2972, Streptococcus virus ALQ132, Streptococcus virus 01205, Streptococcus virus Sfi11, Streptococcus virus 7201, Streptococcus virus DT1, Streptococcus virus phiAbc2, Streptococcus virus Sfi19, Streptococcus virus Sfi21, Paenibacillus virus Diva, Paenibacillus virus Hb10c2, Paenibacillus virus Rani, Paenibacillus virus Shelly, Paenibacillus virus Sitara, Paenibacillus virus Willow, Lactococcus virus 712, Lactococcus virus ASCC191, Lactococcus virus ASCC273, Lactococcus virus ASCC281, Lactococcus virus ASCC465, Lactococcus virus ASCC532, Lactococcus virus Bibb29, Lactococcus virus bIL170, Lactococcus virus CB13, Lactococcus virus CB14, Lactococcus virus CB19, Lactococcus virus CB20, Lactococcus virus jj50, Lactococcus virus P2, Lactococcus virus P008, Lactococcus virus sk1, Lactococcus virus S14, Bacillus virus Slash, Bacillus virus Stahl, Bacillus virus Staley, Bacillus virus Stills, Gordonia virus Bachita, Gordonia virus ClubL, Gordonia virus OneUp, Gordonia virus Smoothie, Gordonia virus Soups, Bacillus virus SPbeta, Vibrio virus MAR10, Vibrio virus SSP002, Escherichia virus AKFV33, Escherichia virus BF23, Escherichia virus DT57C, Escherichia virus EPS7, Escherichia virus FFH1, Escherichia virus H8, Escherichia virus slur09, Escherichia virus T5, Salmonella virus 118970sa12, Salmonella virus Shivani, Salmonella virus SPC35, Salmonella virus Stitch, Arthrobacter virus Tank, Tsukamurella virus TIN2, Tsukamurella virus TIN3, Tsukamurella virus TIN4, Rhodobacter virus RcSpartan, Rhodobacter virus RcTitan, Mycobacterium virus Anaya, Mycobacterium virus Angelica, Mycobacterium virus Crimd, Mycobacterium virus Fionnbarth, Mycobacterium virus Jaws, Mycobacterium virus Larva, Mycobacterium virus Macncheese, Mycobacterium virus Pixie, Mycobacterium virus TM4, Bacillus virus BMBtp2, Bacillus virus TP21, Geobacillus virus Tp84, Staphylococcus virus 47, Staphylococcus virus 3a, Staphylococcus virus 42e, Staphylococcus virus IPLA35, Staphylococcus virus phi12, Staphylococcus virus phiSLT, Mycobacterium virus 32HC, Rhodococcus virus RGL3, Paenibacillus virus Vegas, Gordonia virus Vendetta, Bacillus virus Wbeta, Mycobacterium virus Wildcat, Gordonia virus Twister6, Gordonia virus Wizard, Gordonia virus Hotorobo, Gordonia virus Monty, Gordonia virus Woes, Xanthomonas virus CP1, Xanthomonas virus OP1, Xanthomonas virus phil7, Xanthomonas virus Xop411, Xanthomonas virus Xp10, Streptomyces virus TP1604, Streptomyces virus YDN12, Alphaproteobacteria virus phiJ1001, Pseudomonas virus LKO4, Pseudomonas virus M6, Pseudomonas virus MP1412, Pseudomonas virus PAE1, Pseudomonas virus Yua, Pseudoalteromonas virus PM2, Pseudomonas virus phi6, Pseudomonas virus phi8, Pseudomonas virus phi12, Pseudomonas virus phi13, Pseudomonas virus phi2954, Pseudomonas virus phiNN, Pseudomonas virus phiYY, Vibrio virus fs1, Vibrio virus VGJ, Ralstonia virus RS603, Ralstonia virus RSM1, Ralstonia virus RSM3, Escherichia virus M13, Escherichia virus I22, Salmonella virus IKe, Acholeplasma virus L51, Vibrio virus fs2, Vibrio virus VFJ, Escherichia virus If1, Propionibacterium virus B5, Pseudomonas virus Pf1, Pseudomonas virus Pf3, Ralstonia virus PE226, Ralstonia virus RSS1, Spiroplasma virus SVTS2, Stenotrophomonas virus PSH1, Stenotrophomonas virus SMA6, Stenotrophomonas virus SMA7, Stenotrophomonas virus SMA9, Vibrio virus CTXphi, Vibrio virus KSF1, Vibrio virus VCY, Vibrio virus Vf33, Vibrio virus VfO3K6, Xanthomonas virus Cf1c, Spiroplasma virus C74, Spiroplasma virus R8A2B, Spiroplasma virus SkV1CR23x, Escherichia virus FI, Escherichia virus Qbeta, Escherichia virus BZ13, Escherichia virus MS2, Escherichia virus alpha3, Escherichia virus ID21, Escherichia virus ID32, Escherichia virus ID62, Escherichia virus NC28, Escherichia virus NC29, Escherichia virus NC35, Escherichia virus phiK, Escherichia virus St1, Escherichia virus WA45, Escherichia virus G4, Escherichia virus ID52, Escherichia virus Talmos, Escherichia virus phiX174, Bdellovibrio virus MAC1, Bdellovibrio virus MH2K, Chlamydia virus Chp1, Chlamydia virus Chp2, Chlamydia virus CPAR39, Chlamydia virus CPG1, Spiroplasma virus SpV4, Acholeplasma virus L2, Pseudomonas virus PR4, Pseudomonas virus PRD1, Bacillus virus AP50, Bacillus virus Bam35, Bacillus virus GIL16, Bacillus virus Wip1, Escherichia virus phi80, Escherichia virus RB42, Escherichia virus T2, Escherichia virus T3, Escherichia virus T6, Escherichia virus VT2-Sa, Escherichia virus VT1-Sakai, Escherichia virus VT2-Sakai, Escherichia virus CP-933V, Escherichia virus P27, Escherichia virus Stx2phi-I, Escherichia virus Stx1phi, Escherichia virus Stx2phi-II, Escherichia virus CP-1639, , based on the Escherichia virus BP-4795, Escherichia virus 86, Escherichia virus Min27, Escherichia virus 2851, Escherichia virus 1717, Escherichia virus YYZ-2008, Escherichia virus EC026_P06, Escherichia virus ECO103_P15, Escherichia virus ECO103_P12, Escherichia virus ECO111_P16, Escherichia virus ECO111_P11, Escherichia virus VT2phi_272, Escherichia virus TL-2011c, Escherichia virus P13374, Escherichia virus Sp5.

In one embodiment, the bacterial virus particles typically target E. coli and include the capsid of a bacteriophage selected in the group consisting of BW73, B278, D6, D108, E, E1, E24, E41, FI-2, FI-4, FI-5, HI8A, Ffl8B, i, MM, Mu, 025, PhI-5, Pk, PSP3, P1, P1D, P2, P4, S1, Wφ, φK13, φ1, φ2, φ7, φ92, 7 A, 8φ, 9φ, 18, 28-1, 186, 299, HH-Escherichia (2), AB48, CM, C4, C16, DD-VI, E4, E7, E28, FI1, FI3, H, H1, H3, H8, K3, M, N, ND-2, ND-3, ND4, ND-5, ND6, ND-7, Ox-I, Ox-2, Ox-3, Ox-4, Ox-5, Ox-6, PhI-I, RB42, RB43, RB49, RB69, S, SaI-I, Sal-2, Sal-3, Sal-4, Sal-5, Sal-6, TC23, TC45, TuII*-6, TuIP-24, TuII*46, TuIP-60, T2, T4, T6, T35, α1, 1, IA, 3, 3A, 3T+, 5φ, 9266Q, CFO103, HK620, J, K, K1F, m59, no. A, no. E, no. 3, no. 9, N4, sd, T3, T7, WPK, W31, ΔH, φC3888, φK3, φK7, φK12, cpV-1, Φ04-CF, Φ05, Φ06, Φ07, φ1, φ1.2, φ20, φ95, φ263, φ1O92, φ1, φ11, Ω8, 1, 3, 7, 8, 26, 27, 28-2, 29, 30, 31, 32, 38, 39, 42, 933W, NN-Escherichia (1), Esc-7-11, AC30, CVX-5, C1, DDUP, EC1, EC2, E21, E29, F1, F26S, F27S, Hi, HK022, HK97, HK139, HK253, HK256, K7, ND-I, PA-2, q, S2, T1, ), T3C, T5, UC-I, w, β4, γ2, λ , ΦD326, φγ, Φ06, Φ7, Φ10, φ80, χ, 2, 4, 4A, 6, 8A, 102, 150, 168, 174, 3000, AC6, AC7, AC28, AC43, AC50, AC57, AC81, AC95, HK243, K1O, ZG/3A, 5, 5A, 21EL, H19-J and 933H.

Pharmaceutical or Veterinary Composition

The present disclosure also provides a pharmaceutical or veterinary composition comprising the bacterial delivery vehicle as defined in the section “Bacterial delivery vehicle” above and a pharmaceutically acceptable carrier.

Generally, for pharmaceutical use, the bacterial delivery vehicles may be formulated as a pharmaceutical preparation or composition comprising at least one bacterial delivery vehicle and at least one pharmaceutically acceptable carrier, diluent or excipient, and optionally one or more further pharmaceutically active compounds. Such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration, for administration by inhalation, by a skin patch, by an implant, by a suppository, etc. In a particular embodiment, said composition is for oral administration. Such administration forms may be solid, semi-solid or liquid, depending on the manner and route of administration. For example, formulations for oral administration may be provided with an enteric coating that will allow the synthetic bacterial delivery vehicles in the formulation to resist the gastric environment and pass into the intestines. More generally, synthetic bacterial delivery vehicle formulations for oral administration may be suitably formulated for delivery into any desired part of the gastrointestinal tract. In addition, suitable suppositories may be used for delivery into the gastrointestinal tract. Various pharmaceutically acceptable carriers, diluents and excipients useful in bacterial delivery vehicle compositions are known to the skilled person

The pharmaceutical or veterinary composition according to the disclosure may further comprise a pharmaceutically acceptable vehicle. A solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet- disintegrating agents. Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

The pharmaceutical or veterinary composition may be prepared as a sterile solid composition that may be suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. The pharmaceutical or veterinary compositions disclosed herein may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like. The particles according to the disclosure can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for enteral administration include sterile solutions, emulsions, and suspensions.

The bacterial delivery vehicles disclosed herein may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and enteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for enteral administration. The liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.

For transdermal administration, the pharmaceutical or veterinary composition can be formulated into ointment, cream or gel form and appropriate penetrants or detergents could be used to facilitate permeation, such as dimethyl sulfoxide, dimethyl acetamide and dimethylformamide.

For transmucosal administration, nasal sprays, rectal or vaginal suppositories can be used. The active compounds can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate.

In another particular embodiment, the present disclosure provides a pharmaceutical or veterinary composition as defined above for use to improve the effectiveness of drugs. Indeed, some bacteria of the microbiome, without being pathogenic by themselves, are known to be able to metabolize drugs and to modify them in ineffective or harmful molecules.

In another particular embodiment, the disclosure provides a composition that may further comprise at least one additional active ingredient, for instance a prebiotic and/or a probiotic and/or an antibiotic, and/or another antibacterial or antibiofilm agent, and/or any agent enhancing the targeting of the bacterial delivery vehicle to a bacteria and/or the delivery of the payload into a bacteria.

As used herein, a “prebiotic” refers to an ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that may confer benefits upon the host. A prebiotic can be a comestible food or beverage or ingredient thereof. A prebiotic may be a selectively fermented ingredient. Prebiotics may include complex carbohydrates, amino acids, peptides, minerals, or other essential nutritional components for the survival of the bacterial composition. Prebiotics include, but are not limited to, amino acids, biotin, fructo-oligosaccharide, galacto-oligosaccharides, hemicelluloses (e.g., arabinoxylan, xylan, xyloglucan, and glucomannan), inulin, chitin, lactulose, mannan oligosaccharides, oligofructose-enriched inulin, gums (e.g., guar gum, gum arabic and carrageenan), oligofructose, oligodextrose, tagatose, resistant maltodextrins (e.g., resistant starch), trans-galactooligosaccharide, pectins (e.g., xylogalactouronan, citrus pectin, apple pectin, and rhamnogalacturonan-I), dietary fibers (e.g., soy fiber, sugarbeet fiber, pea fiber, corn bran, and oat fiber) and xylooligosaccharides.

As used herein, a “probiotic” refers to a dietary supplement based on living microbes which, when taken in adequate quantities, has a beneficial effect on the host organism by strengthening the intestinal ecosystem. Probiotic can comprise a non-pathogenic bacterial or fungal population, e.g., an immunomodulatory bacterial population, such as an anti-inflammatory bacterial population, with or without one or more prebiotics. They contain a sufficiently high number of living and active probiotic microorganisms that can exert a balancing action on gut flora by direct colonisation. It must be noted that, for the purposes of the present description, the term “probiotic” is taken to mean any biologically active form of probiotic, preferably including but not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria or saccharomycetes but even other microorganisms making up the normal gut flora, or also fragments of the bacterial wall or of the DNA of these microorganisms. These compositions are advantageous in being suitable for safe administration to humans and other mammalian subjects and are efficacious for the treatment, prevention, of a disease or disorder caused by bacteria such as bacterial infection. Probiotics include, but are not limited to lactobacilli, bifidobacteria, streptococci, enterococci, propionibacteria, saccharomycetes, lactobacilli, bifidobacteria, or proteobacteria.

The antibiotic can be selected from the group consisting of penicillins such as penicillin G, penicillin K, penicillin N, penicillin O, penicillin V, methicillin, benzylpenicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, epicillin, carbenicillin, ticarcillin, temocillin, mezlocillin, and piperacillin; cephalosporins such as cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cephaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradine, cefroxadine, ceftezole, cefaclor, cefonicid, cefprozil, cefuroxime, cefuzonam, cefmetazole, cefotetan, cefoxitin, loracarbef, cefbuperazone, cefminox, cefotetan, cefoxitin, cefotiam, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefodizime, cefotaxime, cefovecin, cefpimizole, cefpodoxime, cefteram, ceftamere, ceftibuten, ceftiofur, ceftiolene, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, latamoxef, cefclidine, cefepime, cefluprenam, cefoselis, cefozopran, cefpirome, cefquinome, flomoxef, ceftobiprole, ceftaroline, ceftolozane, cefaloram, cefaparole, cefcanel, cefedrolor, cefempidone, cefetrizole, cefivitril, cefmatilen, cefmepidium, cefoxazole, cefrotil, cefsumide, ceftioxide, cefuracetime, and nitrocefin; polymyxins such as polysporin, neosporin, polymyxin B, and polymyxin E, rifampicins such as rifampicin, rifapentine, and rifaximin; Fidaxomicin; quinolones such as cinoxacin, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, ciprofloxacin, enoxacin, fleroxacin, lomefloxacin, nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, grepafloxacin, levofloxacin, pazufloxacin, temafloxacin, tosufloxacin, clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin, sitafloxacin, trovafloxacin, prulifloxacin, delafloxacin, nemonoxacin, and zabofloxacin; sulfonamides such as sulfafurazole, sulfacetamide, sulfadiazine, sulfadimidine, sulfafurazole, sulfisomidine, sulfadoxine, sulfamethoxazole, sulfamoxole, sulfanitran, sulfadimethoxine, sulfametho-xypyridazine, sulfametoxydiazine, sulfadoxine, sulfametopyrazine, and terephtyl; macrolides such as azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin, carbomycin A, josamycin, kitasamycin, midecamycin, oleandomycin, solithromycin, spiramycin, troleandomycin, tylosin, and roxithromycin; ketolides such as telithromycin, and cethromycin; fluoroketolides such as solithromycin; lincosamides such as lincomycin, clindamycin, and pirlimycin; tetracyclines such as demeclocycline, doxycycline, minocycline, oxytetracycline, and tetracycline; aminoglycosides such as amikacin, dibekacin, gentamicin, kanamycin, neomycin, netilmicin, sisomicin, tobramycin, paromomycin, and streptomycin; ansamycins such as geldanamycin, herbimycin, and rifaximin; carbacephems such as loracarbef; carbapenems such as ertapenem, doripenem, imipenem (or cilastatin), and meropenem; glycopeptides such as teicoplanin, vancomycin, telavancin, dalbavancin, and oritavancin; lincosamides such as clindamycin and lincomycin; lipopeptides such as daptomycin; monobactams such as aztreonam; nitrofurans such as furazolidone, and nitrofurantoin; oxazolidinones such as linezolid, posizolid, radezolid, and torezolid; teixobactin, clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifabutin, arsphenamine,chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin (or dalfopristin), thiamphenicol, tigecycline, tinidazole, trimethoprim, alatrofloxacin, fidaxomicin, nalidixic acid, rifampin, derivatives and combination thereof.

Applications

The present disclosure provides a method for in vivo delivery of a DNA payload of interest into a subject comprising, administering to said subject a pharmaceutical or veterinary composition as disclosed herein.

Also provided are methods for treating a disease or disorder caused by bacteria such as bacterial infection using the bacterial delivery vehicles or compositions disclosed herein. The methods include administering a therapeutically efficient amount of bacterial delivery vehicles or compositions disclosed herein to a subject having a bacterial infection in need of treatment.

The present disclosure also provides the pharmaceutical or veterinary compositions disclosed herein or the bacterial delivery vehicles disclosed herein for use in a method for treating a disease or disorder caused by bacteria.

Another object of the disclosure concerns providing the use of a bacterial delivery vehicle as described herein for the manufacture of a medicament intended for the treatment of a disease or disorder caused by bacteria.

In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

Said disease or disorder may be a bacterial infection, a metabolic disorder or a pathology involving bacteria of the human microbiome.

The diseases or disorders caused by bacteria may be selected from the group consisting of abdominal cramps, acne vulgaris, acute epiglottitis, arthritis, bacteraemia, bloody diarrhea, botulism, Brucellosis, brain abscess, chancroid venereal disease, Chlamydia, Crohn’s disease, conjunctivitis, cholecystitis, colorectal cancer, polyposis, dysbiosis, Lyme disease, diarrhea, diphtheria, duodenal ulcers, endocarditis, erysipelothricosis, enteric fever, fever, glomerulonephritis, gastroenteritis, gastric ulcers, Guillain-Barre syndrome tetanus, gonorrhoea, gingivitis, inflammatory bowel diseases, irritable bowel syndrome, leptospirosis, leprosy, listeriosis, tuberculosis, Lady Windermere syndrome, Legionaire’s disease, meningitis, mucopurulent conjunctivitis, multi-drug resistant bacterial infections, multi-drug resistant bacterial carriage, myonecrosis-gas gangrene, mycobacterium avium complex, neonatal necrotizing enterocolitis, nocardiosis, nosocomial infection, otitis, periodontitis, phalyngitis, pneumonia, peritonitis, purpuric fever, Rocky Mountain spotted fever, shigellosis, syphilis, sinusitis, sigmoiditis, septicaemia, subcutaneous abscesses, tularaemia, tracheobronchitis, tonsillitis, typhoid fever, ulcerative colitis, urinary infection, whooping cough.

The disease or disorder caused by bacteria may be a bacterial infection selected from the group consisting of skin infections such as acne, intestinal infections such as esophagitis, gastritis, enteritis, colitis, sigmoiditis, rectitis, and peritonitis, urinary tract infections, vaginal infections, female upper genital tract infections such as salpingitis, endometritis, oophoritis, myometritis, parametritis and infection in the pelvic peritoneum, respiratory tract infections such as pneumonia, intra-amniotic infections, odontogenic infections, endodontic infections, fibrosis, meningitis, bloodstream infections, nosocomial infection such as catheter-related infections, hospital acquired pneumonia, postpartum infection, hospital acquired gastroenteritis, hospital acquired urinary tract infections, and a combination thereof. In an embodiment, the infection according to the disclosure is caused by a bacterium presenting an antibiotic resistance. In a particular embodiment, the infection is caused by a bacterium as listed above in the targeted bacteria.

The disease or disorder caused by bacteria may also be a metabolic disorder, for example, obesity and/or diabetes. The disclosure thus also concerns a pharmaceutical or veterinary composition as disclosed herein for use in the treatment of a metabolic disorder including, for example, obesity and/or diabetes. It further concerns a method for treating a metabolic disorder comprising administering a therapeutically efficient amount of the pharmaceutical or veterinary composition as disclosed herein, and the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for treating a metabolic disorder.

The disease or disorder caused by bacteria may also be a pathology involving bacteria of the human microbiome. Thus, in a particular embodiment, the disclosure concerns a pharmaceutical or veterinary composition as disclosed herein for use in the treatment of pathologies involving bacteria of the human microbiome, such as inflammatory and auto-immune diseases, cancers, infections or brain disorders. It further concerns a method for treating a pathology involving bacteria of the human microbiome comprising administering a therapeutically efficient amount of the pharmaceutical or veterinary composition as disclosed herein, and the use of a pharmaceutical or veterinary composition as disclosed herein for the manufacture of a medicament for treating a pathology involving bacteria of the human microbiome. Indeed, some bacteria of the microbiome, without triggering any infection, can secrete molecules that will induce and/or enhance inflammatory or auto-immune diseases or cancer development. More specifically, the present disclosure relates also to modulating microbiome composition to improve the efficacy of immunotherapies based, for example, on CAR-T (Chimeric Antigen Receptor T) cells, TIL (Tumor Infiltrating Lymphocytes) and Tregs (Regulatory T cells) also known as suppressor T cells. Modulation of the microbiome composition to improve the efficacy of immunotherapies may also include the use of immune checkpoint inhibitors well known in the art such as, without limitation, PD-1 (programmed cell death protein 1) inhibitor, PD-L1 (programmed death ligand 1) inhibitor and CTLA-4 (cytotoxic T lymphocyte associated protein 4).

In certain embodiments, the disease to be treated is cancer or a proliferative disorder, including but not limited to, breast cancer (e.g., triple negative breast cancer, ER+ breast cancer, or ER-breast cancer), basal cell carcinoma, skin cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, brain cancer, medulloblastoma, glioma (including glioblastoma, oligodendroglioma, astrocytoma, ependymoma), neuroblastoma, colorectal cancer, ovarian cancer, liver cancer, pancreatic cancer (e.g., carcinoma, angiosarcoma, adenosarcoma), gastric cancer, gastroesophageal junction cancer, prostate cancer, cervical cancer, bladder cancer, head and neck cancer, lymphoma (e.g., mantle cell lymphoma, diffuse large B-cell lymphoma), removable solid tumors or solid tumors that cannot be removed by surgery, locally advanced solid tumors, metastatic solid tumors, leukemia (e.g., acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia (CML)), or recurrent or refractory tumors.

In one embodiment, the diseases to be treated include, but are not limited to, inflammatory or allergic diseases, including systemic anaphylaxis and hypersensitivity disorders, atopic dermatitis, urticaria, drug allergies, insect sting allergies, food allergies (including celiac disease and the like), and mastocytosis; inflammatory bowel diseases, including Crohn’s disease, ulcerative colitis, ileitis, and enteritis; vasculitis, and Behcet’s syndrome; psoriasis and inflammatory dermatoses, including dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria, viral cutaneous pathologies including those derived from human papillomavirus, HIV or RLV infection, bacterial, flugal, and other parasital cutaneous pathologies, and cutaneous lupus erythematosus; asthma and respiratory allergic diseases, including allergic asthma, exercise induced asthma, allergic rhinitis, otitis media, allergic conjunctivitis, hypersensitivity lung diseases, and chronic obstructive pulmonary disease; autoimmune diseases, including arthritis (including rheumatoid and psoriatic), systemic lupus erythematosus, type I diabetes, myasthenia gravis, multiple sclerosis, Graves’ disease, and glomerulonephritis; graft rejection (including allograft rejection and graft-v-host disease), e.g., skin graft rejection, solid organ transplant rejection, bone marrow transplant rejection; fever; cardiovascular disorders, including acute heart failure, hypotension, hypertension, angina pectoris, myocardial infarction, cardiomyopathy, congestive heart failure, atherosclerosis, coronary artery disease, restenosis, and vascular stenosis; cerebrovascular disorders, including traumatic brain injury, stroke, ischemic reperfusion injury and aneurysm; fibrosis, connective tissue disease, and sarcoidosis, genital and reproductive conditions, including erectile dysfunction; gastrointestinal disorders, including gastritis, ulcers, nausea, pancreatitis, and vomiting; neurologic disorders, including Alzheimer’s disease; sleep disorders, including insomnia, narcolepsy, sleep apnea syndrome, and Pickwick Syndrome; pain; renal disorders; ocular disorders, including glaucoma; and non-bacterial infectious diseases, including HIV.

In some aspects, the disease to be treated may be an autoimmune disease such as autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, autoimmune neutropenia, autoimmunocytopenia, antiphospholipid syndrome, dermatitis, gluten-sensitive enteropathy, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis, Multiple Sclerosis, Neuritis, Uveitis Ophthalmia, Polyendo-crinopathies, Purpura, Reiter’s Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, myocarditis, IgA glomerulonephritis, dense deposit disease, rheumatic heart disease, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism, systemic lupus erythematosus, discoid lupus, Goodpasture’s syndrome, Pemphigus, Graves’ Disease, Myasthenia Gravis, and insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison’s disease, infertility, glomerulonephritis, bullous pemphigoid, Sjogren’s syndrome, diabetes mellitus, adrenergic drug resistance with asthma or cystic fibrosis, chronic active hepatitis, primary biliary cirrhosis, endocrine gland failure, vitiligo, vasculitis, post-MI, cardiotomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, an inflammatory disorder, a granulomatous disorder, an atrophic disorder, or an alloimmune disease.

The subject to be treated may have been diagnosed with, or may be at risk of developing an infection, a disorder and/or a disease preferably due to a bacterium. Diagnostic methods of such infection, disorder and/or disease are well known by the man skilled in the art.

In a particular embodiment, the infection, disorder and/or disease presents a resistance to treatment, preferably the infection, disorder or disease presents an antibiotic resistance.

In a particular embodiment, the subject has never received any treatment prior to the administration of the delivery vehicles according to the invention or of the pharmaceutical or veterinary composition according to the invention.

In a particular embodiment, the subject has already received at least one line of treatment, preferably several lines of treatment, prior to the administration of the delivery vehicles according to the invention or of the pharmaceutical or veterinary composition according to the invention.

Preferably, the treatment is administered regularly, preferably between every day and every month, more preferably between every day and every two weeks, more preferably between every day and every week, even more preferably the treatment is administered every day. In a particular embodiment, the treatment is administered several times a day, preferably 2 or 3 times a day, even more preferably 3 times a day.

The duration of treatment with delivery vehicles according to the invention or with the pharmaceutical or veterinary composition according to the invention, is preferably comprised between 1 day and 20 weeks, more preferably between 1 day and 10 weeks, still more preferably between 1 day and 4 weeks, even more preferably between 1 day and 2 weeks. In a particular embodiment, the duration of the treatment is of or about 1 week. Alternatively, the treatment may last as long as the infection, disorder and/or disease persists.

The form of the pharmaceutical or veterinary compositions, the route of administration and the dose of administration of delivery vehicles according to the invention or of pharmaceutical or veterinary composition according to the invention can be adjusted by the man skilled in the art according to the type and severity of the infection (e.g. depending on the bacteria species involved in the disease, disorder and/or infection and its localization in the patient’s or subject’s body), and to the patient or subject, in particular its age, weight, sex, and general physical condition.

Particularly, the amount of delivery vehicles according to the invention or of pharmaceutical or veterinary composition according to the invention, to be administered has to be determined by standard procedure well known by those of ordinary skills in the art. Physiological data of the patient or subject (e.g. age, size, and weight) and the routes of administration have to be taken into account to determine the appropriate dosage, so as a therapeutically effective amount will be administered to the patient or subject.

For example, the total amount of delivery vehicles according to the invention for each administration is between 10⁴ and 10¹⁵ delivery vehicles.

In a particular embodiment, in the treatment methods or uses, said composition or bacterial delivery vehicle is administered orally.

Some bacteria of the microbiome can also secrete molecules that will affect the brain, such as serotonin and melatonin for use in the treatment of depression, dementia or sleep disorder.

Therefore, a further object of the disclosure is a method for controlling the microbiome of a subject, comprising administering an effective amount of the pharmaceutical or veterinary composition as disclosed herein in said subject.

In a particular embodiment, the disclosure also relates to a method for personalized treatment for an individual in need of treatment for a disease or disorder such as bacterial infection comprising: i) obtaining a biological sample from the individual and determining a group of bacterial DNA sequences from the sample; ii) based on the determining of the sequences, identifying one or more pathogenic bacterial strains or species that were in the sample; and iii) administering to the individual a pharmaceutical or veterinary composition according to the disclosure capable of recognizing each pathogenic bacterial strain or species identified in the sample and to deliver the packaged payload.

In an embodiment, the biological sample comprises pathological and non-pathological bacterial species, and subsequent to administering the pharmaceutical or veterinary composition according to the disclosure to the individual, the amount of pathogenic bacteria on or in the individual are reduced, but the amount of non-pathogenic bacteria is not reduced.

In another particular embodiment, the disclosure concerns a pharmaceutical or veterinary composition according to the disclosure for use to improve the effectiveness of drugs. Indeed, some bacteria of the microbiome, without being pathogenic by themselves, are known to be able to metabolize drugs and to modify them in ineffective or harmful molecules.

In another aspect, the methods and compositions described herein provide long term stable expression of a gene of interest in the microbiome of a host. In such an instance, the delivery vehicle comprises a nucleic acid molecule encoding the gene of interest wherein the nucleic acid is engineered to either integrate into the bacterial chromosome or, alternatively, stably replicate within the targeted microbiome of the host. Once delivered into the bacteria of interest, i.e., the microbiome, the gene of interest will typically be expressed. In a particular embodiment, the disclosure concerns the in-situ bacterial production of any compound of interest, including therapeutic compound such as prophylactic and therapeutic vaccine for mammals. The compound of interest can be produced inside the targeted bacteria, secreted from the targeted bacteria or expressed on the surface of the targeted bacteria. In a more particular embodiment, an antigen is expressed on the surface of the targeted bacteria for prophylactic and/or therapeutic vaccination.

The present disclosure also provides a method for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population comprising contacting the bacterial population with an efficient amount of the bacterial delivery vehicle as defined in the section “Bacterial delivery vehicle” above. The present disclosure further provides the bacterial delivery vehicles as defined in the section “Bacterial delivery vehicle” above, for use in a method for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population, in particular in the treatment of a bacterial infection typically due to virulent and/or antibiotic resistant bacteria. Another object of the disclosure provides the use of the bacterial delivery vehicle as defined in the section “Bacterial delivery vehicle” above for the manufacture of a medicament intended for reducing the amount of virulent and/or antibiotic resistant bacteria in a bacterial population, in particular for the treatment of bacterial infection typically due to virulent and/or antibiotic resistant bacteria.

The present disclosure also relates to a non-therapeutic use of the bacterial delivery particles. For instance, the non-therapeutic use can be a cosmetic use or a use for improving the well-being of a subject, in particular a subject who does not suffer from a disease. Accordingly, the present disclosure also relates to a cosmetic composition or a non-therapeutic composition comprising the bacterial delivery particles of the disclosure.

The present invention further concerns the following embodiments:

-   1. A chimeric receptor binding protein (RBP) resistant to     proteolytic digestion, wherein said RBP comprises a portion of a     receptor binding protein derived from a bacteriophage fused through     a designed linker region consisting of 1 to 70 amino acids, to a     portion of a receptor binding protein derived from a different     bacteriophage, wherein said linker region is designed to be     resistant to proteolytic digestion. -   2. The chimeric RBP according to embodiment 1, wherein the designed     linker region consists of 1 to 30 amino acids. -   3. The chimeric RBP according to embodiment 1 or 2, wherein said     chimeric RBP is resistant to proteolytic digestion by pancreatin,     and said linker region is designed to be resistant to proteolytic     digestion by pancreatin. -   4. The chimeric RBP according to any one of embodiments 1 to 3,     wherein said RBP is a side tail fiber (STF) protein, an L-shape     fiber, a long tail fiber or a tailspike. -   5. The chimeric RBP according to embodiment 4, wherein said chimeric     RBP comprises a portion of a STF protein derived from a lambdoid     bacteriophage fused through a designed linker region consisting of 1     to 70 amino acids or of 1 to 30 amino acids, to a portion of a RBP     protein derived from a different bacteriophage. -   6. The chimeric RBP according to embodiment 4 or 5, wherein said     chimeric RBP comprises an N-terminal region of a STF protein derived     from a lambdoid bacteriophage, fused through a designed linker     region consisting of 1 to 70 amino acids or 1 to 30 amino acids, to     a C-terminal region of a RBP protein derived from a different     bacteriophage, wherein said N-terminal region and C-terminal region     are fused within a site of the N-terminal STF region, called     insertion site, having at least 80% identity with a site selected     from the group consisting of amino acids SAGDAS (SEQ ID NO: 1),     ADAKKS (SEQ ID NO: 2), MDETNR (SEQ ID NO: 3), SASAAA (SEQ ID NO: 4),     and GAGENS (SEQ ID NO: 5). -   7. The chimeric RBP according to embodiment 6, wherein said     insertion site has at least 80% identity with sequence GAGENS (SEQ     ID NO: 5). -   8. The chimeric RBP according to embodiment 6 or 7, wherein said     designed linker region is at the C-terminal end of the insertion     site. -   9. The chimeric RBP according to any one of embodiments 6 to 8,     wherein said designed linker region is part of the N-terminal region     or of the C-terminal region of the chimeric RBP. -   10. The chimeric RBP according to embodiment 9, wherein at least one     amino acid of the designed linker region, corresponding to an amino     acid of the wildtype domain sequence which is likely to be targeted     by trypsin and/or chymotrypsin, is mutated compared to the wildtype     domain sequence. -   11. The chimeric RBP according to embodiment 10, wherein said     designed linker region is part of the C-terminal region of the     chimeric RBP and said at least one amino acid is located within the     15 amino acids following the insertion site. -   12. The chimeric RBP according to embodiment 10 or 11, wherein said     amino acid is selected from the group consisting of lysin (K),     arginine (R), phenylalanine (F), tryptophan (W), tyrosine (Y)     leucine (L) and methionine (M). -   13. The chimeric RBP according to embodiment 9, wherein said     N-terminal region or said C-terminal region comprises the sequence     of the linker region, said sequence being identical to the     corresponding sequence in the N-terminal region or C-terminal region     of the RBP from which it is derived, and said sequence restoring     resistance to proteolytic digestion to said chimeric RBP compared to     a chimeric RBP only differing by the absence of said linker region. -   14. The chimeric RBP according to any one of embodiments 6 to 8,     wherein said engineered linker region comprises or consists of an     heterologous amino acid sequence which is not derived from one of     the RBP from which the N-terminal region and the C-terminal region     of the chimeric RBP are derived. -   15. The chimeric RBP according to embodiment 13 or 14, wherein said     designed linker region comprises a helix or helical bundle. -   16. The chimeric RBP according to any one of embodiments 13 to 15,     wherein said designed linker region consists of 10 to 20 amino     acids. -   17. The chimeric RBP according to any one of embodiments 13 to 16,     wherein said designed linker region comprises or consists of an     amino acid sequence GSATDVMIQL (SEQ ID NO: 6) or GSATDVMIQLA (SEQ ID     NO: 7). -   18. The chimeric RBP according to any one of embodiments 13 to 15,     wherein said designed linker region consists of 50 to 65 amino     acids. -   19. The chimeric RBP according to embodiment 18, wherein said     designed linker region comprises or consists of the amino acid     sequence SEQ ID NO: 34 or SEQ ID NO: 36. -   20. The chimeric RBP according to embodiment 17 or 19, wherein said     sequence is located directly after the insertion site. -   21. The chimeric RBP according to any one of embodiments 6 to 20,     wherein the N-terminal region of said STF protein derived from said     lambdoid bacteriophage corresponds to amino acids 1 to 528 of the     lambda STF protein of sequence SEQ ID NO: 8. -   22. The chimeric RBP according to any one of embodiments 6 to 21,     wherein the C-terminal region of said STF protein derived from said     different bacteriophage corresponds to amino acids 208 to 875 of the     STF protein of sequence SEQ ID NO: 16 or to amino acids 218 to 875     of the STF protein of sequence SEQ ID NO: 16. -   23. The chimeric RBP according to embodiment 22, wherein said     chimeric RBP comprises or consists of the sequence SEQ ID NO: 9, SEQ     ID NO: 10 or SEQ ID NO: 11. -   24. The chimeric RBP according to any one of embodiments 6 to 21,     wherein the C-terminal region of said STF protein derived from said     different bacteriophage corresponds to amino acids 28 to 632 of the     STF protein of sequence SEQ ID NO: 12 or amino acids 62 to 632 of     the STF protein of sequence SEQ ID NO: 12. -   25. The chimeric RBP according to embodiment 24, wherein said     chimeric RBP comprises or consists of the sequence SEQ ID NO: 13,     SEQ ID NO: 14, SEQ ID NO: 38 or SEQ ID NO: 40. -   26. A nucleic acid encoding a chimeric RBP according to any one of     embodiments 1 to 25. -   27. A vector comprising the nucleic acid encoding a chimeric RBP     according to embodiment 26. -   28. A lambdoid bacterial delivery vehicle for use in in vivo     delivery of a DNA payload of interest into a targeted bacterial     cell, wherein said lambdoid delivery vehicle comprises the chimeric     RBP according to any one of embodiments 1 to 25. -   29. The lambdoid delivery vehicle according to embodiment 28,     wherein said chimeric RBP is a chimeric STF protein as defined in     any one of embodiments 4 to 25. -   30. The lambdoid delivery vehicle according to embodiment 29,     wherein said chimeric STF protein is a functional STF protein. -   31. The lambdoid delivery vehicle according to embodiment 30,     further comprising a functional lambdoid bacteriophage gpJ protein     and/or a functional lambdoid bacteriophage gpH protein. -   32. The bacterial delivery vehicle according to any one of     embodiments 29 to 31, wherein the chimeric STF protein has enzyme     activity such as depolymerase activity and the bacterial cell     population of interest comprises encapsulated bacteria. -   33. The bacterial delivery vehicle according to any one of     embodiments 29 to 32, said bacterial delivery vehicle comprising a     chimeric STF of sequence SEQ ID NO: 11 and a chimeric gpJ variant of     sequence SEQ ID NO: 27. -   34. The bacterial delivery vehicle according to any one of     embodiments 31 to 32, wherein one or more of the chimeric STF     protein, the gpJ protein and/or the gpH protein are engineered to     increase the efficiency of transfer of the DNA payload into a     targeted bacterial cell population. -   35. The bacterial delivery vehicle according to any one of     embodiments 28 to 34, wherein the bacterial cell population is     selected from the group consisting of E. coli bacteria, K.     pneumoniae and other species of interest. -   36. The bacterial delivery vehicle according to any one of     embodiments 28 to 35, wherein said bacterial delivery vehicle     comprises said DNA payload of interest. -   37. The bacterial delivery vehicle according to any one of     embodiments 28 to 36, wherein the DNA payload comprises a nucleic     acid of interest selected from the group consisting of Cas nuclease     gene, a Cas9 nuclease gene, a guide RNA, a CRISPR locus, a toxin     gene, a gene expressing an enzyme such as a nuclease or a kinase, a     TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a     membrane protein, a structural protein, a secreted protein, a gene     expressing resistance to an antibiotic or to a drug in general, a     gene expressing a toxic protein or a toxic factor, and a gene     expressing a virulence protein or a virulence factor, and or any of     their combination. -   38. The bacterial delivery vehicle according to embodiment 37,     wherein the nuclease targets cleavage of a host bacterial cell     chromosome or a host bacterial cell plasmid. -   39. The bacterial delivery vehicle according to embodiment 38,     wherein the cleavage occurs in an antibiotic resistant gene. -   40. The bacterial delivery vehicle according to any one of     embodiments 28 to 39, wherein said payload comprises or consists of     the nucleic acid sequence SEQ ID NO: 33 or of the nucleic acid     sequence SEQ ID NO: 42. -   41. The bacterial delivery vehicle according to embodiment 37,     wherein the nucleic acid of interest encodes a therapeutic protein. -   42. The bacterial delivery vehicle according to embodiment 37,     wherein the nucleic acid of interest encodes an antisense nucleic     acid molecule. -   43. A pharmaceutical or veterinary composition comprising the     bacterial delivery vehicle according to any one of embodiments 28 to     42 and a pharmaceutically acceptable carrier. -   44. The pharmaceutical or veterinary composition according to     embodiment 43, wherein said composition is for oral administration. -   45. A method for in vivo delivery of a DNA payload of interest into     a subject comprising, administering to said subject the     pharmaceutical or veterinary composition of embodiment 43 or 44. -   46. A method for treating a disease or disorder caused by bacteria     comprising administering to a subject having a disease or disorder     in need of treatment the pharmaceutical or veterinary composition of     embodiment 43 or 44. -   47. The method according to embodiment 46, wherein said disease or     disorder is a bacterial infection, a metabolic disorder or a     pathology involving bacteria of the human microbiome. -   48. The method according to embodiment 46 or 47, wherein said     composition is administered orally. -   49. The pharmaceutical or veterinary composition according to     embodiment 43 or 44 for use in a method for treating a disease or     disorder caused by bacteria. -   50. The pharmaceutical or veterinary composition for its use     according to embodiment 49, wherein said disease or disorder is a     bacterial infection, a metabolic disorder or a pathology involving     bacteria of the human microbiome. -   51. The pharmaceutical or veterinary composition for its use     according to embodiment 49 or 50, wherein said composition is     administered orally. -   52. A method for reducing the amount of virulent and/or antibiotic     resistant bacteria in a bacterial population comprising contacting     the bacterial population with the bacterial delivery vehicle of any     one of embodiments 28 to 42. -   53. The bacterial delivery vehicle according to any one of     embodiments 28 to 42 for use in a method for reducing the amount of     virulent and/or antibiotic resistant bacteria in a bacterial     population. -   54. A production cell line expressing the chimeric RBP according to     any one of embodiments 1 to 25. -   55. The production cell line according to embodiment 54, comprising     the nucleic acid according to embodiment 26 and/or the vector     according to embodiment 27. -   56. The production cell line according to embodiment 54 or 55,     producing the bacterial delivery vehicle according to any one of     embodiments 28 to 42. -   57. The production cell line according to any one of embodiments 54     to 56, comprising a helper phage which is a lambda prophage     wherein (i) the nucleic acid sequence encoding a wild-type STF     protein has been replaced by a nucleic acid sequence encoding the     chimeric RBP comprising or consisting of the sequence SEQ ID NO:     11, (ii) the nucleic acid sequence encoding a wild-type gpJ protein     has been replaced by a nucleic acid sequence encoding the chimeric     gpJ variant comprising or consisting of the sequence SEQ ID NO: 27,     and (iii) the Cos site has been removed, and wherein optionally (iv)     the helper prophage contains a mutation which prevents spontaneous     cell lysis, such as the Sam7 mutation and (v) the helper prophage     contains a thermosensitive version of the master cI repressor, such     as the cI857 version.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

All publications mentioned herein are incorporated herein by reference. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.

It must be noted that as used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells (e.g., a population of such cells). Similarly, reference to “a nucleic acid” includes one or more of such nucleic acids.

The present invention will be further illustrated by the examples below.

BRIEF DESCRIPTION OF THE SEQUENCES SEQ ID NO: Description 1 Insertion site sequence SAGDAS 2 Insertion site sequence ADAKKS 3 Insertion site sequence MDETNR 4 Insertion site sequence SASAAA 5 Insertion site sequence GAGENS 6 GSATDVMIQL sequence 7 GSATDVMIQLA sequence 8 Lambda STF amino acid sequence 9 STF-V10-[FA] amino acid sequence 10 STF-V10-[AAH] amino acid sequence 11 STF-V10-[Helix] amino acid sequence 12 K5 amino acid sequence 13 K5 5.0 amino acid sequence 14 K5 5.1 amino acid sequence 15 STF-V10 amino acid sequence 16 V10 amino acid sequence 17 STF-V10-[FA] DNA sequence 18 STF-V10-[AAH] DNA sequence 19 STF-V10-[Helix] DNA sequence 20 K5 5.0 DNA sequence 21 K5 5.1 DNA sequence 22 Lambda gpJ amino acid sequence 23 H591 amino acid sequence 24 H591 DNA sequence 25 Z2145 amino acid sequence 26 Z2145 DNA sequence 27 1A2 amino acid sequence 28 1A2 DNA sequence 29 A8 amino acid sequence 30 A8 DNA sequence 31 gpH IAI amino acid sequence 32 Lambda-K5 amino acid sequence 33 Payload p1392 plasmid sequence 34 helical bundle 1 and linker from STF protein from Escherichia phage ZG49 amino acid sequence 35 recoded helical bundle 1 and linker from STF protein from Escherichia phage ZG49 DNA sequence 36 helical bundle 2 and linker from STF protein from Escherichia phage ZG49 amino acid sequence 37 recoded helical bundle 2 and linker from STF protein from Escherichia phage ZG49 DNA sequence 38 K5 9.0 amino acid sequence 39 K5 9.0 DNA sequence 40 K5 9.1 amino acid sequence 41 K5 9.1 DNA sequence 42 payload p1900 plasmid sequence 43 candidate STF protein from Escherichia phage ZG49 amino acid sequence 44 candidate STF protein from Escherichia phage ZG49 DNA sequence 45 payload p775 plasmid sequence 46 primase ori from the PICI of the Escherichia coli strain CFT073 47 restriction site 48 Primase ori deltaGAAABCC 49 Primase ori devoid of restriction sites 50 PICI primase-helicase amino acid sequence 51 PICI primase-helicase DNA sequence

EXAMPLES Example 1

It has been shown that a chimera between lambda STF and V10 STF (originating from a prophage found in 0157 strains), said chimera being of sequence SEQ ID NO: 15, is able to target 0157 strains with high efficiency in vitro by recognizing and degrading the 0157 antigen group IV capsule. However, initial in vivo experiments showed that lambda packaged phagemids containing the V10 chimeric STF did not deliver with high efficiency into 0157 strains colonizing the mouse gut. Efficiencies of delivery in this mouse model were, on average, 20% and the delivery was not improved by increasing the dosage given to the mouse (MOI).

One possible reason for this observation was that the chimeric lambda particles containing V10 fusions were stable in in vitro conditions, where delivery and killing experiments were done in the presence of known reagents (for instance, LB), but lost part of their activity once they passed through the mouse gut.

It had been observed that wild-type lambda particles are able to pass and replicate in the gut suggesting that some part of the engineering process to generate the lambda-V10 fusion had rendered it at least less stable and partly susceptible to degradation in in vivo conditions. Apart from the lambda STF-V10 fusion, the lambda particles used in these experiments have also been engineered at the gpJ level to modify its primary receptor, and contain the 1A2 gpJ variant (and are thus called herein 1A2-V10 particles). Thus, it was possible that either the 1A2 gpJ variant and/or the STF-V10 fusion were the sources of reduced stability in in vivo conditions.

In vitro assays were set up to differentiate between 1A2 gpJ activity and STF-V10 activity based on the fact that, for some strains, the presence of a functional STF is dispensable for injection, as is the case for the MG1655 K-12 strain. Since the 1A2 gpJ variant recognizes the OmpC receptor of 0157 strains, but not that of MG1655, an MG1655 variant was engineered in which the OmpC receptor was replaced to encode that of the 0157 variant. This strain was called MG1656-OmpCO157. On the other hand, efficient delivery in 0157 strains is completely dependent on the presence of a functional STF containing V10. Hence, by exposing the 1A2-V10 packaged phagemids to different conditions and evaluating the gpJ versus STF-V10 activity in vitro, it was possible to determine which part of the packaged phagemid was unstable.

The 1A2-V10 packaged phagemids were then exposed to simulated intestinal fluid (SIF) in the presence or absence of pancreatin (which contains the digestive enzymes trypsin and chymotrypsin) and bile salts. Specifically, packaged phagemids were produced, diluted 1:100 in the buffer of choice and incubated at 37° C. for 3 hours. After that, the packaged phagemids were directly titrated on MG1656-OmpCO157 and H10 (O157)-delta-stx strains. As a control, the wild-type lambda packaged phagemid produced with CYC3 strains was also exposed to the same conditions. H10-delta-stx is a variant of 0157 strain for which the stx gene has been deleted. Briefly, the wild-type H10 strain was transduced with packaged lambda phagemids containing a lambda-V10 STF chimera and a packaged circuit encoding a Cpf1 nuclease programmed to target the stx2 gene. After transduction, survivor colonies were checked by PCR to verify the presence or absence of the stx gene and only colonies with stx gene deleted were kept.

As can be seen in FIG. 1 , the wild-type lambda particle produced with CYC3 strains was stable under any conditions, as the titers remained the same across all experiments. However, for the 1A2-V10 variant, a constant gpJ activity (central bars in FIG. 1 ) was observed, which indicates that this gpJ variant was not degraded in the presence of pancreatin. Finally, the titers of the 1A2-V10 dropped by a factor of 2 log when titrated in H10-delta-stx (0157) strains only in the presence of pancreatin. Bile salts by themselves did not affect the activity of the packaged phagemids. These results clearly demonstrate that the STF-V10 chimera is at least partially degraded in the presence of pancreatin.

It was hypothesized that the source of reduced stability was not in the V10 moiety itself, but in the way the fusion with the lambda STF was generated. Further, it was hypothesized that although no linker amino acids were inserted in the initial lambda STF-V10 chimera, the context of the fusion was not natural, and hence, had not been selected for stability in the presence of proteolytic enzymes. To test this hypothesis, two types of lambda STF-V10 chimeras were generated: the first type contains point mutations in phenylalanine (F) and lysine (K) residues present in the fusion point between lambda STF and V10 STF (FIG. 2 ); for the second type, a more detailed structural analysis was performed. Structural homology analyses with the original V10 fusion showed a crystallized STF with high identity to the V10 moiety (PDB ID: 5W6S): this STF contains a short helix at its N-terminus which has a homolog in V10, but that was not included in the original lambda STF-V10 chimera. The helix forms a very tight bundle that “fastens” the domain right after it in the crystal structure. Based on the delivery efficiency results that were obtained with the original lambda STF-V10 version, this helix may not be important for activity but it may be important for stability since it may confer a proper folding where exposed trypsin- and chymotrypsin-accessible residues are buried (FIG. 2 ).

Accordingly, three lambda-STF-V10 fusion variants were constructed: V10-[FA] (SEQ ID NO: 9), where a lysine (K) residue was exchanged by an alanine (A); V10-[AAH] (SEQ ID NO: 10), where an FKF tripeptide was exchanged to AAH tripeptide; and V10-Helix (SEQ ID NO: 11), where the short 10-amino acid helix bundle GSATDVMIQLA (SEQ ID NO: 7) was included as part of the chimeric protein just after the insertion site. The insertion site with the lambda STF, GAGENS (SEQ ID NO: 5), was not changed for any of the variants.

The three variants were then exposed to buffer at different pH values (5.0 and 6.8) in the presence or absence of pancreatin as detailed for the original lambda STF-V10 fusion above. As can be seen in FIG. 3 , all variants showed some degree of resistance to pancreatin treatment: the V10-[FA] and V10-[AAH] variants showed between 1 and 1.5 log higher particle levels than the original V10 counterpart, although the stability was not complete and was dependent on pH. However, the V10-Helix variant showed an apparent complete resistance to digestive proteases at any pH tested. Taken together, the results showed that one can engineer lambda STF-V10 variants that are resistant to digestive proteases by only engineering the linker region, and that are good candidates for in vivo use, with V10-Helix showing highly positive results in vitro.

In vivo studies were next conducted. It was difficult to deliver 0157 strains in vivo at a decent efficiency (max 40%, but typically under 20%) and interestingly, the delivery was not improved by increasing the MOI administered to the mouse. However, delivery was observed with the same vector while using a strain deleted for the 0157 antigen (ΔwaaJ mutants). Based on this result, it was possible that the V10 activity somehow may not survive the transit through the GIT.

In vivo assays were conducted to measure the kinetics of shedding of packaged phagemids with 1A2 gpJ and chimeric lambda STF-V10 after oral administration to streptomycin-treated, uncolonized BALB/c mice as well as the residual V10 activity. The specific V10 activity was evaluated by comparing transduction efficiencies on H10Δstx, where 1A2 and V10 are both needed and MG-ompC_O157 where only 1A2 is required. Packaged phagemids were produced at high titer and given to 3 mice in sucrose-bicarbonate buffer to reduce the stomach acidity and to help packaged phagemids to reach the intestine. Stool samples were collected at T0, T2h, T4h, T6h and T8h, and resuspended in PBS. After centrifugation, supernatants containing shed packaged phagemids were used in transduction assays against H10Δstx and MG-ompC_O157.

Interestingly, as can be seen in FIG. 4 , the initial dose of packaged phagemid contained approximately 10% of the particles with V10 activity. Most of the 1A2 activity could be recovered between 6 to 8 hours after oral gavage, which indicates that this gpJ variant is not degraded after transit through the entire Gastrointestinal Tract (GIT). However, the estimated titers measuring the V10 activity were very low. Less than 1% of the recovered packaged phagemids kept their V10 functionality. This result indicates that at least 90% of the packaged phagemid with 1A2 gpJ and chimeric lambda STF-V10 lose their V10 activity in the GIT. The presence of numerous proteolytic enzymes (trypsin and chymotrypsin) secreted by the pancreas in the gut may be responsible for this degradation. This experiment finally demonstrates that 1A2-V10 can survive through the GI tract but loses an important part of its V10 activity which would explain why one cannot deliver in 0157 strains at high efficiency.

Following on from this experiment and the result of in vitro stability testing of 3 new lambda-STF-V10 fusion variants, 2 variants that seemed to better resist the digestive proteases were used: lambda-STF-V10-[FA] and lambda-STF-V10-[Helix], disclosed above. Indeed, in vitro experiments have shown that these packaged phagemids (also called eligobiotics or EB) seemed able to resist in pancreatin-containing medium at least 1h without losing their capacity to deliver into strains where V10 activity is required. This was especially true for the lambda-STF-V10-[Helix] variant. Then, in the exact same conditions as with the original 1A2-V10, the inventors assessed the residual activity of V10 after passage through the entire GI tract of uncolonized BALB/c mice.

As can be seen on FIG. 5 , V10 activity of the variant 1A2-V10-[FA] was approximately at 1% after passage through the gut. As opposed to this observation, the new 1A2-V10-[Helix] showed a V10 activity approximately similar to the total activity of this packaged phagemid after passage through the GIT. These data indicate that 1A2-V10-[Helix] could perform optimally in vivo due to the high stability of its V10 activity (as opposed to the original version of 1A2-V10). To further confirm this stability, a simplified pharmacokinetics study was conducted in mice, where the shedding of the 1A2-V10-[Helix] over time was observed, following oral gavage of uncolonized BALB/c mice with a single dose of this packaged phagemid (administered as a 1:1 mixture with a sucrose/bicarbonate buffer).

As shown in FIG. 6 , the STF activity (required to enter into H10 but not into MG1656) was just as stable over time as the Tip/overall capside functionality, as indicated by the identical pattern of shedding in the stool.

In another experiment, the in vivo delivery of the two new versions through plasmid curing was studied. The lambda-STF-V10-[Helix] and lambda-STF-V10-[FA] packaged phagemids were administered (2 doses, 6 h apart) targeting one part of the pRFP plasmid into mice colonized with H10Δstx/pRFP. Assuming that the payload is fully effective (100% cutting efficacy once expressed in the cell), the delivery can be calculated as the ratio of bacteria that lost the target plasmid over the total number of bacteria. Practically, the plasmid carries a kanamycin resistance gene; this makes it easier to check for colonies that kept versus lost the plasmid by simply patching streptomycin-resistant bacteria onto Kan plates.

As can be seen on FIG. 7 , the curing efficiency was great with this mixture of packaged phagemids as most of the mice displayed a curing percentage of 80% or more (9 mice out of 10). Even though a great peak was observed after a single administration at t = 6 h, the peak of curing efficacy was higher at 24 hours post-treatment likely reflecting the interest of a second administration, although this may be due to transit time variations between animals. Another interesting observation is that pRFP curing (i.e., sensitivity to kanamycin) was still visible at T24h and T48h whereas payload delivery (i.e., resistance to chloramphenicol) had strongly decreased. This indicates that the curing method could give a more stable view of delivery/nuclease efficacy over time. The results clearly demonstrate that the mixture of new packaged phagemids tested is much more capable of targeting strains of interest in the mouse intestine.

In order to optimize for phagemids, PCRs were conducted on several clones from the feces to discriminate between lambda-STF-V10-[Helix] and lambda-STF-V10-[FA]: out of 38 tested clones, 71% had received the payload from lambda-STF-V10-[Helix], indicating that this version was significantly efficient under in vivo conditions.

According to previous results, a decolonization experiment in vivo of the STEC strain H10WT with the new mutant 1A2-V10-[Helix] was conducted. In order to avoid colonization rebound immediately after treatment with packaged phagemids, it was decided to remove the antibiotic pressure (streptomycin) that was used to clear and maintain a niche for Enterobacteriaceae in the gut of mice with conventional specific-pathogen-free flora. Mice were treated with 5 doses of the packaged phagemid, 2 days apart, and compared with a control group treated with 5 doses of buffer (sucrose Bicarbonate).

As can be observed in FIGS. 8 and 9 on the control group, the colonization was not totally stable overtime. A slow decrease day after day can be seen from D6 to D12. However, the buffer did not seem to have an impact on the colonization level. In contrast, the colonization level of the STEC strains presented a great response to treatment. Indeed, a 2 logs reduction was observed after the first dose and more than 3 logs after the second for 4 mice out of 5. After the full 5-dose regimen (D7), a total of 4 logs of killing was obtained. Interestingly, no rebound of the colonization was observed after the last treatment.

To check for a potential resistant population to the packaged phagemids (natural or acquired) at the end of the experiment, surviving colonies on D7/D8 were patched and a transduction experiment was carried out. Interestingly, no resistance (entry or nuclease) was observed in this experiment. Taken together, the results described herein show an increased efficacy of variants, such as the variant 1A2-V10-[Helix] to decolonize STEC strains from the mouse gut.

Example 2

To test if the approach followed with the lambda-STF-V10 chimeric STF in Example 1 above was generalizable to other STF chimeras, a second set of experiments was performed. In this case, a functional chimeric STF was engineered between lambda STF and the K5 tailspike, called lambda-K5 (SEQ ID NO: 37) which has been described in the literature to infect K5-encapsulated E. coli strains and for which a crystal structure is available [11]. The same approach as for lambda-V10 chimera was followed, including the insertion point in the lambda STF protein (GAGENS (SEQ ID NO: 5)). In this case, the readout strain for K5 STF activity was LMR_503 and the readout for gpJ activity was MG1656-OmpCO157, as explained before. Packaged phagemids harboring the 1A2 gpJ (SEQ ID: 27) and the lambda-K5 STF were produced and titrated in both LMR_503 or MG1656-OmpCO157 after treatment with or without pancreatin at pH 6.8.

As can be seen in FIG. 10 , although the lambda-K5 STF chimera was completely functional as measured by its ability to inject into the LMR_503 strain in PBS, it was not very stable in the presence of pancreatin, showing up to 4-log loss in the number of functional particles. This was similar to what was observed for the lambda-STF-V-10 chimeric STF.

Next, the crystal structure was analyzed for the original K5 STF (PDB ID: 2X3H) and it was observed that it also contained a three helical bundle at its N-terminus. However, as opposed to the V10 structure, the helical bundle of K5 was capped by a turn, which in the lambda-K5 STF was directly at the fusion point. It was hypothesized that this non-natural insertion point may be the cause for the pancreatin reduced stability observed. To test this hypothesis, several lambda-K5 variants were constructed in which the fusion point was modified to contain different versions of the helical bundle.

-   Lambda K5 5.0 (SEQ ID NO: 13): contains part of the helical bundle     from V10 (GSATDVMIQL (SEQ ID NO: 6)) fused to the K5 STF without its     original helical bundle -   Lambda K5 5.1 (SEQ ID NO: 14): contains the helical bundle from V10     (GSATDVMIQLA (SED ID NO: 7)) fused to the K5 STF without its     original bundle

Packaged phagemids harboring the 1A2 gpJ and each of the K5 helix chimeras were produced and titrated on MG1656-OmpCO157 or LMR 503, as explained above.

FIGS. 11 and 12 show that the variants containing V10 helix versions K5 5.0 and K5 5.1 were mostly resistant to pancreatin treatment, as there was only 1 log loss compared to other STF fusions. It is also important to note that no functional differences in terms of titers were observed for any of the K5 variants constructed, which suggests a high degree of flexibility in terms of linkers to be used when creating non-homologous STF chimeras.

It has thus been shown that there was no correlation between function (injection in a given strain) and stability, and that the latter was dependent on the amino acid content of the fusion point. Additionally, the inventors showed that the sequence GSATDVMIQL(A) (SEQ ID NO: 6 and 7) originating from V10 Helix can be used as a pancreatin-resistant linker even in proteins that contain no homology to V10 STF (K5 STF) and protect the new chimera from degradation by pancreatin.

Example 3

Alternative pancreatin-resistant linkers conferring stability to a lambda STF-K5 chimera were designed from a STF protein having homology, at its C-terminal portion, with the C-terminal portion of the K5 STF starting at amino acid G62, namely candidate STF protein from scherichia phage ZG49 (SEQ ID NO: 43 and SEQ ID NO: 44).

An analysis of this ZG49 STF protein using HHPRED software (Söding et al. (2005) Nucleic Acids Res. 33:W244-8) showed that it contains a helical bundle from amino acid 212 to amino acid 217. This helical bundle was included in the linkers designed by the inventors. More particularly, these linkers comprise the amino acid sequence located between amino acids G210 or D211 and amino acid E272 of the ZG49 phage STF protein. They are typically of sequence SEQ ID NO: 34 or SEQ ID NO: 36.

Two chimeric STFs were then built that contain the N-terminus of Lambda STF up to amino acid sequence GAGENS (SEQ ID NO: 5), followed by the linker designed above of sequence SEQ ID NO: 34 or SEQ ID NO: 36, and followed by the K5 moiety starting from position G62. The DNA sequences of the designed linkers were recoded for expression in Escherichia coli and were respectively of sequence SEQ ID NO: 35 and SEQ ID NO: 37. The two chimeric STFs were called K5 9.0 (for linker starting at position G210, SEQ ID NO: 38 and SEQ ID NO: 39) and K5 9.1 (for linker starting at position D211, SEQ ID NO: 40 and SEQ ID NO: 41) and only differ in the presence or absence, respectively, of a glycine at the start of the linker.

The production and pancreatin tests of both chimeric STFs were done as shown in Examples 1 and 2, and showed that the use of a linker designed from a STF protein having homology at this C-terminal portion with the K5 STF also provided pancreatin resistance to the chimeric STFs, and even improved the pancreatin resistance of the chimera as compared to K5 5.0 and K5 5.1 (FIG. 15 ).

Finally, in vivo assays were performed to attempt decolonization of the LMR_503 strain, which should be targeted in the gut only if the chimeric STF is resistant to proteolytic enzymes, as has been shown in Example 2. To do this, 10 BALB/c mice were treated with streptomycin and colonized with strain LMR_503. An Eligobiotic® harboring the A8 gpJ and the chimeric K5 9.1 STF was produced carrying a plasmid (p775, SEQ ID NO: 45) encoding a nuclease and a guide targeting the ctx gene found in strain LMR_503. The decolonization assay was identical to that described for strain H10WT, following a single dose of Eligobiotic® (FIG. 16 ).

A 2.6 log median reduction in strain levels was observed after treatment with Eligobiotic®, which shows that the engineering of the K5 9.1 STF was successful, and that K5 9.1 STF was able to withstand proteolytic degradation in the mouse gut.

The inventors thus showed that other linkers could be designed to confer pancreatin resistance to chimeric RBP proteins. In particular, it is herein shown that the sequences SEQ ID NO: SEQ ID NO: 34 and SEQ ID NO:36 designed from the ZG49 phage STF protein can be used as a pancreatin-resistant linker to protect chimera comprising a lambda STF N-terminal portion and a K5 STF C-terminal portion from degradation by pancreatin.

Example 4

To evaluate the effect of DNA payload size on the number of payloads packaged in Eligobiotics®, 3 different payloads were used to produce Eligobiotics® as summarized in Table 1.

TABLE 1 Batches of Eligobiotics® produced Eligobiotic code / batch number Payload Size (kb) eb512 / EB003-DS-008 p1085 12.125 eb393 / EB003-DS-009 p779 12.428 eb827 / EB003-DS-011 p1392 11.615

After fermentation, lysis (3 h incubation at 37° C. with 0.1% Triton X-100, 2000 U/L Benzonase) and clarification on a Zeta Plus Capsule (3M), the Eligobiotics® were purified by anion exchange chromatography on a Sartobind Q capsule (Sartorius). This initial purification was followed by a buffer exchange and concentration step by tangential flow filtration on a Pellicon 2 minicassette Biomax 300 kDa (Millipore). A final polishing step of size exclusion chromatography on Sepharose 6FF resin (GE Healthcare) was performed to yield the purified Eligobiotics®.

Analysis of the Eligobiotics®’s DNA content was performed by analytical ultracentrifugation in a Beckman Coulter Optima AUC using an AN50Ti rotor at 6 krpm. The sedimentation coefficients of different particles present in solution for each EB batch were extracted from sedimentation velocity data (acquired at 260 and 280 nm).

Based on the molecular weight calculated from their sedimentation coefficient and their 260/280 nm ratios, the different populations of particles detected could be separated as Eligobiotics® containing either 3 copies (centered on 290 S) or 4 copies (centered on 330-340 S) of the payload (FIG. 13 ).

Important differences were observed between Eligobiotics® depending on the size of the packaged payload. Although Eligobiotics® packaging the smaller p1392 (11.615 kb) yielded almost exclusively particles containing 4 copies of the payload, small increases (up to 800 bp) in the size of the payload correlate with a shift towards packaging 3 copies. As such, Eligobiotics® produced with p779 (12.428 kb) packaged preferentially 3 copies of the payload while approximately a third of the particles contained 4 copies (FIG. 14 ).

Thus, it appears that p1392 is close to an ideal size to package exclusively 4 copies of payload in Eligobiotics® particles, yielding an homogenous population. Increasing the size of the payload compared to p1392 generates more heterogeneous Eligobiotics® populations, with increasing proportions of particles containing 3 copies of payload. From this dataset, it appears that there is a lower limit for concatemer packaging close to 36 kb, as described in the literature [28]. p1085, with a size of 12.125 kb, could package 3 copies per head (36.375 kb) or 4 copies per head (48.5 kb), although the 4 copies species is preferred as seen in FIG. 14 . Increasing the size to 12.428 kb would allow packaging of 3 copies per head (37.284 kb) and 4 copies per head (49.712 kb); in this case, 4 copies are preferred. From these two data points, the inventors inferred that the lower limit for packaging is indeed around 36 kb but with a lower efficiency. Increasing the size just by 909 bp completely shifts the packaged species to 4 copies: the limit for optimal efficiency of packaging, probably driven by a pressure signal in the capsid, lies within these two sizes. Finally, the 11.615 kb payload packages virtually only 4 copies per head (46.46 kb), as the 3-copy species is slightly below the packaging limit, even at low efficiency (34.845 kb).

From these data, it can also be predicted which sizes would give packaging of single and multimeric species, as shown below in Tables 2 and 3. Smaller sizes yielding single packaged species are generally preferred for several reasons, including ease of manipulation and lower probability of introducing unwanted restriction sites. Finally, sizes that allow for very efficient packaged species that are not too small (26-39 kb) or too large (50-51 kb) are also preferred in some cases as it has been shown that the amount of DNA present in the capsid may alter the packaging and stability of the particles due to intracapsid pressure [29]-[30]. Finally, sizes that are large enough to allow for production of packaged phagemids at high titer are also more particularly preferred.

TABLE 2 Predicted number of concatemers packaged in a capsid depending on the monomer size Number of copies in the concatemer Plasmid size (kb) 2 3 4 5 6 7 8 9 10 11 3 6 9 12 15 18 21 24 27 30 33 4 8 12 16 20 24 28 32 36 40 44 5 10 15 20 25 30 35 40 45 50 55 6 12 18 24 30 36 42 48 54 60 66 7 14 21 28 35 42 49 56 63 70 77 8 16 24 32 40 48 56 64 72 80 88 9 18 27 36 45 54 63 72 81 90 99 10 20 30 40 50 60 70 80 90 100 110 Single conformation possible, 4 copies 11 22 33 44 55 66 77 88 99 110 121 12 24 36 48 60 72 84 96 108 120 132 Single conformation possible 13 26 39 52 65 78 91 104 117 130 143 Single conformation possible 14 28 42 56 70 84 98 112 126 140 154 Single conformation possible 15 30 45 60 75 90 105 120 135 150 165 Single conformation possible 16 32 48 64 80 96 112 128 144 160 176 Single conformation possible, high limit 17 34 51 68 85 102 119 136 153 170 187 Single conformation possible 18 36 54 72 90 108 126 144 162 180 198 Single conformation possible 19 38 57 76 95 114 133 152 171 190 209 Single conformation possible 20 40 60 80 100 120 140 160 180 200 220 Single conformation possible 21 42 63 84 105 126 147 168 189 210 231 Single conformation possible 22 44 66 88 110 132 154 176 198 220 242 Single conformation possible 23 46 69 92 115 138 161 184 207 230 253 Single conformation possible 24 48 72 96 120 144 168 192 216 240 264

Cells with heavy dark borders and in bold represent better species, cells with thin borders and non-bolded represent species either too small or too large for optimal packaging. The lower and higher limits for efficient packaging have been set to 36 kb and 51 kb, respectively.

TABLE 3 Predicted number of concatemers packaged in a capsid depending on the monomer size between 9 and 13 kb Number of copies in the concatemer Plasmid size (kb) 2 3 4 5 6 9 18 27 36 45 54 9.25 18.5 27.75 37 46.25 55.5 9.5 19 28.5 38 47.5 57 9.75 19.5 29.25 39 48.75 58.5 10 20 30 40 50 60 Single conformation possible, 4 copies 10.25 20.5 30.75 41 51.25 61.5 Single conformation possible, 4 copies 10.5 21 31.5 42 52.5 63 Single conformation possible, 4 copies 10.75 21.5 32.25 43 53.75 64.5 Single conformation possible, 4 copies 11 22 33 44 55 66 Single conformation possible, 4 copies 11.25 22.5 33.75 45 56.25 67.5 Single conformation possible, 4 copies 11.5 23 34.5 46 57.5 69 Single conformation possible, 4 copies 11.75 23.5 35.25 47 58.75 70.5 12 24 36 48 60 72 12.25 24.5 36.75 49 61.25 73.5 12.5 25 37.5 50 62.5 75 Single conformation possible 12.75 25.5 38.25 51 63.75 76.5 Single conformation possible 13 26 39 52 65 78

Cells with heavy dark borders and in bold represent better species, cells with thin borders and non-bolded represent species either too small or too large for optimal packaging. The lower and higher limits for efficient packaging have been set to 36 kb and 51 kb, respectively.

REFERENCES

E. Jończyk, M. Klak, R. Międzybrodzki, and A. Górski, “The influence of external factors on bacteriophages—review,” Folia Microbiol. (Praha), vol. 56, no. 3, pp. 191-200, May 2011, doi: 10.1007/s12223-011-0039-8.

K. Dąbrowska, “Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review,” Med. Res. Rev., vol. 39, no. 5, pp. 2000-2025, September 2019, doi: 10.1002/med.21572.

H. W. Smith, M. B. Huggins, and K. M. Shaw, “Factors influencing the survival and multiplication of bacteriophages in calves and in their environment,” J. Gen. Microbiol., vol. 133, no. 5, pp. 1127-1135, May 1987, doi: 10.1099/00221287-133-5-1127.

K. Verthé, S. Possemiers, N. Boon, M. Vaneechoutte, and W. Verstraete, “Stability and activity of an Enterobacter aerogenes-specific bacteriophage under simulated gastro-intestinal conditions,” Appl. Microbiol. Biotechnol., vol. 65, no. 4, pp. 465-472, September 2004, doi: 10.1007/s00253-004-1585-7.

N. Jamalludeen, R. P. Johnson, P. E. Shewen, and C. L. Gyles, “Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs,” Vet. Microbiol., vol. 136, no. 1, pp. 135-141, April 2009, doi: 10.1016/j.vetmic.2008.10.021.

Y. Tanji, T. Shimada, H. Fukudomi, K. Miyanaga, Y. Nakai, and H. Unno, “Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice,” J. Biosci. Bioeng., vol. 100, no. 3, pp. 280-287, September 2005, doi: 10.1263/jbb. 100.280.

J. H. Northrop, “THE EFFECT OF PROTEOLYTIC ENZYMES ON E. COLI PHAGES AND ON NATIVE PROTEINS,” J. Gen. Physiol., vol. 48, pp. 73-78, September 1964, doi: 10.1085/jgp.48.1.73.

P. K. Chanda and S. N. Chatterjee, “Properties of the cholera phage PL 163/10,” Acta Virol., vol. 19, no. 3, pp. 197-203, May 1975.

Y. Zivanovic et al., J. Virol., vol. 88, no. 2, pp. 1162-1174, January 2014.

J. Wang, M. Hofnung, and A. Charbit, “The C-terminal portion of the tail fiber protein of bacteriophage lambda is responsible for binding to LamB, its receptor at the surface of Escherichia coli K-12,” J. Bacteriol., vol. 182, no. 2, pp. 508-512, January 2000, doi: 10.1128/jb. 182.2.508-512.2000.

James E Thompson, Meraj Pourhossein, Amy Waterhouse, Thomas Hudson, Marie Goldrick, Jeremy P Derrick, Ian S Roberts, “The K5 lyase KflA combines a viral tail spike structure with a bacterial polysaccharide lyase mechanism”, J Biol Chem, vol. 285, no. 31, pp. 23963-9, July 2010. 

1. A lambdoid bacterial delivery vehicle comprising a chimeric receptor binding protein (RBP) resistant to proteolytic digestion, wherein said chimeric RBP comprises an N-terminal region of a side tail fiber (STF) protein from a lambdoid bacteriophage, fused through a designed linker region consisting of 1 to 70 amino acids or 1 to 30 amino acids, to a C-terminal region of a RBP protein from a different bacteriophage, wherein said N-terminal region and C-terminal region are fused within an insertion site of the N-terminal STF region, said insertion site having at least 80% identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 1), ADAKKS (SEQ ID NO: 2), MDETNR (SEQ ID NO: 3), SASAAA (SEQ ID NO: 4) and GAGENS (SEQ ID NO: 5); and wherein said designed linker region comprises a helix or helical bundle and wherein said linker region is resistant to proteolytic cleavage.
 2. The bacterial delivery vehicle according to claim 1, wherein the designed linker region consists of 1 to 30 amino acids.
 3. The bacterial delivery vehicle according to claim 1, wherein said chimeric RBP is resistant to proteolytic digestion by pancreatin, and said linker region is designed to be resistant to proteolytic digestion by pancreatin.
 4. The bacterial delivery vehicle according to claim 1, wherein said insertion site has at least 80% identity with sequence GAGENS (SEQ ID NO: 5).
 5. The bacterial delivery vehicle according to claim 1, wherein said designed linker region is at the C-terminal end of the insertion site.
 6. The bacterial delivery vehicle according to claim 1, wherein said designed linker region is part of the N-terminal region of the C-terminal region of the chimeric RBP.
 7. The bacterial delivery vehicle according to claim 6, wherein said N-terminal region or said C-terminal region comprises the sequence of the linker region, said sequence being identical to the corresponding sequence in the N-terminal region or C-terminal region of the RBP from which it is derived, and said sequence restoring resistance to proteolytic digestion to said chimeric RBP compared to a chimeric RBP only differing by the absence of said linker region.
 8. The bacterial delivery vehicle according to claim 1, wherein said designed linker region comprises, or consists of, an heterologous amino acid sequence which is not from one of the RBP from which the N-terminal region and the C-terminal region of the chimeric RBP are derived.
 9. The bacterial delivery vehicle according to claim 1, wherein said designed linker region comprises, or consists of, an amino acid sequence GSATDVMIQL (SEQ ID NO: 6) or GSATDVMIQLA (SEQ ID NO: 7).
 10. The bacterial delivery vehicle according to claim 1, wherein said designed linker region comprises, or consists of, the amino acid sequence of SEQ ID NO: 34 or SEQ ID NO:
 36. 11. The bacterial delivery vehicle according to claim 1, wherein the N-terminal region of said STF protein from said lambdoid bacteriophage corresponds to amino acids 1 to 528 of the lambda STF protein of SEQ ID NO:
 8. 12. The bacterial delivery vehicle according to claim 1, wherein the C-terminal region of said STF protein from said different bacteriophage corresponds to amino acids 208 to 875 of the STF protein of SEQ ID NO: 16 or to amino acids 218 to 875 of the STF protein of SEQ ID NO:
 16. 13. The bacterial delivery vehicle according to claim 12, wherein said chimeric RBP comprises, or consists of, the sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO:
 11. 14. The bacterial delivery vehicle according to claim 1, wherein the C-terminal region of said STF protein from said different bacteriophage corresponds to amino acids 28 to 632 of the STF protein of SEQ ID NO: 12 or amino acids 62 to 632 of the STF protein of SEQ ID NO:
 12. 15. The bacterial delivery vehicle according to claim 14, wherein said chimeric RBP comprises, or consists of, the sequence SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 38 or SEQ ID NO:
 40. 16. The bacterial delivery vehicle according to claim 1, said bacterial delivery vehicle comprising a chimeric RBP comprising or consisting of the sequence of SEQ ID NO: 11 and a chimeric gpJ variant comprising or consisting of the sequence of SEQ ID NO:
 27. 17. The bacterial delivery vehicle according to claim 1, wherein said bacterial delivery vehicle comprises a DNA payload of interest.
 18. The bacterial delivery vehicle according to claim 17, wherein said DNA payload comprises: a nucleic acid of interest selected from the group consisting of a Cas nuclease gene, a Cas 9 nuclease gene, a guide RNA, a CRISPR locus, a toxin gene, a gene expressing an enzyme, a gene encoding a bacterial receptor, a gene encoding a membrane protein, a gene encoding a structural protein, a gene encoding a secreted protein, a gene expressing resistance to an antibiotic, a gene expressing resistance to a drug, a gene expressing a toxic protein, a gene encoding a toxic factor, a gene expressing a virulence protein, a gene expressing a virulence factor, and any of their combinations, or a nucleic acid of interest encoding a therapeutic protein or an antisense nucleic acid molecule.
 19. The bacterial delivery vehicle according to claim 18, wherein said enzyme is selected from the group consisting of a nuclease, a kinase, a TALEN, a ZFN, a meganuclease and a recombinase.
 20. The bacterial delivery vehicle according to claim 17, wherein said payload comprises or consists of the nucleic acid sequence of SEQ ID NO: 33 or of the nucleic acid sequence of SEQ ID NO:
 42. 21. The bacterial delivery vehicle according to claim 1, for use in in vivo delivery of said DNA payload of interest into a targeted bacterial cell.
 22. A pharmaceutical or veterinary composition comprising: a lambdoid bacterial delivery vehicle comprising a chimeric receptor binding protein (RBP) resistant to proteolytic digestion, wherein said chimeric RBP comprises an N-terminal region of a side tail fiber (STF) protein from a lambdoid bacteriophage, fused through a designed linker region consisting of 1 to 70 amino acids or 1 to 30 amino acids, to a C-terminal region of a RBP protein from a different bacteriophage, wherein said N-terminal region and C-terminal region are fused within an insertion site of the N-terminal STF region, said insertion site having at least 80% identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 1), ADAKKS (SEQ ID NO: 2), MDETNR (SEQ ID NO: 3), SASAAA (SEQ ID NO: 4) and GAGENS (SEQ ID NO: 5); and wherein said designed linker region comprises a helix or helical bundle and wherein said linker region is resistant to proteolytic cleavage; and a pharmaceutically acceptable carrier.
 23. The pharmaceutical or veterinary composition according to claim 22, wherein said lambdoid bacterial delivery vehicle is for use in in vivo delivery of a DNA payload of interest into a targeted bacterial cell.
 24. A method for in vivo delivery of a DNA payload of interest into a subject comprising administering to said subject a pharmaceutical or veterinary composition comprising: a lambdoid bacterial delivery vehicle for use in in vivo delivery of a DNA payload of interest into a targeted bacterial cell, wherein said lambdoid delivery vehicle comprises a chimeric receptor binding protein (RBP) resistant to proteolytic digestion, wherein said chimeric RBP comprises an N-terminal region of a side tail fiber (STF) protein from a lambdoid bacteriophage, fused through a designed linker region consisting of 1 to 70 amino acids or 1 to 30 amino acids, to a C-terminal region of a RBP protein from a different bacteriophage, wherein said N-terminal region and C-terminal region are fused within an insertion site of the N-terminal STF region, said insertion site having at least 80% identity with a site selected from the group consisting of amino acids SAGDAS (SEQ ID NO: 1), ADAKKS (SEQ ID NO: 2), MDETNR (SEQ ID NO: 3), SASAAA (SEQ ID NO: 4) and GAGENS (SEQ ID NO: 5); and wherein said designed linker region comprises a helix or helical bundle and wherein said linker region is resistant to proteolytic cleavage; and a pharmaceutically acceptable carrier.
 25. The method according to claim 24, for treating and/or preventing a disease or disorder caused or mediated by bacteria, wherein a therapeutically effective amount of said pharmaceutical or veterinary composition is administered to a subject having a disease or disorder in need of treatment. 